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Background: Pre-eclampsia is a leading cause of maternal and perinatal mortality and morbidity.
Early identification of women at risk is needed to plan management.
Objectives: To assess the performance of existing pre-eclampsia prediction models and to develop and
validate models for pre-eclampsia using individual participant data meta-analysis. We also estimated
the prognostic value of individual markers.
Design: This was an individual participant data meta-analysis of cohort studies.
Setting: Source data from secondary and tertiary care.
Predictors: We identified predictors from systematic reviews, and prioritised for importance in an
international survey.
Primary outcomes: Early-onset (delivery at < 34 weeks’ gestation), late-onset (delivery at ≥ 34 weeks’
gestation) and any-onset pre-eclampsia.
Analysis: We externally validated existing prediction models in UK cohorts and reported their performance
in terms of discrimination and calibration.We developed and validated 12 new models based on clinical
characteristics, clinical characteristics and biochemical markers, and clinical characteristics and ultrasound
markers in the first and second trimesters. We summarised the data set-specific performance of each
model using a random-effects meta-analysis. Discrimination was considered promising for C-statistics
of ≥ 0.7, and calibration was considered good if the slope was near 1 and calibration-in-the-large was
near 0. Heterogeneity was quantified using I2 and τ2. A decision curve analysis was undertaken to
determine the clinical utility (net benefit) of the models. We reported the unadjusted prognostic value
of individual predictors for pre-eclampsia as odds ratios with 95% confidence and prediction intervals.
Results: The International Prediction of Pregnancy Complications network comprised 78 studies
(3,570,993 singleton pregnancies) identified from systematic reviews of tests to predict pre-eclampsia.
Twenty-four of the 131 published prediction models could be validated in 11 UK cohorts. Summary
C-statistics were between 0.6 and 0.7 for most models, and calibration was generally poor owing to
large between-study heterogeneity, suggesting model overfitting. The clinical utility of the models varied
between showing net harm to showing minimal or no net benefit. The average discrimination for IPPIC
models ranged between 0.68 and 0.83. This was highest for the second-trimester clinical characteristics
and biochemical markers model to predict early-onset pre-eclampsia, and lowest for the first-trimester
clinical characteristics models to predict any pre-eclampsia. Calibration performance was heterogeneous
across studies. Net benefit was observed for International Prediction of Pregnancy Complications first
and second-trimester clinical characteristics and clinical characteristics and biochemical markers models
predicting any pre-eclampsia, when validated in singleton nulliparous women managed in the UK NHS.
History of hypertension, parity, smoking, mode of conception, placental growth factor and uterine artery
pulsatility index had the strongest unadjusted associations with pre-eclampsia.
Limitations: Variations in study population characteristics, type of predictors reported, too few events
in some validation cohorts and the type of measurements contributed to heterogeneity in performance
of the International Prediction of Pregnancy Complications models. Some published models were not
validated because model predictors were unavailable in the individual participant data.
Conclusion: For models that could be validated, predictive performance was generally poor across data
sets. Although the International Prediction of Pregnancy Complications models show good predictive
performance on average, and in the singleton nulliparous population, heterogeneity in calibration
performance is likely across settings.
Future work: Recalibration of model parameters within populations may improve calibration
performance. Additional strong predictors need to be identified to improve model performance and
consistency. Validation, including examination of calibration heterogeneity, is required for the models
we could not validate.
Study registration: This study is registered as PROSPERO CRD42015029349.
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What is the problem?
Pre-eclampsia, a condition in pregnancy that results in raised blood pressure and protein in the urine,
is a major cause of complications for the mother and baby.
What is needed?
A way of accurately identifying women at high risk of pre-eclampsia to allow clinicians to start
preventative interventions such as administering aspirin or frequently monitoring women during pregnancy.
Where are the research gaps?
Although over 100 tools (models) have been reported worldwide to predict pre-eclampsia, to date their
performance in women managed in the UK NHS is unknown.
What did we plan to do?
We planned to comprehensively identify all published models that predict the risk of pre-eclampsia
occurring at any time during pregnancy and to assess if this prediction is accurate in the UK population.
If the existing models did not perform satisfactorily, we aimed to develop new prediction models.
What did we find?
We formed the International Prediction of Pregnancy Complications network, which provided data
from a large number of studies (78 studies, 25 countries, 125 researchers, 3,570,993 singleton
pregnancies). We were able to assess the performance of 24 out of the 131 models published to
predict pre-eclampsia in 11 UK data sets. The models did not accurately predict the risk of pre-
eclampsia across all UK data sets, and their performance varied within individual data sets. We
developed new prediction models that showed promising performance on average across all data sets,
but their ability to correctly identify women who develop pre-eclampsia varied between populations.
The models were more clinically useful when used in the care of first-time mothers pregnant with one
child, compared to a strategy of treating them all as if they were at high-risk of pre-eclampsia.
What does this mean?
Before using the International Prediction of Pregnancy Complications models in various populations,
they need to be adjusted for characteristics of the particular population and the setting of application.
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Pre-eclampsia is a leading cause of maternal and perinatal mortality and morbidity. Current methods of
risk assessment for pre-eclampsia are based mainly on clinical history alone and have limited accuracy.
Prediction models that incorporate additional information on biochemical and ultrasound markers
could improve the predictive performance. Numerous multivariable pre-eclampsia models have been
developed to date, but only a few have been externally validated, and none is recommended for use in
routine clinical practice. Robust data are needed to externally validate existing models to determine
their transportability across new populations and their clinical utility.
Objectives
Primary
The primary objectives were to use individual participant data meta-analysis:
l to validate (across multiple populations and settings) existing models for predicting early-onset,
late-onset and any-onset pre-eclampsia based on clinical characteristics only, clinical and biochemical
markers, clinical and ultrasound markers, and clinical, biochemical and ultrasound markers
l to develop and validate (across multiple populations and settings) multivariable prediction models
for early-onset, late-onset and any-onset pre-eclampsia where existing prediction models have
limited performance, or where no such models exist for the relevant pre-eclampsia outcomes
l to estimate the net benefit (clinical utility) of existing and new models to inform clinical decision
making based on thresholds of predicted risk
l to estimate the prognostic value of individual clinical, biochemical and ultrasound markers for
predicting pre-eclampsia.
Secondary
l To assess the differential performance of the existing models in various predefined subgroups based
on population characteristics (unselected; selected) and timing of model use (first trimester;
second trimester).
l To study the added accuracy when novel metabolic and microRNA-based biochemical markers are
added to the developed model based on clinical, ultrasound and biochemical markers.
Methods
We undertook an individual participant data meta-analysis in line with existing recommendations on
prognostic research model development and validation and complied with reporting guidelines for
prediction models and individual participant data meta-analysis. We undertook relevant systematic
reviews to identify systematic reviews on clinical characteristics, biochemical and ultrasound markers
for prediction of pre-eclampsia; prediction models for pre-eclampsia; and relevant studies, birth cohorts
or data sets. Primary studies and large birth and population-based cohorts that provided relevant
information for assessing the accuracy of clinical, biochemical and ultrasound predictors of pre-
eclampsia were included. The primary outcomes were early-onset (delivery at < 34 weeks’ gestation),
late-onset (delivery at ≥ 34 weeks’ gestation) and any-onset pre-eclampsia. We established the
International Prediction of Pregnancy Complications collaborative network, and researchers from this
group shared their primary data, which required extensive cleaning, standardisation and quality checking.
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We externally validated published pre-eclampsia prediction models that reported the full model
equation in International Prediction of Pregnancy Complications UK data sets. Partially missing
predictors or outcome values missing for < 95% of individuals in a data set were multiply imputed
under the missing at random assumption using multiple imputation by chained equations. Imputation
was carried out separately in each dataset to account for the clustering of individuals within a data set.
The predictive performance of each model was examined using measures of discrimination (C-statistics;
no discrimination 0.5 to perfect discrimination 1, with values of ≥ 0.7 deemed most promising) and
calibration of predicted to observed risks (calibration slope, with an ideal value of 1; and calibration-in-
the-large, with an ideal value of 0) first in the individual participant data for each available data set and
then across data sets at the meta-analysis level. We also compared the clinical utility (net benefit) of
validated prediction models for each pre-eclampsia outcome using a decision curve analysis.
We then developed and validated new prediction models for early-onset, late-onset and any-onset
pre-eclampsia based on clinical characteristic variables alone, clinical characteristics and biochemical
markers, and clinical characteristics and ultrasound markers. For each model developed, we summarised
the data set-specific performance (C-statistic, calibration slope and calibration-in-the-large), using a
random-effects meta-analysis, in terms of the average performance and (to examine potential
generalisability across settings) the heterogeneity in performance. We also assessed the clinical utility
of developed models using a decision curve analysis.
Outside model development, we also used the full International Prediction of Pregnancy Complications
data set to obtain summary-unadjusted estimates of the prognostic effects of prioritised candidate
predictors for early-onset, late-onset and any-onset pre-eclampsia, along with 95% confidence intervals
and 95% prediction intervals, using a two-stage individual participant data meta-analysis of complete
cases of singleton pregnancies. The two-stage approach involves first fitting a logistic regression model
for each study and then pooling the log-odds ratios using a conventional random-effects meta-analysis.
Clustering of participants within data sets was accounted for by analysing each data set separately in
the first stage.
Results
One hundred and twenty-five researchers from 73 teams in 25 countries joined the International
Prediction of Pregnancy Complications network (by October 2017) and provided access to anonymised
individual data of 3,674,684 pregnancies (78 data sets). More than half of the data sets (58%, 45/78)
were prospective cohort studies, 15% (12/78) were randomised controlled trials and 17% (13/78) were
large prospective registry data sets or birth cohorts. One data set included individual participant data
from 31 randomised controlled trials.
External validation of existing pre-eclampsia prediction models
Of the 131 models identified, 24 could be validated in one or more of the 11 International Prediction
of Pregnancy Complications UK data sets. Eight models predicted any-onset pre-eclampsia (three on
clinical characteristics only, three with additional biochemical markers and two with additional ultrasound
markers), nine predicted early-onset pre-eclampsia (seven included clinical characteristics only, and one
each included additional biochemical or ultrasound markers), and seven predicted late-onset pre-eclampsia
(five included clinical characteristics only, and one each included additional biochemical and ultrasound
markers). Discrimination performance of the models was modest, with summary C-statistics of around
0.6–0.7 for most models. Calibration was generally poor across the data sets, with large heterogeneity
in performance across different International Prediction of Pregnancy Complications data sets, with
most of the models demonstrating signs of overfitting (summary calibration slope of < 1) and predictions
that were systematically too high or too low (calibration-in-the-large ≠ 0, suggesting poor prediction of
overall risk across populations). In most of the data sets, the net benefit of using the models was only
slightly greater than the strategy of considering all women to have pre-eclampsia.
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Development and validation of International Prediction of Pregnancy Complications
pre-eclampsia prediction models
Twelve International Prediction of Pregnancy Complications pre-eclampsia models were developed:
four each to predict any-onset, early-onset and late-onset pre-eclampsia (two models each in the
first and second trimesters using clinical characteristics, and with additional biochemical markers).
We developed each model by meta-analysing 3–11 International Prediction of Pregnancy Complications
data sets. The clinical characteristics only models comprised maternal age, body mass index, parity,
history of pre-eclampsia, hypertension, diabetes or autoimmune disease and systolic or diastolic blood
pressure. In addition to the clinical characteristic predictors, the biochemical marker models included
soluble fms-like tyrosine kinase-1, pregnancy-associated plasma protein A and placental growth factor.
For predicting any pre-eclampsia, all second-trimester models (clinical only, clinical and biochemical
predictors) showed promising discrimination (average C-statistics of ≥ 0.7); first trimester clinical only,
and clinical and biochemical models had summary C-statistics of 0.68 and 0.70, respectively. All models
to predict early-onset pre-eclampsia had promising discrimination; the first trimester (clinical only,
clinical and biochemical) models had summary C-statistics of 0.72 (95% confidence interval 0.59 to
0.82) and 0.76 (95% confidence interval 0.58 to 0.88) respectively; the corresponding values for
second-trimester clinical only and clinical and biochemical models were 0.72 (95% confidence interval
0.60 to 0.82) and 0.83 (95% confidence interval 0.63 to 0.93). For predicting late-onset pre-eclampsia,
the second-trimester models (clinical only, clinical and biochemical predictors) showed promising
discrimination (average C-statistics ≥ 0.7); the first-trimester models’ C-statistics ranged from 0.68 to
0.69. Summary calibration measures often had wide confidence intervals, and there was often large
between-study heterogeneity in the calibration performance, particularly for clinical and biochemical
marker models. The net benefit of the models varied across individual data sets, ranging from harm to
very little benefit to no benefit.
When validated in individual cohorts with over 100 pre-eclampsia events, the first-trimester clinical
model for any pre-eclampsia was well calibrated in the Baschat study (any pregnant women in the
USA) (Baschat AA, Magder LS, Doyle LE, Atlas RO, Jenkins CB, Blitzer MG. Prediction of preeclampsia
utilizing the first trimester screening examination. Am J Obstet Gynecol 2014;211:514.e1–7); the
predictions were too high for individuals in the World Health Organization study (women with risk
factors for pre-eclampsia from low-, middle- and high-income countries) (Widmer M, Cuesta C,
Khan KS, Conde-Agudelo A, Carroli G, Fusey S, et al. Accuracy of angiogenic biomarkers at 20 weeks'
gestation in predicting the risk of pre-eclampsia: a WHO multicentre study. Pregnancy Hypertens
2015;5:330–8) and low for those at high risk in the Pregnancy Outcome Prediction (POP) (nulliparous,
singleton pregnancies in the UK) [Sovio U, White IR, Dacey A, Pasupathy D, Smith GCS. Screening for
fetal growth restriction with universal third trimester ultrasonography in nulliparous women in the
Pregnancy Outcome Prediction (POP) study: a prospective cohort study. Lancet 2015;386:2089–97].
We observed a consistent net benefit for all International Prediction of Pregnancy Complications
models when validated in the POP cohort for probability thresholds of ≥ 5%. Very little or no net
benefit was observed in other data sets.
Summarising the unadjusted prognostic effect of individual predictors of pre-eclampsia
Any-onset pre-eclampsia
We observed a strong unadjusted association between any-onset pre-eclampsia and history of
hypertension (odds ratio 4.76, 95% confidence interval 3.56 to 6.35; I2 = 98.39%), multiparity (odds
ratio 0.88, 95% confidence interval 0.79 to 0.99; I2 = 96.6%), smoking during pregnancy (odds ratio
0.84, 95% confidence interval 0.76 to 0.93; I2 = 86.46%) and spontaneous mode of conception (odds
ratio 0.73, 95% confidence interval 0.64 to 0.84; I2 = 58.67%), and increasing placental growth factor
in the first (odds ratio 0.22, 95% confidence interval 0.09 to 0.50, I2 = 85.44), second (odds ratio 0.66,
95% confidence interval 0.53 to 0.83; I2 = 87.27%) or third trimester (odds ratio 0.59, 95% confidence
interval 0.45 to 0.77; I2 = 96.78%) showed a reduction in the odds of any-onset pre-eclampsia.
DOI: 10.3310/hta24720 Health Technology Assessment 2020 Vol. 24 No. 72
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Allotey et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
xxxi
Early-onset pre-eclampsia
Increasing second-trimester measurement of uterine artery pulsatility index values had the strongest
association with early-onset pre-eclampsia (odds ratio 14.73, 95% confidence interval 8.12 to 26.72;
I2 = 60.11%). All statistically significant predictors had evidence of an increase in the odds of early-onset
pre-eclampsia with increasing values, except placental growth factor measured in the first (odds ratio 0.08,
95% confidence interval 0.02 to 0.35; I2 = 55.69%) or second trimester (odds ratio 0.07; 95% confidence
interval 0.01 to 0.43; I2 = 97.18%), which showed a decrease in odds with increasing values.
Late-onset pre-eclampsia
The strongest association with late-onset pre-eclampsia was observed for increasing uterine artery
pulsatility index values measured in the second trimester (odds ratio 2.95, 95% confidence interval
2.31 to 3.76; I2 = 20.77%). Multiparity (odds ratio 0.87, 95% confidence interval 0.78 to 0.97;
I2 = 95.16%) and increasing values of first (odds ratio 0.33, 95% confidence interval 0.16 to 0.68;
I2 = 82.67%), second (odds ratio 0.81, 95% confidence interval 0.69 to 0.94; I2 = 76.39%) or third
(odds ratio 0.68, 95% confidence interval 0.57 to 0.81; I2 = 93.60%) trimester measurement of placental
growth factor and first-trimester soluble fms-like tyrosine kinase-1 (odds ratio 0.98, 95% confidence
interval 0.97 to 0.99; I2 = 37.07%) showed a decrease in the odds of late-onset pre-eclampsia.
There was considerable heterogeneity for most prognostic effects, with wide 95% prediction intervals
for the potential prognostic effect of factors in new populations.
Conclusions
Among the 24 existing prediction models that could be validated in individual participant data
meta-analysis, their predictive performance was generally poor across data sets (both on average
and in terms of heterogeneity in calibration of predicted risks with observed risks), with very limited
evidence of clinical utility. Some of the heterogeneity in predictive performance of the models is
likely due to different methods and timing of measurement, for example in blood pressure and
biochemical marker values. Although the International Prediction of Pregnancy Complications models
show promising predictive performance on average across data sets, heterogeneity across settings is
likely in calibration performance. Ultrasound markers did not improve the predictive performance of
the developed International Prediction of Pregnancy Complications clinical characteristic only models.
The International Prediction of Pregnancy Complications pre-eclampsia models show consistent net
benefit when applied to a cohort of singleton, nulliparous women in the UK. Before application in
practice, calibration performance may need to be improved by recalibrating model parameters, such
as the intercept, to particular populations and settings.
Recommendations for further research
Going forward, standardisation of measurement methods, for example across laboratories and
hospitals, might reduce heterogeneity in calibration performance. A related point is that prediction
models in this field need to be clearer with regard to how included predictors should be measured and
exactly when this should occur. Validation, including examination of calibration heterogeneity, is still
required for the models that we could not validate. The transportability of these and the International
Prediction of Pregnancy Complications models needs to be assessed in multiple large data sets
across different settings and populations, as does their acceptability to both women and health-care
professionals. The impact of using the models in clinical practice needs to be evaluated beyond pre-
eclampsia prediction to include the identification of women most at risk of other severe pregnancy
complications. Updated models may be needed in local populations, using recalibration of the
International Prediction of Pregnancy Complications models in local data sets, to improve calibration
performance. Furthermore, additional strong predictors need to be identified to improve model
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performance and consistency. New cohorts must standardise the predictors and outcomes measured,
including their timing and measurement methods, to enable more homogenous data sets to be
combined in individual participant data meta-analyses. In terms of the prognostic ability of particular
factors, further analysis of the International Prediction of Pregnancy Complications data using
multilevel multiple imputation for missing data and adjusting for confounders would provide a better
evaluation of prognostic association.
Study registration
This study is registered as PROSPERO CRD42015029349.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 72.
See the NIHR Journals Library website for further project information.
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Pre-eclampsia is a pregnancy-specific condition associated with hypertension and multiorgandysfunction such as proteinuria, renal or hepatic impairment and fetal growth restriction.1–5 It is a
heterogeneous disorder with a wide spectrum of multiorgan involvement, which reflects its various
pathophysiological pathways. Pre-eclampsia affects between 2% and 8% of pregnancies worldwide6
and is a leading cause of both maternal and perinatal morbidity and mortality.7–10 Each year, 18% of all
maternal deaths can be attributed to pre-eclampsia and its complications, with most of these occurring
in low- and middle-income countries.11,12 In the long term, pre-eclampsia is associated with an increased
maternal risk of ischaemic heart disease, chronic hypertension, stroke and end-stage renal disease.13,14
Children from pre-eclamptic pregnancies also have higher risks of cardiovascular diseases,15,16 mental
health disorders and cognitive impairment.17,18
Two subgroups of pre-eclampsia are well recognised: early-onset, requiring delivery before 34 weeks’
gestation, and late-onset, with delivery occurring at or after 34 weeks’ gestation.19–21 Early-onset
pre-eclampsia is considered to be a pathophysiologically different disease from late-onset pre-eclampsia
in the mechanism leading to placental dysfunction and clinical timing during pregnancy.22 Early-onset
pre-eclampsia is associated with a considerably higher increased risk of maternal complications, such as
a 20-fold higher rate of mortality, than the late-onset type, and early delivery is the only treatment.23–25
In addition to the prematurity-related complications, the risks of stillbirth and adverse perinatal
outcomes are much higher in women with early-onset disease.26
Although the proportion of women with early-onset pre-eclampsia is < 1% of all pregnancies, the
complexity of treatment gives rise to high health-care costs.27,28 Affected women are often admitted
to a tertiary care facility, and 30% experience complications that may necessitate management in
an intensive care unit.29 Infants usually need prolonged care for the management of complications,
including lifelong disabilities, arising as a result of premature delivery. The additional NHS costs
incurred in caring for a baby born at or before 28 weeks and a baby born between 28 and 33 weeks
are £94,190 and £61,509, respectively.30 The cost to the NHS of caring for preterm babies, linked to
neonatal care, such as incubation, and hospital readmissions, has been estimated at £939M annually.30
Late-onset pre-eclampsia, including pre-eclampsia at term, also poses a significant health burden.
It accounts for the majority of pre-eclampsia diagnoses in pregnancy. One-fifth of all women with
late-onset disease have maternal complications such as HELLP (haemolysis, elevated liver enzymes
and low platelet count) syndrome, and more than half of eclamptic seizures occur at term.28,31,32
Pregnant women who are at high risk of pre-eclampsia require close monitoring and are usually
started on prophylactic aspirin in early pregnancy to reduce the risk of development of pre-eclampsia
and occurrence of adverse outcomes. Early commencement of this has the potential for maximum
benefit,33 which may be limited to early-onset disease.34 It is important to be able to quantify a
woman’s risk of developing pre-eclampsia during the course of pregnancy to help guide clinical
decisions and monitoring strategies. The National Institute for Health and Care Excellence prioritises
screening for early-onset pre-eclampsia in its research recommendations on antenatal care of women.35
Currently, the assessment of a woman’s risk of developing pre-eclampsia is based mainly on clinical
history,36 but such risk-based predictions have been shown to have limited accuracy.37 Risk factors
based on clinical characteristics have also been shown to have quantitatively different associations
with early- and late-onset pre-eclampsia,26 and, similarly, biochemical and ultrasound markers have
variations in their performance in predicting the two types of pre-eclampsia.37–39 Prediction models
incorporating additional tests for biochemical and ultrasound markers may improve the predictive
performance of models.40–42 It is, however, unlikely that a single model will accurately predict both
early- and late-onset pre-eclampsia.26
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There are more than 60 multivariable prediction models developed to predict pre-eclampsia, using
various combinations of clinical, biochemical and ultrasound risk factors.43 Such models and tests for
predicting pre-eclampsia have been based on findings from aggregate meta-analysis and primary
studies, and none is recommended for use in routine clinical practice. This is because there is an
absence of information about the reproducibility of the models or their predictive performance in
different settings.
Although interventions such as aspirin have been found to significantly reduce the risk of early-onset
pre-eclampsia in women predicted to be at ‘high risk’ of pre-eclampsia using a model, lack of robust
information on the accuracy of this model means that we could not rule out potential benefit in
women considered to be ‘low risk’. Before they can be used in clinical practice, prediction models
need to be appropriately validated in multiple data sets external to that used to develop the model.
This often takes many years to accomplish in a primary study, and, as a result, very few models have
been externally validated to date.43–46 Individual studies also often have an insufficient sample size to
externally validate the relatively rare but serious condition of early-onset pre-eclampsia.26
Meta-analysis of individual participant data (IPD), whereby the raw participant-level information is
obtained and synthesised across multiple data sets, overcomes the limitations above.47–50 The availability
of the raw data substantially increases the sample size beyond what is achievable in a single study, and
offers a unique opportunity to evaluate the generalisability of predictive performance of existing models
across a range of clinical settings. Using IPD meta-analysis allows the standardisation of predictors
and outcome definitions, takes into account the performance of many candidate prognostic variables,
directly handles missing predictors and outcomes data, accounts for heterogeneity in baseline risks,
and, most importantly, develops, validates and tailors the use of the most accurate prediction models to
the appropriate population.
The unmet need for prediction models for pre-eclampsia, particularly early-onset pre-eclampsia, is
mainly a result of lack of information on the generalisability of the models and their performances in
external cohorts. Hence, before more resources are spent on developing further models, what is
needed is external validation of existing models. If existing models’ performances are suboptimal,
then further development of new models is warranted with sufficient sample size.
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Chapter 2 Objectives
Material in this chapter has been adapted from Allotey et al.51 This is an Open Access articledistributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0)
license, which permits others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text
below includes minor additions and formatting changes to the original text.
We planned to externally validate and update prediction models for (1) early-onset (delivery at
< 34 weeks’ gestation), (2) late-onset (delivery at ≥ 34 weeks’ gestation) and (3) any-onset
pre-eclampsia, and to further develop new prediction models for the above outcomes, if required,
using IPD meta-analysis.
Primary objectives
l To validate and improve or tailor the performance of existing models in relevant population groups
for predicting early-onset, late-onset and any-onset pre-eclampsia in our IPD data set based on:
¢ clinical characteristics only
¢ clinical and biochemical markers
¢ clinical and ultrasound markers
¢ clinical, biochemical and ultrasound markers.
l Using IPD meta-analysis, to develop and externally validate (using internal–external cross-validation)
multivariable prediction models for early, late and any-onset pre-eclampsia in the following
circumstances:
¢ where existing predictive strategies cannot be adjusted for the target population
¢ where no such models exist for the relevant pre-eclampsia outcomes.
l To estimate the prognostic value of individual clinical, biochemical and ultrasound markers for
predicting pre-eclampsia by IPD meta-analysis.
Secondary objectives
l To assess the differential performance of the existing models in various predefined subgroups based
on population characteristics (unselected; selected) and timing of model use (first trimester;
second trimester).
l To study the added accuracy when novel metabolic and microRNA-based biochemical markers are
added to the developed model based on clinical, ultrasound and biochemical markers.
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Material in this chapter has been adapted from Allotey et al.51 This is an Open Access articledistributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0)
license, which permits others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text
below includes minor additions and formatting changes to the original text.
Part of this chapter have been reproduced from Snell et al.52 Open Access This article is licensed under
a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation,
distribution and reproduction in any medium or format, as long as you give appropriate credit to the
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's
Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not
included in the article's Creative Commons licence and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright
holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative
Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/)
applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Our IPD meta-analysis followed existing recommendations on prognostic research model development
and validation53–55 and adhered to reporting guidelines for prediction models and IPD meta-analysis.56,57
We used a prospective protocol51 registered on the International Prospective Register of Systematic
Reviews (PROSPERO) as CRD42015029349.58
Eligibility criteria
Criteria for including relevant cohorts and studies in the individual participant data
We included primary studies (prospective and retrospective cohort studies, as well as cohorts nested
within randomised trials), and large birth and population-based cohorts with information to assess the
accuracy of clinical, biochemical and ultrasound predictors in women at low, high or any risk to predict
early-, late- or any-onset pre-eclampsia and its associated complications. The process of identifying and
selecting studies to invite to form the IPPIC network is described in detail in our published protocol,
as well as in the following sections (see Literature search and study identification, The IPPIC pre-eclampsia
network and Study selection, individual participant data collection and harmonisation). Studies or cohorts
that addressed the structured question in Table 1 were included in the IPD. The predictors considered
for evaluation were chosen a priori and were clearly defined and standardised.39,60–72
The primary outcomes were early-onset (delivery at < 34 weeks’ gestation), late-onset (delivery at
≥ 34 weeks’ gestation) and any-onset pre-eclampsia. The authors reported the definition of the primary
outcome of pre-eclampsia along with gestational age at delivery, which was used to define early- and
late-onset disease. Definitions of pre-eclampsia included proteinuric and non-proteinuric pre-eclampsia.35,73
The secondary outcomes were composite adverse maternal or fetal and neonatal outcomes.
Literature search and study identification
We undertook a systematic review of reviews to identify relevant systematic reviews on clinical
characteristics, biochemical and ultrasound markers for prediction of pre-eclampsia.37 We adhered
to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines on
DOI: 10.3310/hta24720 Health Technology Assessment 2020 Vol. 24 No. 72
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Allotey et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
5
reporting, and the review was based on a prospective protocol. The systematic review methods have
been published elsewhere, but, briefly, two reviewers independently screened abstracts, extracted data
and carried out quality assessment.37 We defined the inclusion and exclusion criteria for the systematic
reviews, the outcome of interest (pre-eclampsia) and the predictors. We also updated our previous
literature search of prediction models for pre-eclampsia43 (July 2012–December 2017) to identify
additional models. We searched the following databases: MEDLINE, EMBASE, Bioscience Information
Services (BIOSIS), Latin American and Caribbean Health Sciences Literature (LILACS), PASCAL, Science
Citation Index, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled
TABLE 1 Structured question for IPD meta-analysis on prediction of pre-eclampsia
Question components Definition
Population Pregnant women
Predictors Maternal clinical characteristics at antenatal booking
Maternal characteristics: age, BMI, height, weight, ethnicity, smoking, alcohol or substance misuse
Medical history: pre-existing chronic kidney disease, heritable thrombophilias, autoimmune
disease such as systemic lupus erythematosus and antiphospholipid syndrome, type 1 and 2
diabetes and hypertensive diseases
Obstetric history: parity, previous pre-eclampsia, gestational diabetes, pregnancy interval of
> 10 years, family history of pre-eclampsia, family history of cardiovascular disease, previous
miscarriages, preterm birth, stillbirth or SGA fetus
Current pregnancy: multiple pregnancy, mode of conception, early pregnancy bleeding, MAP,
SBP and DBP, socioeconomic status, new partner, diet or exercise in pregnancy, urine
dipstick, PCR, 24-hour protein
Biochemical markers (first or second trimester): PAPP-A, sFlt-1, PlGF, AFP, human chorionic
gonadotropin, sENG, CRP, hypertriglyceridaemia and PAI-1
Ultrasound markers (first or second trimester)
CRL, abdominal circumference, expected fetal weight centile, uterine and umbilical artery
Doppler (resistance index, pulsatility index, unilateral or bilateral notching)
Outcomes Primary outcomes
Early-onset (delivery at < 34 weeks’ gestation), late-onset (delivery at ≥ 34 weeks’ gestation)
and any-onset pre-eclampsia
Secondary outcomes
Maternal complications: eclampsia, HELLP syndrome, abruption, hepatic and renal failure,
cortical blindness, pulmonary oedema, postpartum haemorrhage, disseminated intravascular
coagulation, preterm delivery, admission to high-dependency unit/intensive care unit,
maternal death, caesarean section, gestational diabetes mellitus
Fetal and neonatal complications: birthweight in kg and centile (using the Gestation Network
bulk centile calculator59), SGA fetus, stillbirth, neonatal death, hypoxic-ischaemic
encephalopathy, respiratory distress syndrome, septicaemia, admission to neonatal unit
Study design Observational studies and cohorts nested within randomised trials
AFP, alpha-fetoprotein; BMI, body mass index; CRL, crown–rump length; CRP, C-reactive protein; DBP, diastolic blood
pressure; MAP, mean arterial blood pressure; PAI-1, plasminogen activator inhibitor-1; PAPP-A, pregnancy-associated
plasma protein A; PCR, protein–creatinine ratio; PIGF, placental growth factor; SBP, systolic blood pressure;
sENG, soluble endoglin; sFlt-1, soluble fms-like tyrosine kinase-1; SGA, small for gestational age.
Adapted from Allotey et al.51 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
The table includes minor additions and formatting changes to the original table.
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Trials (CENTRAL), National Institute of Child and Human Development Data and Specimen Hub,
Database of Abstracts of Reviews of Effects (DARE) and Health Technology Assessment database
without any language restrictions. Research reported in grey literature was sought by searching a
range of relevant databases including the Inside Conferences, Systems for Information in Grey Literature,
MotherChild Link Registry (www.linkregistry.org/search.aspx), Dissertation Abstracts and ClinicalTrials.gov.
Data extraction following the update of our literature search for prediction models for pre-eclampsia
was carried out by two reviewers independently.
We used additional sources such as internet searches using general search engines (e.g. Google;
www.google.co.uk/) and meta-search engines (e.g. Copernic; www.copernic.com/), and directly contacted
researchers to identify relevant studies, birth cohorts or data sets that may have been missed. Collaborative
groups such as the Global Pregnancy Collaboration (CoLab), Pre-eclampsia and Eclampsia Monitoring,
Prevention and Treatment (PRE-EMPT) and the Global Obstetrics Network (GONet) were also approached
to identify primary studies, unpublished research and birth cohorts.74–76 We did not include studies, birth
cohorts or data sets after October 2017, as we needed time to clean and format the data prior to any
analysis. The details of the search strategy are provided in Appendix 2.
The IPPIC pre-eclampsia network
We established a collaborative network of investigators (IPPIC) from research groups that have
undertaken studies on clinical characteristics, biochemical and ultrasound markers in the prediction of
early- and any-onset pre-eclampsia. The network is a global effort bringing together 125 researchers,
clinicians and epidemiologists from 25 countries and is supported by the World Health Organization
(WHO). We invited authors of all primary studies identified from this review and also invited
investigators of primary studies and large birth and population-based cohorts that were not included
in existing reviews but were identified through our links with other collaborative groups74–76 if these
provided relevant information to assess the accuracy of clinical, biochemical and ultrasound predictors
of pre-eclampsia.
Study selection, individual participant data collection and harmonisation
The collaborative group agreed the minimum data to be requested for the IPD meta-analysis, and a
custom-built database was set up based on these specifications. The minimum data requested were
pre-eclampsia outcome with gestational age at delivery, as well as any of the clinical, biochemical and
ultrasound predictors of pre-eclampsia listed in Table 1. Authors of the primary studies and data sets
were contacted to ask if they would share their IPD in any format, along with data dictionaries or
descriptions. We identified and invited authors and investigators from 180 data sets to join the project
and share their IPD, with at least two further reminders to share data for the project. We continued to
contact authors to request that they share their data until the October 2017 deadline for receiving
new data sets was reached. When a data set received contained IPD from multiple studies, we checked
the identity of each study to avoid duplication.
Original pseudonymised data sets were uploaded to a secure data storage environment (SafeHaven)
at the Pragmatic Clinical Trials Unit, Queen Mary University of London, accessible only from a virtual
desktop where manipulation of the data along with relevant data checks and documentation took place.
The final merged data set, individual formatted files and documentation of all the transformations made
were securely transferred to a web-based server at Centro Rosarino de Estudios Perinatales, Rosario,
Argentina, a WHO Collaborative Centre in Child and Maternal Health. An independent Data Access
Committee and data access process were established to facilitate access to and use of the data for
future research.
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Data extraction
We considered all recorded variables for inclusion, including those not reported in the published
studies. At the study level, we extracted data on the providing collaborator, study design, data source,
study period and study inclusion and exclusion criteria. At the participant level, we extracted
information on individual participant characteristics and outcome data, as specified in Table 1.
Data harmonisation and recovery
Maternal age at baseline was recorded as a continuous variable in years in all data sets except three, in
which age was calculated using the date of study or booking visit and the date of birth. Data on parity,
defined as the number of pregnancies > 24 weeks’ gestation, were mostly recorded in the binary format
(nulliparous/multiparous). Any continuous data for parity were therefore also transformed to the binary
form. However, we retained the continuous data for any relevant analyses. Assumptions were made when
harmonising the ethnicity variable, and this was recoded as white, black, Asian, Hispanic, mixed and other.
Pre-gestational diabetes, type 1 diabetes and type 2 diabetes were harmonised as history of diabetes,
and history of systemic lupus, multiple sclerosis, idiopathic thrombocytopenia, rheumatoid arthritis or
antiphospholipid syndrome were harmonised as history of autoimmune disease. We also harmonised
history of glomerulonephritis, nephrotic syndrome, nephritis or nephropathy as history of renal disease.
Maternal characteristic data, such as history of disease and previous pregnancy, were recovered by
screening the participant inclusion and exclusion criteria of published articles when this information
had not been provided in the original data set. We added data based on existing information contained
in the data set and from published articles. For example, we inputted the data as ‘no previous history
of pre-eclampsia’ if all participants in the data set were nulliparous.
Body mass index (BMI) (measured in kg/m2), systolic blood pressure (SBP), diastolic blood pressure (DBP)
and mean arterial blood pressure (MAP) were recorded as continuous measures.Where MAP was not
provided but SBP and DBP were, we derived MAP using the formula MAP = (SBP+ 2 × DBP)/3. Where
BMI was not provided in the data set it was derived using weight (kg)/height (m2). We derived the
estimated fetal and birth weight centiles using the Perinatal Institute GROW centile calculator.77 Mean
values of uterine and umbilical artery pulsatility index were mostly reported in data sets. When these
were not available, we derived mean uterine and umbilical artery pulsatility index by averaging the left
and right pulsatility index measurements. Data on biochemical marker platform, assay and measurement
range were obtained for each relevant recorded biochemical marker in the data sets. Conversion factors
were applied where necessary to harmonise the units of measurement. Placental growth factor (PlGF)
was mostly reported in the data sets as pg/ml and standardised as such, pregnancy-associated plasma
protein A (PAPP-A) was standardised as mIU/l and soluble fms-like tyrosine kinase-1 (sFlt-1) was
standardised as pg/ml. The authors’ reported definition of the primary outcome of pre-eclampsia along
with gestational age at delivery was used to define early- and late-onset disease.
Clinical examinations, biochemical and ultrasound markers were further categorised into the trimester
in which they were measured. We defined first-trimester values as ≤ 14 weeks, second-trimester
values as > 14–28 weeks and third-trimester values as > 28 weeks. Where more than one variable
measurement was available for a woman in a trimester, we chose the first or the earliest measurement.
Harmonisation of the data sets followed the predefined process shown in Figure 1. A final list of the
variables collected and harmonised for the project is provided in Appendix 3.
Data quality
Range and consistency checks were carried out on all data sets received, and summary tables were
produced. Missing data > 10% for each variable, range checks for continuous variable measures,
obvious errors, and inconsistencies between pre-identified variables or outlying values were queried
and rectified with input from the original authors. Two reminders were sent to the original author to
respond to queries, and if no response was received, a decision to exclude the variable in question was
made by the project team.
METHODS
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We carried out a prospective online prioritisation survey of IPPIC Network collaborators to identify
the most clinically relevant predictors of pre-eclampsia for consideration in the development of the
prediction models. Collaborators ranked the importance of the predictor variables identified on a scale
from one (not important) to five (very important). The results were analysed as mode and interquartile
range (IQR) to show variability and consensus in opinions. We a priori identified an IQR of ≤ 1 as
indicating consensus between responders. Variables with mode of ≥ 4 and IQR of ≤ 1 were categorised
as important, and those with mode of < 4 and IQR > 1 were categorised as unimportant. Variables with
mode of 3 and IQR of ≤ 1 were reviewed and recategorised for importance at a consensus meeting.
Quality assessment
We assessed the risk of bias in individual studies and data sets using a modified version of the
Prediction study Risk of Bias Assessment Tool (PROBAST).78 The tool assessed the quality of data
sets and individual studies across three domains: participant selection, predictors and outcomes. We
classified the risk of bias to be low, high or unclear for each of the relevant domains. Each domain
included signalling questions that were rated as ‘yes’, ‘probably yes’, ‘probably no’, ‘no’ or ‘no information’.
Any signalling question rated as ‘probably no’ or ‘no’ indicated a potential for bias in the IPD received
for that study, which was therefore classed as having a high risk of bias in that domain. The overall risk
of bias of an IPD data set was considered low if the data set scored low in all domains, high if any one
domain had a high risk of bias, and unclear for any other classifications.
Sample size considerations
No formal sample size requirements were necessary for the meta-analysis. However, to develop a
sound prediction model, as a rule of thumb, 10 events are required for each candidate predictor variable.
Early-onset pre-eclampsia is uncommon, occurring in only about 0.25–0.50% of all pregnancies. We
conservatively estimated that our IPD data set of > 3 million pregnancies would allow us access to
about 7500 women with pregnancies complicated by early-onset pre-eclampsia if they all recorded all
of the predictors of interest. This would enable us to develop and robustly validate prediction models
for the outcomes of any-onset, early-onset and late-onset pre-eclampsia.
Data synthesis
Analysis for prioritisation of pre-eclampsia predictors was carried out using SPSS version 24 (IBM SPSS
Statistics for Windows, IBM Corporation, Armonk, NY, USA). IPD meta-analysis to estimate the
prognostic value of individual predictors was carried out using Stata® version 12.1 (StataCorp LP,
College Station, TX, USA) and R version 3.4.3 (The R Foundation for Statistical Computing, Vienna,
Austria). External validation of existing models and model development were carried out using Stata
MP version 15 (StataCorp LP, College Station, TX, USA) and R version 3.4.3. The combination of
Stata and R was over a single software package to utilise the appropriate packages for each task.
For example, multilevel imputation across data sets can be carried out using the ‘jomo’ package in R,
which currently has no equivalent package in Stata.
External validation of existing pre-eclampsia prediction models
We validated each published pre-eclampsia prediction model that reported the full model equation
with intercept and predictor effects in IPD from the UK. Analysis was restricted to the IPPIC-UK data
sets to allow for the determination of the predictive performance of available models in the context
of the UK health-care system and to reduce the heterogeneity in the definition of the outcome, which
can vary across IPPIC data sets for different countries.4,35 We included UK data sets or subsets of
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international data sets with UK participants if country of recruitment was recorded. We validated a
prediction model only if at least one IPD data set contained values of all the predictors included in the
model. We excluded data sets with no variation in the model predictions across individuals (i.e. every
individual had the same predicted probability as a result of strict eligibility criteria). Smaller data sets
with no outcome event or a single outcome event were also excluded, as were women with multifetal
pregnancies, as the published models were intended to predict the risk of pre-eclampsia in women with
singleton pregnancies only.
Missing data
Second-trimester measurements of BMI and MAP were used for model validation if the first-trimester
values were missing from the data set.
Any predictors partially missing or outcome values missing for < 95% of individuals in a data set were
multiply imputed under the missing at random assumption using multiple imputation by chained
equations.79,80 Imputation was carried out separately in each UK data set, which acknowledged the
clustering of individuals within a data set. We generated 100 imputed data sets for each data set with
any missing predictor or outcome values. Linear regression was used to impute for approximately
normally distributed continuous variables, predictive mean matching for skewed continuous variables,
logistic regression for binary variables, and multinomial logistic regression for categorical variables.
Complete predictors were also included in the imputation models as auxiliary variables. To retain
congeniality between the imputation and predictive models, the scale used to impute the continuous
predictors was chosen to match the prediction models.81 We undertook imputation checks by looking
at histograms, summary statistics and tables of values across imputations, as well as by checking the
trace plots for convergence issues.
We summarised the total number of participants, the number of events for each data set, and the
overall numbers available for each model validation. We applied the model to each individual i in each






for logistic regression equations; others detailed separately). For each prediction model, we summarised
the overall distribution of the LP by data set using the median, IQR and full range, averaging statistics
across imputations.82
The predictive performance of each model was examined using measures of discrimination and
calibration, first in the IPD for each available data set and then across data sets at the meta-analysis
level. Discrimination is the ability of the model to separate between women who develop pre-
eclampsia and those who do not, and was summarised using the C-statistic (equivalent to the area
under the receiver operating characteristic curve for a logistic regression prediction model), with a
value of 1 indicating perfect discrimination and a value of 0.5 indicating no discrimination beyond
chance. We considered values > 0.7 to be most promising, given previously reported values in the
literature, while noting the width of the confidence intervals (CIs).83 Calibration refers to how well the
risk predictions from the model agree with the observed outcome risks for individuals in a data set.
Calibration was assessed using two measures: calibration slope, which is the slope of the regression
line fitted to the relationship between predicted and observed risk probabilities on the logit scale (ideal
value of 1); and calibration-in-the-large, which indicates whether risk predictions are systematically too
high or too low (ideal value of 0). We produced calibration plots in each data set to visually compare
observed and predicted probabilities when there were enough events to categorise participants into
risk groups. The predicted probability of pre-eclampsia for each individual was obtained by pooling the
imputation-specific estimates of the model’s LP and then applying the logit transformation.82
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Where data had been imputed in a particular IPD data set, the predictive performance measures were
calculated in each of the imputed data sets, and Rubin’s rules were then applied to combine statistics
(and corresponding standard errors) across imputations.84 As the C-statistic is a proportion, it is unlikely
to be normally distributed. Hence, we combined C-statistics across imputations on the logit scale,85 and
standard errors for logit C-statistics were calculated using the delta method, as recommended.86
When it was possible to validate a model in multiple data sets, we summarised the performance
measures across data sets using a random-effects meta-analysis estimated using restricted maximum
likelihood (for each performance measure separately).86,87 Summary (average) performance statistics
were reported with 95% CI (derived using the Hartung–Knapp–Sidik–Jonkman variance correction).88
We also reported the estimate of between-study heterogeneity (τ2) and the proportion of variability
due to between-study heterogeneity (I2). We generated plots to show and compare the average
performance (across data sets) of multiple models, along with CIs.
For each pre-eclampsia outcome (early, late or any onset), we compared prediction models using
decision curve analysis in the data sets used most frequently in the external validation of the
prediction models, enabling within-data set comparison of the models.89,90 Decision curves show the net
benefit (i.e. the benefit versus the harm) over a range of threshold probabilities (i.e. for treating women
with a predicted risk above the threshold value) and can be compared with treat-all and treat-none










where ‘true positives’ and ‘false positives’ represent the numbers of individuals with a predicted
probability ≥ pt who have and do not have the outcome of interest, respectively, and N is the total
sample size.89,90 Probability thresholds of between 5% and 20% will be clinically meaningful for making
decisions about preventative interventions such as aspirin, including commencement of high-dose
(150 mg) aspirin in the first trimester. Therefore, the model with the greatest net benefit for a
particular threshold is considered to have the greatest clinical value.
Development and validation of pre-eclampsia prediction models
To develop new pre-eclampsia prediction models, non-UK data sets were considered in addition to the
UK-only data sets. Prospective cohorts and trials were considered for inclusion in the development set.
We excluded case–control studies as they cannot be used to estimate the baseline risk (intercept).
The number and proportion of missing values for each potential predictor and outcome were
summarised by data set. Predictors were considered to be systematically missing for a data set if they
were not recorded for any individuals or were recorded for very few individuals (< 10%) in that data
set. No data sets included all potential predictors of interest; therefore, it was necessary to use a
subset of predictors thought to be most predictive and of most interest.
A prioritised list of predictors was drawn up based on consensus among clinical experts in the
collaborative group (see Prioritisation of predictors). To select data sets for development of a new
prediction model (including maternal characteristics and clinical examination variables), it was
necessary to compromise between the number of data sets included and the potential predictors that
could be considered for inclusion in the models. The aim was to do this in such a way as to maximise
both. We undertook the following process:
1. Ranked the prioritised predictors from the most to least relevant based on the scores from the
clinical consensus meeting.
2. Excluded predictors that were rarely recorded across data sets (predictors recorded in data sets
that total ≤ 5% of all events).
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3. Summarised the number of data sets, total sample size and number of events included if all
remaining predictors were included.
4. If no data sets or very few data sets included all remaining predictors, the lowest-ranking predictor
from the set of predictors was dropped.
5. Repeated steps 3 and 4 until a reasonable number of data sets, sample size and number of events
were achieved and, ideally, when excluding further predictors would not mean a significant gain in
data sets included.
Subsets of the development data identified for models with clinical and maternal characteristics were used
to develop models additionally including biochemical markers or ultrasound markers. These models built
on the clinical models, and therefore they required the same clinical variables plus biochemical markers or
ultrasound markers.When fitting the biochemical marker models, data sets were included only if both
PlGF and sFlt-1 were recorded; however, each biochemical marker could be measured at either trimester
1 or trimester 2. These two biochemical markers were most commonly recorded together, so ensuring that
both PlGF and sFlt-1 were recorded in the data sets meant that the relationship between biochemical
markers (and trimester of measurement) could be better estimated and used in the imputation models,
thereby reducing some uncertainty in the imputed values and reducing the risk of convergence issues.
Missing data
Multiple imputation was implemented using multivariable joint modelling to account for missing data
and clustering of participants within data sets. This approach was selected (rather than imputation
within data sets, as in External validation of existing pre-eclampsia models) to increase the number of data
sets used for model development, as many of the potential predictors of interest were systematically
missing (i.e. not recorded for anyone) in one or more data sets. The ‘jomo’91 package in R was designed
to impute for multilevel (clustered) data and can therefore be used to impute for variables that are
systematically missing in some IPPIC data sets, as well as for partially missing variables.92 This package
uses a Bayesian approach (Markov chain Monte Carlo sampling), so it is necessary to allow a burn-in
for the chain to converge before sampling an imputed data set. Rather than repeating the whole process
(including the burn-in) for each imputation, imputed data sets are sampled from the same chain by
specifying the number of iterations to be left between the samples taken. Prior to running the full
imputation, a dummy run was performed to check the chains for signs of non-convergence and to
determine a suitable burn-in and sampling interval. Based on these checks, a burn-in of 20,000 was
used for imputation of the data used to develop clinical characteristics models and was increased to
30,000 for data used to develop models additionally including biochemical markers or ultrasound
markers. After the burn-in, imputations were sampled every 1000 iterations, until 25 imputed data sets
had been sampled.
The imputation model included all potential predictors (for trimesters 1 and 2) and outcomes
(early- and late-onset pre-eclampsia). Data were imputed separately (using different sets of data sets
and predictors) for developing models including only maternal and clinical characteristics, and then for
models additionally including biochemical markers or ultrasound markers.
For models with maternal and clinical characteristics, data were imputed for SBP and DBP rather than
MAP, as MAP simply combines SBP and DBP and, therefore, imputing them separately would provide
more flexibility in how they can be modelled subsequently. A preliminary complete-case analysis was
performed to look for potential non-linear relationships between potential predictors and outcomes
using multivariable fractional polynomial models. This led to BMI being considered on the original
scale, as well as non-linearly using the natural logarithm transformation [ln(BMI)] and BMI–2. Data sets
were imputed assuming each of these functions for BMI to enable non-linearity to be considered during
model development. Biochemical markers and ultrasound markers were considered on their original
scale and on the log-transformed scale (which was decided a priori), and therefore data sets were
imputed separately for the transformed and the original biochemical markers or ultrasound markers.
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After imputation, the distributions of values for variables were checked by plotting the mean ± SD for
continuous variables against the imputation number (including the original complete data, imputation
0, for reference). For categorical variables, the proportions in each category were compared across
imputations and with the original complete data. Methods for imputing for systematically missing
predictors are still relatively new and therefore a cautious approach was taken. If the distribution of
imputed values for a systematically missing predictor was unusual or extreme, then further examination
was done to check the plausibility of the imputation. Alongside this, convergence of the Markov chain
Monte Carlo samples was checked. If systematically missing predictor values could not reliably be
imputed for a variable in a particular data set (e.g. adequate convergence was not achieved even after
a long burn-in), then that data set was excluded from model development when that predictor would
be considered (e.g. first-trimester BMI in a first-trimester prediction model).
Model development and validation
Prediction models were developed using random intercept logistic regression with backward elimination
for variable selection. The random intercept was used to account for clustering of women within
individual data sets. At each stage of the variable selection process, the same model (i.e. including the
same predictors) was fitted to all imputations, and pooled Wald tests (using Rubin’s rules) were used for
backwards elimination, with a p-value of > 0.157 (proxy for Akaike information criterion) for exclusion.93,94
Models were developed separately for each pre-eclampsia outcome (any, early and late onset) using
predictors recorded at trimester 1 and separately at trimester 2. Furthermore, for each outcome
predicted at each trimester, three models were considered: using only clinical characteristics, using
clinical characteristics plus biochemical markers, and using clinical characteristics plus ultrasound
markers. Therefore, we aimed to develop 18 models in total (one for each combination of the three
outcomes, two trimesters and three predictor sets). We were unable to develop models that included
clinical characteristics, biochemical and ultrasound markers as no data sets included all relevant
predictors of interest.
For each model developed, its predictive performance was assessed in an internal validation using
study-specific and overall estimates of discrimination and calibration. After model development, the
fitted model (with the average intercept) was applied back into each individual data set to obtain,
for each participant, values of the LP and predicted probability of the pre-eclampsia outcome from the
developed model. These were then used to calculate the performance statistics described in External
validation of existing pre-eclampsia prediction models. For each data set, the ‘pool last’ approach was
followed, whereby imputation-specific performance statistics were calculated and then pooled across
imputations using Rubin’s rules and using a transformed scale where necessary (such as pooling logit
C-statistics).95 Calibration plots were also produced for data sets that had more than 100 events.
The predicted probability of pre-eclampsia for each individual was obtained by pooling the imputation-
specific estimates of the model’s LP and then applying the logit transformation.82
Summarising study-specific performance after model development is recommended by Royston et al.96
and Debray et al.,47 and gives an indication of how the model will perform with new data from
populations represented by the included studies. For each model developed, the data set-specific
performance statistics were summarised across the data sets using a random-effects meta-analysis,
in the same way as described in External validation of existing pre-eclampsia prediction models.
The performance statistics of models developed using different functional forms of BMI were
compared (in terms of overall predictive performance and homogeneity of performance across data
sets) after repeating the model development process in the imputed data sets for each functional form.
The model that provided the best overall predictive performance across the different statistics was
selected, thereby also selecting the functional form for BMI (if it remained in the model). The same
strategy of comparing performance statistics was used for models with biochemical markers and
ultrasound markers, to determine whether they should be modelled on their original scale or using a
natural logarithm transformation.
METHODS
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For each developed model, to correct for optimism during model development (also known as overfitting),
the predictor effects (beta estimates) were shrunk by multiplying each beta estimate by a global shrinkage
factor.97–99 The shrinkage factor was taken to be the summary calibration slope from the internal validation
process (i.e. the pooled calibration slope from the meta-analysis of data set-specific calibration slope
estimates). Bootstrapping was not practical computationally given the need to incorporate both non-
linear trend examinations, backwards selection, and multiple imputation (including for systematically
missing predictors). Following application of shrinkage, the model’s intercept was re-estimated to ensure
that predictions were correct on average. This then provided the final model equation.
For each of the final models, decision curves were produced within each data set included in model
development and validation. This shows the net benefit across different probability thresholds and
compares the use of the model with treat-all and treat-none strategies.
Summarising the prognostic effect of individual predictors of pre-eclampsia
For each outcome (early-onset pre-eclampsia, late-onset pre-eclampsia and any-onset pre-eclampsia)
and each candidate predictor (clinical, biochemical, and ultrasound marker) prioritised in Prioritisation of
predictors, we separately performed an unadjusted two-stage IPD meta-analysis of the prognostic effect
to obtain a summary estimate, 95% CI and 95% prediction interval for that predictor. The 95% prediction
interval presents the heterogeneity on the same scale as the original outcome and estimates where the
true effects are to be expected for similar exchangeable studies.100 We used the two-stage approach
because of the large numbers of studies.
The two-step approach first involves fitting a logistic regression model for each study to obtain the
odds ratio (OR) for the prognostic effect, and then pooling the log ORs using a conventional random-
effects meta-analysis. The random-effects model allows for heterogeneity between studies, and was
estimated using restricted maximum likelihood. The 95% CI of the pooled effect was derived using the
Hartung–Knapp approach.101,102 Heterogeneity was summarised using the I2-statistic (which provides the
proportion of total variability due to between-study heterogeneity) and 95% prediction intervals.100
The trend across multiple categories and continuous variables was considered linear.
A pragmatic decision was made to perform all analyses on complete cases of singleton pregnancies on the
IPPIC international data set only, that is, no statistical imputation method was carried out for missing
outcome or predictor data. This was because of the length of time it would take to impute and perform
pre- and post-imputation checks for the 78 data sets of the IPPIC international IPD, with different
combinations of predictors in each data set, with some data sets as large as 600,000 pregnancies. The
clustering of participants within data sets was accounted for by analysing each data set separately in the
first stage. Clustering of pregnancies by women was not accounted for because of the small number of
clusters of women who had been pregnant multiple times. Models were univariable and thus predictors
were not adjusted for. Adjustment would have reduced statistical power owing to missing observations
and would have distorted the combining of associations in the IPD second stage due to different
availability of adjustable variables by data set. The analysis excluded all women with multifetal pregnancies
(e.g. twins/triplets); however, we also explored the relationships between multiple birth as a predictor and
all pre-eclampsia outcomes.
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Chapter 4 Characteristics and quality of data
sets included in the individual participant data
meta-analysis
Study identification and individual participant data acquisition
One hundred and twenty-five researchers from 73 teams in 25 countries had joined the IPPIC
network by October 2017 and provided access to pseudonymised individual data for 3,674,684
pregnancies.42,103–178 The most common reason for not obtaining the IPD was not receiving a response
from the author to the request to share data (28/180) (Figure 2).
Our search up to September 2014 of reviews that evaluated the performance of single or combined
tests for predicting pre-eclampsia identified 73 citations. After evaluation of the abstracts, we included
62 published reviews evaluating one or more tests for predicting pre-eclampsia (Table 2). Clinical
characteristics were studied in 32.3% (20/62) of published reviews, biochemical markers were studied
in 59.7% (37/62) and ultrasound markers were studied in 8.1% (5/62).
Characteristics of data sets in the IPPIC data repository
Seventy-eight data sets contributed data to the IPPIC data repository.42,103–178 More than half of the
data sets received (58%, 45/78) were prospective cohort studies; 15% (12/78) were randomised







Total number of studies identified from systematic review
of clinical characteristics, biochemical and ultrasound
markers in the prediction of early and any onset pre-
eclampsia and recommendation from collaborative groups
(n = 180)
Studies for which IPD were not obtained
(n = 102) 
• No response, n = 28
• IPD still being processed for transfer by October 2017 deadline, n = 25
• Mail delivery failure, n = 18
• Study still ongoing, n = 9
• Contact lost, n = 7
• IPD part of another cohort, n = 6
• Refused to share IPD, n = 4
• Lack of time to share IPD, n = 3
• Data from IPD lost, n = 2
FIGURE 2 Flow diagram of studies included in the IPD meta-analysis, showing reasons why IPD were not obtained.
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TABLE 2 Review of reviews on predictors of pre-eclampsia
Systematic review




women Risk factors evaluated Outcome reported
Maternal clinical characteristics
Cnossen 2007179 36 1,699,073 BMI Any-onset pre-eclampsia
O’Brien 2003180 13 1,400,000 Any-onset pre-eclampsia
Wang 2013181 29 1,980,761 Any-onset pre-eclampsia
Duckitt 2005182 2 64,789 Multiple clinical features Any-onset pre-eclampsia
Alpoim 2013183 2 1875 ABO blood group status Early-onset pre-eclampsia
England 2007184 48 N/A Smoking Early-onset pre-eclampsia
Rebelo 2013185 23 4265 CRP, BMI Any-onset pre-eclampsia
Duckitt 2005182 2 37,988 Parity Any-onset pre-eclampsia
Luo 2007186 26 N/A Any-onset pre-eclampsia
Duckitt 2005182 2 65,314 Age Any-onset pre-eclampsia
Duckitt 2005182 2 907 Blood pressure Any-onset pre-eclampsia
Cnossen 2008187 34 60,599 Any-onset pre-eclampsia
Sgolastra 2013188 15 5023 Periodontal disease Any-onset pre-eclampsia
Kunnen 2010189 15 N/A Early-onset pre-eclampsia
Morris 2012190 20 2978 Proteinuria Any-onset pre-eclampsia
Sanchez-Ramos
2013191
24 3186 Early-onset pre-eclampsia
Wolf 2014192 11 5411 Leisure-time physical activity Any-onset pre-eclampsia
Palmer 2013193 11 N/A Occupational exposures Any-onset pre-eclampsia
Bonzini 2007194 9 N/A Any-onset pre-eclampsia
Cnossen 2006195 5 572 Uric acid Any-onset pre-eclampsia
Uterine artery Doppler ultrasound
Velauthar 201439 18 55,974 First-trimester Doppler Early-onset pre-eclampsia
Chien 2000196 27 12,994 Any-trimester Doppler Any-onset pre-eclampsia
Cnossen 200863 74 79,547 Any-onset pre-eclampsia
Kleinrouweler
2013197
8 6708 Second-trimester Doppler Early-onset pre-eclampsia




Kosmas 2003199 19 5145 Factor V Leiden Any-onset pre-eclampsia
Dudding 2008200 6 6755 Any-onset pre-eclampsia
Rodger 2010201 10 21,833 Any-onset pre-eclampsia
Xia 2012202 36 9203 MTHFR gene C677T
polymorphism
Any-onset pre-eclampsia
Kosmas 2004203 23 6213 Any-onset pre-eclampsia
Zusterzeel 2000204 4 579 Any-onset pre-eclampsia
Li 2014205 49 18,009 Any-onset pre-eclampsia
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TABLE 2 Review of reviews on predictors of pre-eclampsia (continued )
Systematic review




women Risk factors evaluated Outcome reported
Wang 2013206 51 17,749 Any-onset pre-eclampsia
Widmer 2007207 10 1173 sFlt-1 Early-onset pre-eclampsia
Jacobs 2011208 11 N/A Early-onset pre-eclampsia
Kleinrouweler 201265 19 6708 Early-onset pre-eclampsia
Widmer 2007207 14 2045 PIGF Early-onset pre-eclampsia
Kleinrouweler 201265 27 N/A Any-onset pre-eclampsia
Huppertz 2013209 19 16,153 PP13 Early-onset pre-eclampsia
Schneuer 2012210 7 2989 Early-onset pre-eclampsia
Lau 2013211 41 1940 TNF-alpha, IL-6 and IL-10 Any-onset pre-eclampsia
Tabesh 2013212 8 2485 Serum vitamin D Any-onset pre-eclampsia
Morgan 2013213 12 5003 PAI-1 promoter polymorphism Any-onset pre-eclampsia
Dai 2013214 29 3228 eNOS polymorphisms Any-onset pre-eclampsia
Chen 2012215 18 N/A Any-onset pre-eclampsia
Qi 2013216 33 10,671 Any-onset pre-eclampsia
Zhao 2013217 11 3088 PAI-1 promoter polymorphism Any-onset pre-eclampsia
Zhao 2012218 8 1995 AGTR1 +1166A>C
polymorphism
Any-onset pre-eclampsia
Zhong 2012219 11 1749 ACE I/D polymorphism Any-onset pre-eclampsia
Chen 2012215 30 8340 Any-onset pre-eclampsia
Ni 2012220 22 7534 AGT M235T polymorphism Any-onset pre-eclampsia
Kleinrouweler 201265 3 N/A VEGF Any-onset pre-eclampsia
Hui 2012221 37 115,290 Wide range of serum markers Any-onset pre-eclampsia
Giguere 2011222 37 N/A 71 different markers Early-onset pre-eclampsia
Abou-Nassar 2011223 28 5991 Antiphospholipid antibodies Any-onset pre-eclampsia
do Prado 2010224 12 7950 Any-onset pre-eclampsia
Gupta 2009225 17 745 Lipid peroxidation Any-onset pre-eclampsia
Bombell 2008226 16 2374 TNF (–308A) polymorphism Any-onset pre-eclampsia
Zafarmand 2008227 17 5275 Angiotensinogen gene M235T
polymorphism
Any-onset pre-eclampsia
Morris 200868 44 169,637 Inhibin A, AFP and three
others
Any-onset pre-eclampsia
Wiwanitkit 2006228 6 1690 PAI-1 Any-onset pre-eclampsia
Leeflang 200766 5 573 FFN Any-onset pre-eclampsia
ACE, angiotensin-converting enzyme; AFP, alpha-fetoprotein; CRP, C-reactive protein; FFN, fetal fibronectin;
IL-6, interleukin 6; IL-10, interleukin 10; N/A, not applicable; PAI-1, plasminogen activator inhibitor-1; PP13, placental
protein 13; TNF, tumour necrosis factor; VEGF, vascular endothelial growth factor.
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was IPD made up of 31 RCTs. Most of the data sets were from participants in Europe (60%, 47/78),
18% (14/78) were from North America, 6% (5/78) were from South America, 5% (4/78) were from
Asia and Australia, and one (1%) was from Africa. Three of the data sets provided included participants
from multiple countries, such as Argentina, Colombia, Kenya, India, Peru, Thailand and New Zealand.
Ninety-seven per cent (3,570,993) of the 3,674,684 pregnancies in the IPPIC repository were singleton
pregnancies. Individual data set size ranged from 42 to 1,663,167 pregnancies, and the total number of
reported pre-eclampsia outcomes in each data set ranged from 0 to 4252 for early-onset pre-eclampsia,
from 0 to 38,305 for late-onset pre-eclampsia and from 3 to 42,608 for any-onset pre-eclampsia
(see Appendix 4). About one-third of the data sets received were on women with high-risk pregnancies
only (29%, 23/78), 14% (11/78) of the data sets were on women with low-risk pregnancies and more
than half (55%, 43/78) of the data sets included women with pregnancies of any risk. Detailed study
characteristics of all IPPIC data sets are provided in Appendix 5 and a summary of the missing data for
prioritised predictors and each pre-eclampsia outcome is provided in Appendix 6.
Prioritisation of predictors of pre-eclampsia
In April 2017, the online survey was designed and run using smartsurvey.co.uk (see Appendix 7).
Ninety-eight members of the IPPIC collaborative network who had agreed to share data by this date
were sent an e-mail introducing the survey and explaining the participation requirements and survey
objectives. Collaborators had 7 days within which to complete the online survey.
Fifty-four candidate predictor variables were identified (37 clinical characteristics, nine biochemical
markers and eight ultrasound markers) and ranked by 33 (34%) IPPIC collaborators. Seventy per cent
(23/33) of responders were from Europe, 12% were from both the American (4/33) and Asian (4/33)
continents, and 6% (2/33) were from Africa. A consensus group made up of five clinical academics
reviewed 13 candidate predictor variables ranked by the online survey participants as being ‘moderately
important’. This included eight clinical characteristic variables, two biochemical markers and three
ultrasound markers. Two each of the clinical characteristic variables and ultrasound markers reviewed
by the consensus group (mode of conception, substance misuse in current pregnancy, umbilical artery
pulsatility index and estimated fetal weight centile) were included following assessment by the group.
Overall, fewer than half (48%, 26/54) of all assessed predictors were ranked as being important, with
54% (20/37) of clinical characteristics, 33% (3/9) of biochemical markers and 38% (3/8) of ultrasound
markers being prioritised as important in predicting pre-eclampsia (Table 3).
Quality of the IPPIC data sets
Risk-of-bias assessment using the PROBAST resulted in 77% (60/78) of the included IPD data sets
being classified as having an overall low risk of bias, while 22% (17/78) were classified as having an
unclear risk of bias. Only one data set (1%, 1/78) received an overall high risk of bias assessment. All of
the included data sets had a low risk of bias in the domain of participant selection. For the domain of
predictors, 94% (73/78) had a low risk of bias, while 1% (1/78) had a high and 5% (4/78) an unclear
risk of bias assessment. The risk of bias in the outcome domain was unclear for 22% (17/78) of the
included data sets and low in the rest (78%, 61/78). Detailed assessment of the risk of bias for the
IPPIC data sets is presented in Appendix 8.
Characteristics of identified prediction models
From our updated literature search (up to December 2017), we identified 131 models developed to
predict pre-eclampsia. About half of these (53%, 70/131) reported the model equation in the publication,
CHARACTERISTICS AND QUALITY OF DATA SETS
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TABLE 3 Predictors of pre-eclampsia prioritised by online survey and consensus meeting
Important Unimportant
Clinical characteristics
Previous any pre-eclampsia Previous miscarriage
Chronic or pre-existing hypertension History of early pregnancy bleeding in current pregnancy
SBP Alcohol use
BMI Diet in pregnancy
DBP Physical activity
Parity Interval between pregnancies
History of renal disease Family history of cardiovascular disease
Multiple pregnancy History of gestational diabetes
History of pre-existing diabetes Gestational diabetes in current pregnancy
Age Socioeconomic status
Previous autoimmune disease Previous stillbirth
Family history of pre-eclampsia in first degree relative Previous preterm delivery






Substance misuse in current pregnancy
Ethnicity
Ultrasound markers
Uterine artery pulsatility index CRL
Umbilical artery pulsatility index Umbilical artery resistance index
Estimated fetal weight centile Abdominal circumference
Notching on ultrasound scan








AFP, alpha-fetoprotein; CRL, crown–rump length; CRP, C-reactive protein; PAI-1, plasminogen activator inhibitor-1;
PCR, protein–creatinine ratio; sENG, soluble endoglin; SGA, small for gestational age.
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and only one-fifth of all models (18%, 24/131) from 12 publications met the inclusion criteria for the
external validation of their predictive performance in the IPPIC-UK data sets.115,128,147,229–237 The primary
reasons for not including a model for external validation were the full prediction formula not being
reported in the publication (47%, 61/131) and the absence of the predictor information in the IPPIC-UK
data sets (27%, 35/131). Other reasons for not validating the models include pre-eclampsia being poorly
defined in the study (8%, 10/131) and not enough events in the IPPIC-UK data set to validate the model
(1%, 1/131). Figure 3 is the flow chart of prediction model selection for external validation, and Appendix 9
shows published pre-eclampsia prediction models reporting a model equation.
Previous systematic review of
pre-eclampsia prediction models
(MEDLINE up to 1 July 2012)
(n = 45 articles; 76 models) 
Prediction models identified for external validation
(n = 24) 
• Any-onset pre-eclampsia, n = 8
• Early-onset pre-eclampsia, n = 9
• Late-onset pre-eclampsia, n = 7
Update of search (MEDLINE
July 2012–December 2017)
(n = 1673 articles) 
Full-text articles assessed for
eligibility
(n = 57) 
Prediction models identified
(n = 55 models) 
Excluded after screening 
full-text articles
(n = 31) 
Excluded after screening 
titles and abstract
(n = 1616) 
Articles included
(n = 26) 
Total number of models identified
(n = 131 models)  
Models excluded
 (n = 107)
• Pre-eclampsia outcome poorly defined, n = 10
• Full model equation not reported in article, n = 61
• Models with predictors systematically missing in IPD, n = 35
• Too few events in IPPIC-UK data sets for validation, n = 1
FIGURE 3 Flow chart of pre-eclampsia prediction model selection for external validation in IPPIC-UK data set using
IPD meta-analysis. Reproduced from Snell et al.52 Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium
or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons licence, and indicate if changes were made. The images or other third party material in this article are included
in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not
included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or
exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this
licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated in a credit line to the data.
CHARACTERISTICS AND QUALITY OF DATA SETS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
22
Chapter 5 External validation of existing
pre-eclampsia prediction models
Characteristics of included prediction models
We identified 24 prediction models that could be externally validated in the IPPIC-UK cohorts. Eight
models predicted any-onset pre-eclampsia, nine models predicted early-onset pre-eclampsia and seven
models predicted late-onset pre-eclampsia. About half of these models (13/24, 54%) were developed in
unselected singleton pregnancies at any risk of pre-eclampsia. Two-thirds of the models included only
clinical characteristics as predictors (15/24, 63%), one-fifth (5/24, 21%) included clinical characteristics
and biochemical markers, and one-sixth (4/24, 17%) included clinical characteristics and ultrasound
markers. It was not possible to validate any of the models that included all three predictor categories
(clinical characteristics, biochemical markers and ultrasound markers).
The majority of models (22/24, 92%) were developed using binary logistic regression. The two models
by Wright et al.236 modelled the outcome of ‘gestational age at delivery with pre-eclampsia’ using
competing risks models. The models by Wright et al.236 used pre-eclampsia before 34 weeks to
define early-onset pre-eclampsia. Over 80% of the models that we validated involved first-trimester
predictors (88%, 21/24); only three included second-trimester predictors. Details of the validated
models are given in Table 4.
TABLE 4 Pre-eclampsia prediction model equations externally validated in the IPPIC-UK data sets
Model
number Authors, year Predictor category Prediction model equation for LPa
First-trimester any-onset pre-eclampsia models
1 Plasencia et al.,
2007231
Clinical characteristics LP= –6.253+ 1.432 (if African Caribbean ethnicity)+
1.465 (if mixed ethnicity)+ 0.084 (BMI)+ 0.81 (if patient’s
mother had PE) – 1.539 (if parous without previous PE)+
1.049 (if parous with previous PE)
2 Poon et al., 2008233 Clinical characteristics LP = –6.311 + 1.299 (if African Caribbean ethnicity) +
0.092 (BMI) + 0.855 (if woman’s mother had PE) –
1.481 (if parous without previous PE) + 0.933
(if parous with previous PE)
3 Wright et al., 2015236 Clinical characteristics Mean gestational age at delivery with PE= 54.3637 –
0.0206886 (age, years – 35, if age ≥ 35) + 0.11711
(height, cm – 164) – 2.6786 (if African Caribbean
ethnicity) – 1.129 (if South Asian ethnicity) – 7.2897
(if chronic hypertension) – 3.0519 (if systemic lupus
erythematosus or antiphospholipid syndrome) – 1.6327
(if conception by in vitro fertilisation) – 8.1667 (if
parous with previous PE) + 0.0271988 (if parous with
previous PE, previous gestation in weeks – 24)2 – 4.335
(if parous with no previous PE) – 4.15137651 (if parous
with no previous PE, interval between pregnancies in
years)–1 + 9.21473572 (if parous with no previous PE,
interval between pregnancies in years)–0.5 – 0.0694096
(if no chronic hypertension, weight in kg – 69) – 1.7154
(if no chronic hypertension and family history of PE) –
3.3899 (if no chronic hypertension and diabetes
mellitus type 1 or 2)
continued
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TABLE 4 Pre-eclampsia prediction model equations externally validated in the IPPIC-UK data sets (continued )
Model
number Authors, year Predictor category Prediction model equation for LPa




LP = –8.72 + 0.157 (if nulliparous) + 0.341 (if history of
hypertension) + 0.635 (if prior PE)+ 0.064 (MAP) –
0.186 (PAPP-A, Ln MoM)




LP = –3.25 + 0.51 (if PAPP-A < 10th percentile)+ 0.93
(if BMI > 25) + 0.94 (if chronic hypertension)+ 0.97
(if diabetes) + 0.61 (if African American ethnicity)
6 Odibo et al., 2011147 Clinical characteristics
and biochemical markers
LP = –3.389 – 0.716 (PAPP-A, MoM) + 0.05 (BMI)+
0.319 (if black ethnicity) + 1.57 (if history of chronic
hypertension)
7 Odibo et al., 2011147 Clinical characteristics
and ultrasound markers
LP = –3.895 – 0.593 (mean uterine artery PI) + 0.944
(if pre-gestational diabetes) + 0.059 (BMI) + 1.532
(if history of chronic hypertension)
First-trimester early-onset pre-eclampsia models
8 Baschat et al.,
2014115
Clinical characteristics LP= –5.803+ 0.302 (if diabetes)+ 0.767 (if hypertension)
+ 0.00948 (MAP)
9 Crovetto et al.,
2015229
Clinical characteristics LP = –5.177 + 2.383 (if black ethnicity) – 1.105
(if nulliparous)+ 3.543 (if parous with previous
PE) + 2.229 (if chronic hypertension) + 2.201
(if renal disease)
10 Kuc et al., 2013230 Clinical characteristics LP = –6.790 – 0.119 (maternal height, cm)+ 4.8565
(maternal weight, Ln kg) + 1.845 (if nulliparous) +
0.086 (maternal age, years)+ 1.353 (if smoker)
11 Plasencia et al.,
2007231
Clinical characteristics LP = –6.431 + 1.680 (if African Caribbean ethnicity)
+ 1.889 (if mixed ethnicity) + 2.822 (if parous with
previous PE)
12 Poon et al., 2010232 Clinical characteristics LP = –5.674 + 1.267 (if black ethnicity) + 2.193
(if history of chronic hypertension) – 1.184 (if parous
without previous PE) + 1.362 (if parous with previous
PE) + 1.537 (if conceived with ovulation induction)
13 Scazzocchio et al.,
2013235
Clinical characteristics LP = –7.703 + 0.086 (BMI)+ 1.708 (if chronic
hypertension) + 4.033 (if renal disease)+ 1.931
(if parous with previous PE) + 0.005 (if parous with
no previous PE)
14 Wright et al., 2015236 Clinical characteristics Same as model 3
15 Poon et al., 2009234 Clinical characteristics
and biochemical markers
LP = –6.413 – 3.612 (PAPP-A, Ln MoM) + 1.803
(if history of chronic hypertension)+ 1.564 (if black
ethnicity) – 1.005 (if parous without previous PE) +
1.491 (if parous with previous PE)
First-trimester late-onset pre-eclampsia models
16 Crovetto et al.,
2015229
Clinical characteristics LP = –5.873 – 0.462 (if white ethnicity) + 0.109
(BMI) – 0.825 (if nulliparous) + 2.726 (if parous with
previous PE) + 1.956 (if chronic hypertension) – 0.575
(if smoker)
17 Kuc et al., 2013230 Clinical characteristics LP = –14.374 + 2.300 (maternal weight, Ln kg) + 1.303
(if nulliparous)+ 0.068 (maternal age, years)
18 Plasencia et al.,
2007231
Clinical characteristics LP = –6.585 + 1.368 (if African Caribbean ethnicity)
+ 1.311 (if mixed ethnicity) + 0.091 (BMI)+ 0.960
(if woman’s mother had PE) – 1.663 (if parous without
previous PE)
19 Poon et al., 2010232 Clinical characteristics LP = –7.860 + 0.034 (maternal age, years)+ 0.096
(BMI) + 1.089 (if black ethnicity) + 0.980 (if Indian or
Pakistani ethnicity) + 1.196 (if mixed ethnicity) + 1.070
(if woman’s mother had PE) – 1.413 (if parous without
previous PE) + 0.780 (if parous with previous PE)
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Characteristics of the IPPIC-UK validation cohorts
Of the 78 data sets in IPPIC repository, 15 (19%, 15/78) were UK data sets. About three-quarters
(73%, 11/15) of IPPIC-UK cohorts contained relevant data needed for external validation.42,103,108,114,121,
122,137,149,150,161,163 Four data sets106,112,137,177 did not include the predictor needed to validate the published
prediction models.
TABLE 4 Pre-eclampsia prediction model equations externally validated in the IPPIC-UK data sets (continued )
Model
number Authors, year Predictor category Prediction model equation for LPa
20 Scazzocchio et al.,
2013235
Clinical characteristics LP = 6.135 + 2.124 (if previous PE) + 1.571 (if chronic
hypertension) + 0.958 (if diabetes) + 1.416
(if thrombophilic condition) – 0.487 (if multiparous)
+ 0.093 (BMI)
21 Poon et al., 2009234 Clinical characteristics
and biochemical markers
LP = –6.652 – 0.884 (PAPP-A, Ln MoM) + 1.127
(if family history of PE)+ 1.222 (if black ethnicity) +
0.936 (if Indian or Pakistani ethnicity) + 1.335 (if mixed
ethnicity) + 0.084 (BMI) – 1.255 (if parous without
previous PE)+ 0.818 (if parous with previous PE)
Second-trimester any-onset pre-eclampsia models
22 Yu et al., 2005238 Clinical characteristics
and ultrasound markers
LP = 1.8552 + 5.9228 (mean uterine artery PI)–2 –
14.4474 (mean uterine artery PI)–1 = – 0.5478
(if smoker) + 0.6719 (bilateral notch) + 0.0372 (age)
+ 0.4949 (if black ethnicity) + 1.5033 (if history of
PE) – 1.2217 (if previous term live birth) + 0.0367
(T2 BMI)
Second-trimester early-onset pre-eclampsia models
23 Yu et al., 2005238 Clinical characteristics
and ultrasound markers
LP = –9.81223 + 2.10910 (mean uterine artery PI)3 –
1.79921 (mean uterine artery PI)3 + 1.059463
(if bilateral notch)
Second-trimester late-onset pre-eclampsia models
24 Yu et al., 2005238 Clinical characteristics
and ultrasound markers
LP = 0.7901 + 5.1473 (mean uterine artery PI)–2 –
12.5152 (mean uterine artery PI)–1 – 0.5575
(if smoker) + 0.5333 (if bilateral notch) + 0.0328
(age)+ 0.4958 (if black ethnicity) + 1.5109 (if history
of PE) + 1.1556 (if previous term live birth) + 0.0378
(BMI)
PE, pre-eclampsia; MoM, multiple of the mean; PI, pulsatility index.
a For logistic regression, logit(p) = LP, where the LP = α + β1 × x1 + β2 × x2 + . . ., and absolute predicted probabilities (p)
can be obtained using the transformation shown in Equation 1. The model for ‘mean gestational age at delivery with
PE’ assumes a normal distribution with the predicted mean gestational age and SD 6.8833. The risk of delivery with
PE is then calculated as the area under the normal curve between 24 weeks and either 42 weeks for any-onset PE
(model 3) or 34 weeks for early-onset PE (model 14). For more detail, see Wright et al.236
Ln indicates that a variable was modelled on the natural logarithm scale.
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Four of the included IPPIC-UK studies were prospective cohorts,42,108,161 three were prospective registry
data sets103,114,163 and four were cohorts (control arm) from randomised trials.121,122,149,150 All studies
reported on early-, late- and any-onset pre-eclampsia. About half of the included IPPIC-UK cohorts
consisted of unselected pregnant women (6/11); four included high-risk women such as those with
abnormal uterine artery Doppler measurement,121,137 history of pre-eclampsia or underlying medical
conditions150 and maternal obesity;122,149 one42 included only low-risk nulliparous women, and one161
included all nulliparous singleton pregnancies.
All women in the Screening for Pregnancy Endpoints (SCOPE)42 and Pregnancy Outcome Prediction
(POP)161 studies were nulliparous. The percentage of nulliparous women in the other data sets ranged
from 43% to 65%. Among the nine data sets with multiparous women, five recorded previous pre-
eclampsia with percentages ranging from 0%122 to 27%.150 The mean age was similar across studies.
The median BMI was higher in EMPOWaR,122 Poston et al. 2006150 and Poston et al. 2015149 than in
other studies. Most data sets that recorded ethnicity predominantly consisted of white women, apart
from Allen et al.108 and Velauthar et al.39 (47% and 50% Asian women, respectively). All data sets were
considered to be at low risk of bias for quality of participant selection (11/11, 100%); 91% (10/11) were
considered to be at low risk and 9% (1/11) were considered to be at unclear risk of bias for predictor
reporting; and 45% (5/11) were considered to be at low risk and 55% (6/11) were considered to be at
unclear risk of bias for outcome reporting (see Appendix 8).
Detailed study characteristics (see Appendix 5) and summary statistics for the data sets used for
external validation, along with a summary of the missing data for each predictor and outcome,
are provided in Appendices 10 and 11, respectively.
External validation and meta-analysis of predictive performance
We were able to externally validate each of the 24 published models in at least one and in up to eight
data sets. Initially, we could use only one data set of nulliparous women (SCOPE UK42) to validate
models 3 (Wright et al.236) and 14 (Wright et al.236) owing to a lack of information on ‘interval between
pregnancies’ in data sets. However, to increase the sample size available for validation (and the number
of events), we included nulliparous subgroups in other data sets for validating these models if all other
predictors were recorded. Models 3 (Wright et al.236) and 14 (Wright et al.236) were ‘competing risk’
models and did not provide LP values. Therefore, where necessary (e.g. for the assessment of calibration),
we used logit probabilities for validation and for comparison with the other models. We were able to
validate only models (22–24)238 with second-trimester predictors (Yu et al.238 for all three models) in the
POP study.161 We did not impute second-trimester predictors in the other data sets as these were not
recorded or were missing for a large proportion of individuals.
A summary of the LP and predicted probability distributions for each model and validation data set is
given in Appendix 12. Median predicted probabilities were generally low for models, which is expected
for a rare outcome. However, the median predicted probability in validation data sets was higher for
model 10 for early-onset pre-eclampsia and for model 17 for late-onset pre-eclampsia (Kuc et al.230
for both). The median predicted probability was 0.034–0.367 across validation data sets for model 10
(Kuc et al.230) and 0.063–0.310 across validation data sets for model 17 (Kuc et al.230).
Performance of the models
The summary (average) performance statistics across all validation data sets for each model are given
in Table 5 and data set-specific performance statistics in data sets with > 100 pre-eclampsia events are
provided for each model in Table 6. The summary performance statistics are also shown graphically for
all models in Figure 4. Direct comparison of the prediction models is difficult owing to different data
sets (and numbers of individuals and outcomes) contributing to the validation of each prediction model
(see Appendix 13).
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TABLE 5 Summary meta-analysis estimates of predictive performance for each model across validation data sets
Model




Summary estimate of performance statistic (95% CI); measures of heterogeneity
(I2, τ2 where possible to estimate)
C-statistica Calibration slope Calibration-in-the-large
Any-onset pre-eclampsia
Trimester 1 models
1 Clinical Plasencia et al., 2007231 3 102 0.686 (0.531 to 0.809);
I2 = 1%, τ2 = 0.001
0.693 (–0.026 to 1.413);
I2 = 45%, τ2 = 0.035
0.143 (–1.471 to 1.757);
I2 = 91%, τ2 = 0.38
2 Poon et al., 2008233 3 102 0.688 (0.533 to 0.810);
I2 = 3%, τ2 = 0.002
0.715 (–0.032 to 1.462);
I2 = 45%, τ2 = 0.037
0.002 (–1.653 to 1.657);
I2 = 92%, τ2 = 0.402
3 Wright et al., 2015236 3 76 0.624 (0.481 to 0.748);
I2 = 0%, τ2 = 0
0.642 (–0.182 to 1.467);
I2 = 0%, τ2 = 0
0.954 (–1.127 to 3.034);
I2 = 93%, τ2 = 0.640
4 Clinical and
biochemical markers
Baschat et al., 2014115 2 287 0.708 (0.467 to 0.870);
I2 = 0%, τ2 = 0
1.238 (0.000 to 2.475);
I2 = 0%, τ2 = 0
–0.427 (–14.405 to 13.551);
I2 = 98%, τ2 = 2.382
5 Goetzinger et al.,
2010128
3 343 0.659 (0.303 to 0.896);
I2 = 93%, τ2 = 0.315
1.124 (–0.595 to 2.843);
I2 = 76%, τ2 = 0.356
–0.965 (–3.041 to 1.111);
I2 = 97%, τ2 = 0.667
6 Odibo et al., 2011147 3 1774 0.715 (0.506 to 0.860);
I2 = 90%, τ2 = 0.101
1.163 (0.243 to 2.083);
I2 = 93%, τ2 = 0.104
–0.786 (–2.615 to 1.044);
I2 = 99%, τ2 = 0.511
7 Clinical and
ultrasound markers





















































































































































































































































































































































TABLE 5 Summary meta-analysis estimates of predictive performance for each model across validation data sets (continued )
Model




Summary estimate of performance statistic (95% CI); measures of heterogeneity
(I2, τ2 where possible to estimate)
C-statistica Calibration slope Calibration-in-the-large
Early-onset pre-eclampsia
Trimester 1 models
8 Clinical Baschat et al., 2014115 5 204 0.675 (0.617 to 0.728);
I2 = 0%, τ2 = 0
2.041 (0.560 to 3.522);
I2 = 69%, τ2 = 0.692
–0.102 (–1.699 to 1.494);
I2 = 97%, τ2 = 1.535
9 Crovetto et al., 2015229 3b 21 0.575 (0.208 to 0.875);
I2 = 69%, τ2 = 0.288
0.642 (–4.006 to 5.291);
I2 = 81%, τ2 = 0.217
–0.576 (–4.967 to 3.814);
I2 = 95%, τ2 = 2.925
10 Kuc et al., 2013230 6 1449 0.661 (0.613 to 0.706);
I2 = 32%, τ2 = 0.011
0.423 (0.294 to 0.552);
I2 = 33%, τ2 = 0.004
–4.330 (–5.411 to –3.250);
I2 = 99%, τ2 = 0.946
11 Plasencia et al., 2007231 4b 27 0.491 (0.429 to 0.553);
I2 = 38%, τ2 = 0.005
0.513 (–2.050 to 3.076);
I2 = 0%, τ2 = 0
0.472 (–0.797 to 1.740);
I2 = 74%, τ2 = 0.452
12 Poon et al., 2010232 3 21 0.636 (0.308 to 0.873);
I2 = 34%, τ2 = 0.105
0.991 (0.022 to 1.959);
I2 = 0%, τ2 = 0
–1.091 (–4.885 to 2.702);
I2 = 93%, τ2 = 2.175
13 Scazzocchio et al.,
2013235
3 21 0.743 (0.374 to 0.933);
I2 = 14%, τ2 = 0.057
0.751 (0.144 to 1.358);
I2 = 0%, τ2 = 0
–0.699 (–3.885 to 2.486);
I2 = 90%, τ2 = 1.481
14 Wright et al., 2015236 2 9 0.742 (0.040 to 0.995);
I2 = 0%, τ2 = 0
0.919 (–4.378 to 6.216);
I2 = 0%, τ2 = 0
0.282 (–14.337 to 14.900);
I2 = 90%, τ2 = 2.395
15 Clinical and
biochemical markers












































































Summary estimate of performance statistic (95% CI); measures of heterogeneity
(I2, τ2 where possible to estimate)
C-statistica Calibration slope Calibration-in-the-large
Late-onset pre-eclampsia
Trimester 1 models
16 Clinical Crovetto et al., 2015229 5 384 0.634 (0.461 to 0.778);
I2 = 87%, τ2 = 0.264
0.558 (–0.008 to 1.125);
I2 = 92%, τ2 = 0.179
–0.048 (–1.647 to 1.551);
I2 = 98%, τ2 = 1.615
17 Kuc et al., 2013230 8 5716 0.623 (0.572 to 0.671);
I2 = 87%, τ2 = 0.025
0.657 (0.496 to 0.818);
I2 = 60%, τ2 = 0.007
–1.911 (–2.235 to –1.586);
I2 = 98%, τ2 = 0.124
18 Plasencia et al., 2007231 3 90 0.672 (0.539 to 0.782);
I2 = 0%, τ2 = 0
0.612 (0.042 to 1.182);
I2 = 14%, τ2 = 0.008
0.202 (–1.113 to 1.517);
I2 = 85%, τ2 = 0.234
19 Poon et al., 2010232 3 90 0.647 (0.475 to 0.787);
I2 = 25%, τ2 = 0.020
0.565 (0.081 to 1.050);
I2 = 0%, τ2 = 0
0.121 (–1.594 to 1.837);
I2 = 91%, τ2 = 0.430
20 Scazzocchio et al.,
2013235
1 26 0.597 (0.478 to 0.705) 0.562 (–0.168 to 1.291) 0.524 (0.128 to 0.920)
21 Clinical and
biochemical markers




Yu et al., 2005238 1 263 0.607 (0.570 to 0.642) 0.077 (0.005 to 0.148) NE
NE, not estimable.
a The C-statistic was pooled on the logit scale; therefore, I2 and τ2 are for logit(C-statistic).
b Number of studies is one fewer for calibration slope of models 9 and 11. The calibration slope could not be estimated reliably in SCOPE UK and was, therefore, excluded from the
meta-analysis.
Reproduced from Snell et al.52 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation,
distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons
licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise
in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative
Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit



























































































































































































































































































































































Performance statistic (95% CI)
C-statistic Calibration slope Calibration-in-the-large
Trimester 1 any-onset pre-eclampsia models




POP161 4212 273 (6.5) 0.704 (0.670 to 0.737) 1.237 (1.034 to 1.439) 0.658 (0.533 to 0.782)
5 Goetzinger et al.,
2010128
POP161 4212 273 (6.5) 0.764 (0.730 to 0.795) 1.706 (1.499 to 1.913) –0.070 (–0.195 to 0.054)
6 Odibo et al.,
2011147
St George’s163 54,635 1487 (2.7) 0.672 (0.654 to 0.690) 0.962 (0.885 to 1.039) –0.897 (–0.950 to –0.845)
POP161 4212 273 (6.5) 0.779 (0.744 to 0.812) 1.490 (1.329 to 1.651) –0.033 (–0.159 to 0.094)
Trimester 1 early-onset pre-eclampsia models
8 Baschat et al.,
2014115
Clinical Poston et al.
2006150
2422 144 (6.0) 0.672 (0.626 to 0.716) 1.281 (0.898 to 1.664) 1.797 (1.628 to 1.967)
10 Kuc et al., 2013230 St George’s163 54,635 151 (0.3) 0.635 (0.587 to 0.679) 0.343 (0.227 to 0.460) –4.510 (–4.674 to –4.347)
AMND114 136,635 1237 (0.9) 0.681 (0.665 to 0.696) 0.470 (0.430 to 0.511) –3.387 (–3.445 to –3.330)
Trimester 1 late-onset pre-eclampsia models
16 Crovetto et al.,
2015229
Clinical POP161 4212 263 (6.2) 0.781 (0.745 to 0.813) 1.248 (1.120 to 1.376) 1.309 (1.177 to 1.441)
17 Kuc et al., 2013230 ALSPAC103 14,344 266 (1.9) 0.657 (0.616 to 0.696) 0.761 (0.550 to 0.973) –1.574 (–1.699 to –1.448)
St George’s163 54,635 1336 (2.4) 0.636 (0.621 to 0.651) 0.632 (0.560 to 0.704) –1.970 (–2.025 to –1.915)
AMND114 136,635 3733 (2.7) 0.844 (0.640 to 0.943) 0.746 (0.449 to 1.042) –1.439 (–2.092 to –0.787)
POP161 4212 263 (6.2) 0.599 (0.561 to 0.636) 0.673 (0.452 to 0.894) –1.487 (–1.613 to –1.361)
Trimester 2 any-onset pre-eclampsia models
22 Yu et al., 2005238 Clinical and
ultrasound
POP161 4212 273 (6.5) 0.610 (0.574 to 0.645) 0.075 (0.007 to 0.144) NE
Trimester 2 late-onset pre-eclampsia models
24 Yu et al., 2005238 Clinical and
ultrasound
POP161 4212 263 (6.2) 0.607 (0.570 to 0.642) 0.077 (0.005 to 0.148) NE
AMND, Aberdeen Maternity and Neonatal Databank; NE, not estimable owing to perfect prediction (same predicted probability for all individuals who had the event).













































































22: Yu, 2005238 0.61 (0.57 to 0.64)     1
0.53 (0.39 to 0.66)     1
0.71 (0.51 to 0.86)     3
0.66 (0.30 to 0.90)     3
0.71 (0.47 to 0.87)     2
0.62 (0.48 to 0.75)     3
0.69 (0.53 to 0.81)     3









































0.67 (0.62 to 0.73)     5
0.57 (0.21 to 0.87)     3
0.66 (0.61 to 0.71)     6
0.49 (0.43 to 0.55)     4
0.64 (0.31 to 0.87)     3
0.74 (0.37 to 0.93)     3
0.74 (0.04 to 0.99)     2
0.74 (0.51 to 0.89)     1



































FIGURE 4 Plot of the summary meta-analysis estimates and CIs of the C-statistic (pooled across IPPIC-UK validation data sets) for each prediction model. (a) Any-onset pre-eclampsia;
(b) early-onset pre-eclampsia; and (c) late-onset pre-eclampsia. This figure contains information from several sources.115,128,147,229–236,238 C, clinical characteristics only; C + B, clinical
















































































































































































































































































































































































0.63 (0.46 to 0.78)     5
0.62 (0.57 to 0.67)     8
0.67 (0.54 to 0.78)     3
0.65 (0.48 to 0.79)     3
0.60 (0.48 to 0.71)     1
0.68 (0.55 to 0.79)     1







FIGURE 4 Plot of the summary meta-analysis estimates and CIs of the C-statistic (pooled across IPPIC-UK validation data sets) for each prediction model. (a) Any-onset pre-eclampsia;
(b) early-onset pre-eclampsia; and (c) late-onset pre-eclampsia. This figure contains information from several sources.115,128,147,229–236,238 C, clinical characteristics only; C + B, clinical




































































First-trimester clinical characteristics only models
Two (Plasencia et al., model 1;231 Poon et al., model 2233) of the three first-trimester clinical
characteristics models were validated in three cohorts with total pre-eclampsia events > 100. The
summary C-statistics were low (< 0.7), and the summary calibration slopes were < 1 for both models.
First-trimester clinical and biochemical models
There was a sufficient number of pre-eclampsia events in total (> 100) for all three clinical and biochemical
first-trimester models (Baschat et al., model 4;115 Goetzinger et al., model 5;128 Odibo et al., model 6147).
Of these, only two models had summary C-statistics > 0.7; but only one model’s (Odibo et al., model 6147)
C-statistic had a lower limit of the 95% CI > 0.50. Their summary calibration slopes were > 1, indicating
potential underfitting with predictions that do not span a wide enough range of probabilities compared
with what is observed in the validation data sets. One model (Odibo et al., model 7147) including first-
trimester clinical and ultrasound predictors could be validated only in a data set with a very small number
of events (i.e. 28 pre-eclampsia outcomes).
When validated in individual cohorts that had at least 100 pre-eclampsia events, promising discrimination
was observed for all three models with C-statistics of 0.70 (Baschat et al., model 4115), 0.76 (Goetzinger
et al., model 5128) and 0.78 (Odibo et al., model 6147) in the POP study161 cohort of singleton nulliparous
women; the corresponding calibration slopes were 1.24, 1.71 and 1.49, indicating underfitting of risks
(range of predictions too narrow). Models 5 (Goetzinger et al.128) and 6 (Odibo et al.147) systematically
predicted risks that were too high in all of the validation data sets (calibration-in-the-large < 0).
Second-trimester models
Only one model (Yu et al., model 22238), which comprised clinical and ultrasound predictors, could be
validated. Both discrimination (C-statistic 0.61) and calibration slope were poor (0.075).
Early-onset pre-eclampsia
First-trimester clinical models
Of the seven models, only two (Baschat et al., model 8;115 Kuc et al., model 10230) could be validated in
data sets with adequate total numbers of pre-eclampsia events (> 100). Both had low discrimination,
with summary C-statistics < 0.7; the calibration was poor, with calibration slopes of 2.04 and 0.42,
respectively.
The performance of the two models (Baschat et al., model 8;115 Kuc et al., model 10230) in individual
cohorts with event size > 100 was low, with C-statistics ranging from 0.63 to 0.68; the calibration
slope estimate was either too high (1.28) or too low (0.34, 0.47), respectively. Model 10230
systematically predicted too high in all their validation data sets (calibration-in-the-large < 0).
First-trimester clinical and biochemical models
The one model (Poon et al., model 15234) with clinical and biochemical first-trimester predictors had an
insufficient number of events (n = 10) to provide adequate validation.
Second-trimester models
One model (Yu et al., model 23238) comprising clinical and ultrasound markers had an insufficient
number of events (n = 10) to provide adequate validation.
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Two of the five models (Crovetto et al., model 16;229 Kuc et al., model 17230) were validated across
cohorts with total event sizes above 100 and had low summary C-statistics (< 0.7). The summary
calibration slope ranged from 0.56 to 0.80 for all five models. CIs were generally wide, with only a few
data sets for most model validations and small numbers of pre-eclampsia outcomes per meta-analysis
(see Figure 4).
When the performance of the two first-trimester clinical models was assessed within individual
cohorts with pre-eclampsia event numbers above 100, model 16 (Crovetto et al.229) showed promising
discrimination (C-statistic 0.78) and a calibration slope of 1.25 in the POP study. The other model
(Kuc et al.,230 model 17) showed low discrimination and poor calibration (C-statistic 0.60, calibration
slope 0.67) in the POP cohort, low discrimination in St George’s and ALSPAC cohorts (C-statistic 0.64
and 0.66, respectively), and high discrimination (C-statistic 0.84) with a calibration slope of 0.75 in the
Aberdeen Maternity and Neonatal Databank (AMND) cohort.103,114,161,163
First-trimester clinical and biochemical models
The one model (Poon et al., model 21234) with clinical and biochemical markers had an insufficient
number of pre-eclampsia events (n = 13) to provide adequate validation.
Second-trimester models
The only model (Yu et al., model 24238) with second-trimester clinical and ultrasound markers was
validated in a single data set (263 events) and showed low C-statistic (0.61) and poor calibration
(calibration slope 0.08).
Heterogeneity
Where it was possible to estimate it, heterogeneity across studies varied from small (e.g. models 1, 2
and 3 had I2 ≤ 3%, τ2 ≤ 0.002) to large (e.g. models 5 and 6 had I2 ≥ 90%, τ2 ≥ 0.1) for the C-statistic
(on the logit scale), and from moderate to large in the calibration slope for two-thirds of all models (17/24).
All models validated in multiple IPD data sets had high levels of heterogeneity in calibration-in-the-large
performance, with the I2 often > 90% (see Table 5).
For the majority of models (67%, 16/24), the summary calibration slope was ≤ 0.7. Although this could
be a result of chance for some models (95% CIs include 1), it is likely to suggest overfitting in the
model development (as the ideal value is 1, and values < 1 indicate predictions that are too extreme)
(Figure 5). The exceptions to this were models 4, 5 and 6 (for any-onset pre-eclampsia) and model 8
(for early-onset pre-eclampsia).
Many of the models did not have summary calibration-in-the-large values close to zero, and, even if the
average is near zero, this could be due to it performing poorly in the individual validation data sets and
averaging out near zero, such as for models 2, 8 and 16.
The predictive performance is likely to be optimistic in small development studies with few pre-eclampsia
events, and predictor effects will be too large. If not corrected for (e.g. by penalisation/shrinkage methods),
this will result in predictions that are too extreme when validated (hence calibration slope < 1); in other
words, the predictor effects will not be as strong as they were thought to be at model development.
By indicating whether predictions are systematically too high or too low, calibration-in-the-large may
suggest the need for recalibration of the model intercept. There was very large uncertainty in the summary
estimates of calibration-in-the-large for most models, which reflects often small numbers of events and
large heterogeneity across the individual data sets contributing towards the validation (Figure 6).
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0.69 (−0.03 to 1.41)     3
0.72 (−0.03 to 1.46)     3
0.64 (−0.18 to 1.47)     3
1.24 (−0.00 to 2.48)     2
1.12 (−0.60 to 2.84)     3
1.16 (0.24 to 2.08)        3
0.28 (−0.64 to 1.19)     1
0.08 (0.01 to 0.14)        1















































2.04 (0.56 to 3.52)      5
0.42 (0.29 to 0.55)      6
0.99 (0.02 to 1.96)      3
0.75 (0.14 to 1.36)      3
0.45 (0.21 to 0.69)      1
0.56 (0.29 to 0.82)      1
0.92 (−4.38 to 6.22)   2
0.64 (−4.01 to 5.29)   2







FIGURE 5 Plot of the summary meta-analysis estimates and CIs of calibration (pooled across IPPIC-UK validation data sets) for each prediction model. (a) Any-onset pre-eclampsia;
(b) early-onset pre-eclampsia; and (c) late-onset pre-eclampsia. This figure contains information from several sources.115,128,147,229–236,238 C, clinical characteristics only; C + B, clinical















































































































































































































































































































































































0.56 (−0.01 to 1.12)     5
0.66 (0.50 to 0.82)        8
0.61 (0.04 to 1.18)        3
0.57 (0.08 to 1.05)        3
0.80 (0.26 to 1.34)        1
0.08 (0.01 to 0.15)        1








FIGURE 5 Plot of the summary meta-analysis estimates and CIs of calibration (pooled across IPPIC-UK validation data sets) for each prediction model. (a) Any-onset pre-eclampsia;
(b) early-onset pre-eclampsia; and (c) late-onset pre-eclampsia. This figure contains information from several sources.115,128,147,229–236,238 C, clinical characteristics only; C + B, clinical















































































included (n) Events (n) Trimester
Predictor
type
−5 −4 −3 −2 −1 0 1 2
30.14 (−1.47 to 1.76)
0.00 (−1.65 to 1.66)
0.95 (−1.13 to 3.03)
−0.43 (−14.40 to 13.55)
−0.97 (−3.04 to 1.11)
−0.79 (−2.62 to 1.04)








































































−0.10 (−1.70 to 1.49)
−0.58 (−4.97 to 3.81)
−4.33 (−5.41 to 3.25)
0.47 (−0.80 to 1.74)
0.28 (−14.34 to 14.90)
2.47 (1.72 to 3.23)
−2.67 (−3.35 to −1.99)
−0.70 (−3.89 to 2.49)
−1.09 (−4.89 to 2.70)







FIGURE 6 Plot of the summary meta-analysis estimates and CIs of calibration-in-the-large (pooled across IPPIC-UK validation datasets) for each prediction model. (a) Any-onset
pre-eclampsia; (b) early-onset pre-eclampsia; and (c) late-onset pre-eclampsia. This figure contains information from several sources.115,128,147,229–236,238 C, clinical characteristics only;
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−0.05 (−1.65 to 1.55)
−1.91 (−2.23 to −1.59)
0.20 (−1.11 to 1.52)
0.12 (−1.59 to 1.84)
0.52 (0.13 to 0.92)







FIGURE 6 Plot of the summary meta-analysis estimates and CIs of calibration-in-the-large (pooled across IPPIC-UK validation datasets) for each prediction model. (a) Any-onset
pre-eclampsia; (b) early-onset pre-eclampsia; and (c) late-onset pre-eclampsia. This figure contains information from several sources.115,128,147,229–236,238 C, clinical characteristics only;



































































To illustrate the general concern about poor calibration, calibration plots are presented for models
validated in data sets with > 100 events (Figures 7–9). These clearly show the extent of miscalibration,
with predicted outcome risk from the models being far greater than the observed probabilities across
the entire range of predicted risk in most cases. For any-onset pre-eclampsia, the exceptions to this
are model 4 (Baschat et al., 2014115) and model 5 (Goetzinger et al., 2010128), when validated in POP
(see Figure 7).161 Model 4 and model 5 predictions are too low for those at greatest risk. For early-onset
pre-eclampsia, model 8 (Baschat et al., 2014115), validated in Poston 2006150 (see Figure 8), shows that
predictions were all very low (all predicted probabilities < 3%) but the observed frequency of events
was higher (up to around 20%). Model 10 (Kuc et al., 2013230), validated in the St George’s cohort,163
predicted an average of near 50% for the highest risk group; however, their observed risk was still
very close to zero. For late-onset pre-eclampsia, model 16 (Crovetto et al., 2015229) underpredicted risk,
particularly in those at highest risk in POP,161 and model 17 (Kuc et al., 2013230) overpredicted risk in
both St George’s163 and AMND114 (see Figure 9).
Decision curve analysis
Comparisons of models for any-, early- and late-onset pre-eclampsia using decision curve analysis were
carried out in the SCOPE,42 Allen et al.,108 Poston et al. 2015149 and POP161 data sets. Net benefit values
are often best multiplied by 1000 to reveal the extra number of women who would be correctly
treated per 1000 women who used the model, with none treated incorrectly.








































































































FIGURE 7 Calibration plots for models predicting any-onset pre-eclampsia using first-trimester clinical characteristics
and biochemical markers in data sets with > 100 outcome events. (a) Model 4115 in POP;161 (b) model 5128 in POP;161
(c) model 6147 in St George’s;163 and (d) model 6147 in POP.161 Reproduced from Snell et al.52 Open Access This article
is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation,
distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s)
and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other
third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a
credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is
not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the
copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons
Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available
in this article, unless otherwise stated in a credit line to the data.
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FIGURE 8 Calibration plots for models predicting early-onset pre-eclampsia using first-trimester clinical characteristics
marker in data sets with > 100 outcome events. (a) Model 8115 in Poston 2006;150 (b) model 10230 in St George’s;163 and





















































FIGURE 9 Calibration plots for models predicting late-onset pre-eclampsia using first-trimester clinical characteristics
marker in data sets with > 100 outcome events. (a) Model 16229 in POP;161 (b) model 17230 in ALSPAC;103 (c) model 17230
in St George’s;163 (d) model 17230 in AMND;114 and (e) model 17230 in POP.161 (continued )
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Any-onset pre-eclampsia
Models validated in cohorts with > 100 events
The Goetzinger et al.128 and Odibo et al.147 models (models 5 and 6) showed a positive net benefit
between relevant predicted probability thresholds of 4% to 20% in the POP data set161 comprising any
nulliparous women with a singleton pregnancy. The Baschat et al.115 model (model 4) also showed a net
benefit from 5% to 20% in the POP data set.161 These models, however, showed a net harm across
thresholds in the Allen et al.108 and Poston et al. 2015149 data sets (Figure 10).
Early-onset pre-eclampsia
Decision curves for early-onset pre-eclampsia are given in Appendix 14. These did not show any net
benefit, with some models showing potential harm compared with a treat-none strategy. This is likely to be
because of how rare the outcome is and how few events there were in the data sets used for validation.
Late-onset pre-eclampsia
Models validated in cohorts with > 100 events
For late-onset pre-eclampsia, the Crovetto et al.229 model (model 16) performed better than the Kuc
et al. 2013230 model (model 17) in POP,161 with net benefit at thresholds of 4–20%; however, this model
















































































FIGURE 9 Calibration plots for models predicting late-onset pre-eclampsia using first-trimester clinical characteristics
marker in data sets with > 100 outcome events. (a) Model 16229 in POP;161 (b) model 17230 in ALSPAC;103 (c) model 17230
in St George’s;163 (d) model 17230 in AMND;114 and (e) model 17230 in POP.161
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FIGURE 10 Decision curves for prediction models of any-onset pre-eclampsia in the (a) SCOPE UK,42 (b) Allen et al.,108
(c) Poston et al. 2015149 and (d) POP161 data sets. Reproduced from Snell et al.52 Open Access This article is licensed
under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and
reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party
material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line
to the material. If material is not included in the article's Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the
copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons
Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available
in this article, unless otherwise stated in a credit line to the data. (continued )
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FIGURE 10 Decision curves for prediction models of any-onset pre-eclampsia in the (a) SCOPE UK,42 (b) Allen et al.,108
(c) Poston et al. 2015149 and (d) POP161 data sets. Reproduced from Snell et al.52 Open Access This article is licensed under
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permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the
copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons
Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available
in this article, unless otherwise stated in a credit line to the data.
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FIGURE 11 Decision curves for prediction models of late-onset pre-eclampsia in (a) SCOPE UK,42 (b) Allen et al.,108
(c) Poston et al. 2015149 and (d) POP161 data sets. Net benefit values on the y-axis are often best multiplied by 1000 to
reveal the extra number of women who would be correctly treated per 1000 women who used the model, with none
treated incorrectly. Reproduced from Snell et al.52 Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium
or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons licence, and indicate if changes were made. The images or other third party material in this article are included
in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not
included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or
exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this
licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated in a credit line to the data. (continued )
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FIGURE 11 Decision curves for prediction models of late-onset pre-eclampsia in (a) SCOPE UK,42 (b) Allen et al.,108
(c) Poston et al. 2015149 and (d) POP161 data sets. Net benefit values on the y-axis are often best multiplied by 1000 to
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Summary
In summary, although some existing models showed a reasonable ability to discriminate between
women who had a pre-eclampsia outcome and those who did not, calibration performance was, overall,
poor across the data sets, with large heterogeneity in the calibration performance across different
IPPIC data sets. Many of the models demonstrated likely overfitting at model development, with
predictions that were too extreme compared with the observed risk in the data sets (calibration slope
< 1). A model prediction could also be systematically too low or too high depending on the data set
used to validate it (calibration-in-the-large ≠ 0). The models were validated in a rather heterogeneous
group of data sets that had different eligibility criteria. These findings suggest that the differences
between women in the data sets are not adequately captured by the set of predictors included in
the models. There was also little difference in predictive performance when biochemical markers or
ultrasound markers were combined with maternal and clinical characteristics, compared with models
with only maternal and clinical characteristics. An important limitation to this work is that it was
possible to externally validate only 24 out of the 70 existing models that reported model equations.
None of the existing models validated performed well enough to warrant recalibration. Owing to
the large heterogeneity in predictive performance of these existing models across data sets, simple
recalibration strategies were unlikely to improve the overall performance or reduce heterogeneity in
performance. Therefore, in Chapter 6 we go on to develop and internally validate new prediction
models for pre-eclampsia outcomes using the combined IPPIC data to ascertain whether or not this
can address the shortcomings of existing models.
EXTERNAL VALIDATION OF EXISTING PRE-ECLAMPSIA PREDICTION MODELS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
46
Chapter 6 Development and validation of
pre-eclampsia prediction models
In this chapter, we describe the results of developing new prediction models using the IPPIC data sets.The methods for this chapter are detailed in Chapter 3, Development and validation of pre-eclampsia
prediction models. We aimed to develop 18 models, one for each combination of the three outcomes
(any-onset, early-onset and late-onset pre-eclampsia), two trimesters (predictors measured at trimester 1
or at trimester 2) and three predictor sets (clinical characteristics only, clinical characteristics plus
biochemical markers, and clinical characteristics plus ultrasound markers).
Summary of international data sets and predictor availability
A total of 78 data sets were included in the IPPIC project. As explained in Chapter 3, the available
data sets did not record all of the variables of interest, or the same combination of variables as other
data sets. The timing of measurements also differed (i.e. trimester 1, trimester 2 or both). Potential
predictors deemed ‘important’ based on the clinical consensus (see Table 3) were ranked according to
the mean of their scores (ranging from 1, not important, to 5, very important; Table 7).







n (% of all)
Maternal clinical characteristics
1 Previous any PE 4.91 55 (69) 33,583 (33)
2 Chronic or pre-existing hypertension 4.67 70 (86) 90,084 (89)
3 SBP (first or second trimester) 4.48 41 (51) 12,879 (13)
4 BMI (first or second trimester) 4.45 52 (65) 34,453 (34)
5 DBP (first or second trimester) 4.45 41 (51) 12,879 (13)
6 Parity 4.30 52 (65) 41,020 (41)
13 MAP (first or second trimester) 4.27 44 (55) 13,018 (13)
7 History of renal disease 4.24 50 (63) 84,595 (84)
8 Multiple pregnancy 4.12 60 (75) 87,961 (87)
9 History of pre-existing diabetes 4.12 63 (79) 93,588 (93)
10 Age 3.94 73 (91) 97,724 (97)
14 PCR (first or second trimester) 3.91 1 (1) 278 (< 1)
12 Family history of PE in first-degree relative 3.85 14 (18) 995 (1)
11 Previous autoimmune disease 3.82 43 (54) 37,664 (37)
17 Previous SGA 3.79 18 (23) 4064 (4)
15 Urine dipstick (first or second trimester) 3.73 12 (15) 2209 (2)
16 Ethnicity 3.61 57 (71) 72,248 (72)
18 Smoking 3.06 57 (71) 94,252 (94)
19 Mode of conception 2.97 23 (29) 31,096 (31)
20 Substance misuse in current pregnancy 2.48 17 (21) 13,844 (14)
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None of the individual IPPIC data sets had all of the clinical characteristics of interest, and therefore some
variables had to be excluded to form the model development sets. We first excluded variables that were
not recorded in many data sets or for which few data were available across the data sets with that
variable (removed if the proportion of events in data sets with the variable accounted for < 5% of events
across all data sets). Protein–creatinine ratio (PCR), urine dipstick, family history of pre-eclampsia and
previous small for gestational age fetus were all excluded. We also excluded multiple pregnancy as we
aimed to develop models applicable to women with singleton pregnancies. Variables were then removed
according to their ranking (lowest-ranking first) until we had a reasonable number of data sets for model
development. Substance misuse, mode of conception, smoking and ethnicity were removed. Twelve data
sets had all of the remaining clinical variables of interest, and these are summarised in Table 8.
Biochemical and ultrasound markers were recorded in very few data sets (see Table 7). To develop
models including either biochemical or ultrasound markers in addition to clinical characteristics,
only subsets of the 12 data sets could be used. Four data sets included biochemical markers and six
data sets included ultrasound markers. Estimated fetal weight centile was excluded as a potential
predictor as none of the data sets recorded this variable.
Missingness and multiple imputation
Data sets were included if they recorded either first-trimester or second-trimester measurements
for the potential predictors of interest; therefore, many variables were systematically missing (not
recorded or recorded for < 10% of individuals) in a data set and some were partially missing (missing
for some individuals) in a data set. Table 9 summarises the missingness for variables and outcomes in
the development data sets.
When checking convergence following imputation of systematically missing predictors (as described in
Chapter 3, Development and validation of pre-eclampsia prediction models), values for first-trimester BMI were
deemed poorly imputed for POUCH131 (i.e. convergence was not achieved despite the large burn-in, and
extreme values were imputed), so the data set was excluded when developing models using first-trimester
clinical characteristics. Three studies108,115,173 were excluded from model development using second-
trimester clinical characteristics, owing to poor imputation of blood pressures and BMI.








n (% of all)
Biochemical markers
1 PlGF (first or second trimester) 4.21 19 (24) 3453 (3)
2 sFlt1 (first or second trimester) 3.94 12 (15) 3175 (3)
3 PAPP-A (first or second trimester) 3.15 9 (11) 871 (< 1)
Ultrasound markers
1 Uterine artery PI (first or second trimester) 4.03 20 (25) 2999 (3)
2 Estimated fetal weight centile (first or second
trimester)
3.33 4 (5) 591 (< 1)
3 Umbilical artery PI (first or second trimester) 3.24 8 (10) 887 (< 1)
PCR, protein–creatinine ratio; PE, pre-eclampsia; PI, pulsatility index; SGA, small for gestational age.
Light blue variables were those excluded from model development.
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Nulliparous, n (%) 5628 (100) 584 (56) 674 (43) 736 (43) 3328 (100) 6710 (92) 3097 (100) 1293 (43) 0 (0) 377 (46) 160 (53) 4212 (100)
Previous pre-
eclampsia, n (%)
0 (0) 17 (2) 69 (4) 95 (6) 0 (0) 460 (6) 0 (0) 106 (4) 209 (92) 0 (0) 1 (< 1) 0 (0)
History of
hypertension
24 (< 1) 10 (< 1) 0 (0) 162 (10) 2372 (71) 234 (3) 0 (0) 92 (3) 79 (34) 13 (2) 0 (0) 220 (5)
History of renal
disease
0 (0) 3 (< 1) 0 (0) 4 (< 1) 0 (0) 0 (0) 0 (0) 94 (9) 0 (0) 5 (< 1) 0 (0) 41 (< 1)
History of
diabetes




278 (5) 14 (1) 54 (4) 106 (6) 32 (1) 141 (2) 156 (5) 44 (3) 43 (20) 46 (6) 19 (6) 273 (6)
Early-onset
pre-eclampsia
44 (< 1) 1 (< 1) 5 (< 1) 21 (1) 13 (< 1) 18 (< 1) 12 (< 1) 12 (< 1) 15 (7) 1 (< 1) 2 (< 1) 10 (< 1)
Late-onset
pre-eclampsia
234 (4) 13 (1) 49 (3) 85 (5) 19 (< 1) 123 (2) 144 (5) 32 (2) 28 (13) 45 (6) 17 (6) 263 (6)
















































































































































































































































































































































TABLE 9 Number and proportion of observations missing values for each variable in each data set included in model development
Variable




























Previous PE 0 (0) 0 (0) 8 (1) 0 (0) 0 (0) 1 (0) 0 (0) 1 (0) 2 (1) 0 (0) 0 (0) 0 (0)
History of
hypertension
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0) 0 (0) 1 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Trimester 1 SBP 5490 (98) 5 (0) 1536 (99) 0 (0) 2906 (87) 2581 (35) 3020 (98) 2454 (81) 127 (55) 421 (52) 0 (0) 279 (7)
Trimester 2 SBP 7 (0) 1040 (100) 9 (1) 1704 (100) 3321 (100) 1022 (14) 87 (3) 1653 (55) 183 (80) 254 (31) 304 (100) 4076 (97)
Trimester 1 BMI 5490 (98) 5 (0) 1536 (99) 0 (0) 480 (14) 2585 (36) 3024 (98) 3019 (100) 127 (55) 414 (51) 0 (0) 152 (4)
Trimester 2 BMI 7 (0) 1040 (100) 0 (0) 1704 (100) 2966 (89) 1078 (15) 177 (6) 1 (0) 183 (80) 245 (30) 304 (100) 57 (1)
Trimester 1 DBP 5490 (98) 5 (0) 1536 (99) 0 (0) 2913 (88) 2581 (35) 3020 (98) 2454 (81) 127 (55) 421 (52) 0 (0) 279 (7)
Trimester 2 DBP 7 (0) 1040 (100) 9 (1) 1704 (100) 3321 (100) 1023 (14) 87 (3) 1653 (55) 183 (80) 254 (31) 304 (100) 4076 (97)
Nulliparous 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Trimester 1 MAP 5490 (98) 5 (0) 1536 (99) 0 (0) 2913 (88) 2581 (35) 3020 (98) 2454 (81) 127 (55) 421 (52) 0 (0) 280 (7)
Trimester 2 MAP 7 (0) 1040 (100) 9 (1) 1704 (100) 3321 (100) 1023 (14) 87 (3) 1653 (55) 183 (80) 254 (31) 304 (100) 4076 (97)
History of renal
disease
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1921 (64) 0 (0) 0 (0) 0 (0) 0 (0)
Multiple pregnancy 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 231 (3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
History of diabetes 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Age 0 (0) 1 (0) 0 (0) 0 (0) 11 (0) 1 (0) 99 (3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Trimester 1 PCR 5612 (100) 1045 (100) 1554 (100) 1704 (100) 3328 (100) 7273 (100) 3097 (100) 3019 (100) 230 (100) 812 (100) 304 (100) 4212 (100)
Trimester 2 PCR 4464 (79) 1045 (100) 1549 (100) 1704 (100) 3328 (100) 7273 (100) 3097 (100) 3019 (100) 230 (100) 812 (100) 304 (100) 4212 (100)
Family history of PE 0 (0) 6 (1) 61 (4) 1704 (100) 3328 (100) 7273 (100) 3097 (100) 3019 (100) 230 (100) 812 (100) 304 (100) 4212 (100)
History of
autoimmune disease
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (0) 0 (0) 2458 (81) 0 (0) 0 (0) 0 (0) 0 (0)
Previous SGA 5628 (100) 0 (0) 1554 (100) 1704 (100) 3328 (100) 7273 (100) 3097 (100) 3019 (100) 0 (0) 0 (0) 304 (100) 4212 (100)
Trimester 1 urine
dipstick
5490 (98) 1045 (100) 1554 (100) 1704 (100) 3328 (100) 2584 (36) 3020 (98) 3019 (100) 230 (100) 812 (100) 304 (100) 4212 (100)
Trimester 2 urine
dipstick
7 (0) 1045 (100) 404 (26) 1704 (100) 3328 (100) 1079 (15) 87 (3) 0 (0) 230 (100) 812 (100) 304 (100) 4212 (100)































































































Smoking 0 (0) 0 (0) 0 (0) 0 (0) 6 (0) 2 (0) 6 (0) 6 (0) 230 (100) 0 (0) 0 (0) 0 (0)
Spontaneous
conception
0 (0) 0 (0) 4 (0) 0 (0) 3328 (100) 7273 (100) 3097 (100) 3019 (100) 20 (9) 0 (0) 304 (100) 0 (0)
Substance misuse 0 (0) 0 (0) 1554 (100) 0 (0) 3328 (100) 7273 (100) 3097 (100) 7 (0) 230 (100) 812 (100) 304 (100) 4212 (100)
Biochemical markers
Trimester 1 PlGF 5628 (100) 5 (0) 1554 (100) 704 (41) 3328 (100) 4842 (67) 3097 (100) 3019 (100) 230 (100) 812 (100) 304 (100) 135 (3)
Trimester 2 PlGF 51 (1) 966 (92) 445 (29) 1704 (100) 3328 (100) 4026 (55) 3097 (100) 1715 (57) 230 (100) 812 (100) 304 (100) 191 (5)
Trimester 1 sFlt-1 5628 (100) 1045 (100) 1554 (100) 1704 (100) 3328 (100) 4989 (69) 3097 (100) 3019 (100) 230 (100) 812 (100) 304 (100) 134 (3)
Trimester 2 sFlt-1 48 (1) 1045 (100) 1554 (100) 1704 (100) 3328 (100) 4125 (57) 3097 (100) 1712 (57) 230 (100) 812 (100) 304 (100) 191 (5)
Trimester 1 PAPP-A 5628 (100) 119 (11) 1554 (100) 704 (41) 3328 (100) 7273 (100) 3097 (100) 3019 (100) 230 (100) 812 (100) 304 (100) 134 (3)




5628 (100) 5 (0) 1554 (100) 266 (16) 2895 (87) 7273 (100) 3097 (100) 3019 (100) 230 (100) 812 (100) 304 (100) 4212 (100)
Trimester 2 uterine
artery PI
5628 (100) 1040 (100) 1554 (100) 1704 (100) 3204 (96) 7273 (100) 3097 (100) 3019 (100) 230 (100) 812 (100) 304 (100) 133 (3)
Trimester 1 estimated
fetal weight
5628 (100) 1045 (100) 1554 (100) 1704 (100) 3328 (100) 7273 (100) 3097 (100) 3019 (100) 230 (100) 812 (100) 304 (100) 4212 (100)
Trimester 2 estimated
fetal weight
5628 (100) 1045 (100) 1554 (100) 1704 (100) 3328 (100) 7273 (100) 3097 (100) 3019 (100) 230 (100) 144 (18) 304 (100) 43 (1)
Trimester 1 umbilical
artery PI
5628 (100) 1045 (100) 1554 (100) 1704 (100) 3328 (100) 7273 (100) 3097 (100) 3019 (100) 230 (100) 812 (100) 304 (100) 4212 (100)
Trimester 2 umbilical
artery PI
3102 (55) 1045 (100) 1554 (100) 1704 (100) 3328 (100) 7273 (100) 3097 (100) 3019 (100) 230 (100) 187 (23) 304 (100) 70 (2)
Outcomes
Any-onset PE 5 (0) 0 (0) 47 (3) 0 (0) 985 (30) 0 (0) 150 (5) 1648 (55) 13 (6) 0 (0) 0 (0) 5 (0)
Early-onset PE 5 (0) 0 (0) 47 (3) 0 (0) 1007 (30) 0 (0) 150 (5) 1648 (55) 13 (6) 0 (0) 0 (0) 5 (0)
Late-onset PE 5 (0) 0 (0) 47 (3) 0 (0) 1007 (30) 0 (0) 150 (5) 1648 (55) 13 (6) 0 (0) 0 (0) 5 (0)
PE, pre-eclampsia; PI, pulsatility index.
Light blue variables were excluded from model development; subsets of the data were used for model development including biochemical or ultrasound markers and therefore data sets that were excluded from
















































































































































































































































































































































For model development including biochemical markers, all four data sets were included for the first-
trimester models, and POUCH131 was excluded for the second-trimester models. For model development
including ultrasound markers, two data sets135,161 were excluded for first-trimester models, and three
data sets108,135,149 were excluded for second-trimester models. The relevant imputation checking plots are
provided in Appendix 15 along with an explanation of why these studies were excluded. A summary of the
overall sample size and number of events contributing to model development for each combination of
trimester of measurement (first or second) and predictor set (clinical characteristics, clinical characteristics
plus biochemical markers, clinical characteristics plus ultrasound markers) is given in Table 10.
Models including clinical characteristics only
The model development process was performed for data sets imputed with each form of BMI, namely
BMI, ln(BMI) and BMI–2. The resulting models and performance statistics for all clinical characteristic
models predicting any-onset, early-onset and late-onset pre-eclampsia are presented in Appendix 16.
As an example of how the functional form was decided for BMI, let us consider the model including
first-trimester clinical characteristics for any-onset pre-eclampsia. The model that included BMI rather
than ln(BMI) or BMI–2 had an overall calibration slope closest to 1 (with least heterogeneity across data
sets), calibration-in-the large closest to 0 (with least heterogeneity across data sets), and the C-statistic
with least heterogeneity across data sets (C-statistic estimates were very similar across the three
models). Therefore, the model with BMI was selected. This process was repeated for models developed
using clinical characteristics for all three pre-eclampsia outcomes using first-trimester measurements
for potential predictors, and then separately for models using second-trimester measurements.
A summary of the predictors retained for each model after variable selection is given in Table 11. For all
but one model, BMI was best modelled linearly if it was retained. However, for early-onset pre-eclampsia
(for which there are fewer events), first-trimester BMI was modelled non-linearly using (BMI/10)–2.
The relationship between BMI and risk (log-odds) of early pre-eclampsia is shown in Figure 12. Autoimmune
disease was only retained in the model including second-trimester predictors for early-onset pre-eclampsia.
Nulliparity was dropped from the models for early-onset pre-eclampsia and diabetes was dropped from
the first-trimester model for late-onset pre-eclampsia and all of the second-trimester models. DBP was
not retained in the first-trimester models for any-onset or late-onset pre-eclampsia but was retained in
the model for early-onset pre-eclampsia and all second-trimester models.













First-trimester clinical characteristics 11 29,187 1187 149 1039
Second-trimester clinical
characteristics
9 29,153 1144 152 993
First-trimester clinical characteristics
and biochemical markers




3 17,117 692 72 620
First-trimester clinical characteristics
and ultrasound markers




3 13,168 596 72 524
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The parameter estimates for models with first-trimester predictors and second-trimester predictors
are given in Tables 12 and 13, respectively. These are the developed models before adjustment for
optimism due to overfitting. Increasing values of BMI, previous pre-eclampsia, history of hypertension,
renal disease and diabetes were all associated with an increased risk of the pre-eclampsia outcomes.
Increasing age was associated with a decrease in risk of pre-eclampsia. When retained in the models,
increasing values of SBP and DBP were associated with an increase in risk for any-onset and late-onset
pre-eclampsia, although second-trimester SBP was negatively associated with risk for early-onset
pre-eclampsia.
TABLE 11 Summary of clinical characteristics retained in the models for any-, early- and late-onset pre-eclampsia
Variable













Age ✓ ✓ ✓ ✓ ✓
SBP ✓ ✓ ✓ ✓ ✓
DBP ✓ ✓ ✓ ✓
BMI ✓ linear ✓ (–2) ✓ linear ✓ linear ✓ linear
Nulliparity ✓ ✓ ✓ ✓
Previous PE ✓ ✓ ✓ ✓ ✓ ✓
Renal disease ✓ ✓ ✓ ✓ ✓ ✓
Hypertension ✓ ✓ ✓ ✓ ✓





a Diabetes was omitted from the second-trimester model for early-onset pre-eclampsia because of perfect
prediction problems.
BMI (kg/m2)



















FIGURE 12 Relationship between first-trimester BMI and risk of early-onset pre-eclampsia when using (BMI/10)–2
transformation.
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TABLE 12 Parameter estimates for initial prediction models developed using first-trimester clinical characteristics to predict any-, early- or late-onset pre-eclampsia
Variable
Any-onset PE Early-onset PE Late-onset PE
OR (95% CI) Beta p-value OR (95% CI) Beta p-value OR (95% CI) Beta p-value
Age 0.984 (0.972 to 0.995) –0.016 0.006 0.965 (0.934 to 0.996) –0.036 0.985 (0.973 to 0.997) –0.015 0.018
SBP 1.017 (1.010 to 1.025) 0.017 < 0.001 0.983 (0.959 to 1.006) –0.018 0.089 1.016 (1.008 to 1.025) 0.016 < 0.001
DBP 1.078 (1.032 to 1.126) 0.075
aBMI or (BMI/10)–2 1.041 (1.027 to 1.056) 0.040 < 0.001 0.553 (0.270 to 1.133) –0.593 0.080 1.039 (1.024 to 1.055) 0.039 < 0.001
Nulliparous 2.759 (2.073 to 3.673) 1.015 < 0.001 3.089 (2.268 to 4.206) 1.128 < 0.001
Previous PE 3.952 (2.692 to 5.802) 1.374 < 0.001 5.710 (3.087 to 10.565) 1.742 < 0.001 3.368 (2.204 to 5.145) 1.214 < 0.001
Renal disease 5.163 (2.665 to 10.002) 1.641 < 0.001 9.749 (2.534 to 37.512) 2.277 < 0.001 3.891 (1.919 to 7.892) 1.359 < 0.001
Hypertension 5.555 (4.384 to 7.039) 1.715 < 0.001 1.730 (1.005 to 2.976) 0.548 0.028 6.265 (4.895 to 8.018) 1.835 < 0.001
Diabetes 1.479 (0.883 to 2.477) 0.391 0.137 5.567 (2.449 to 12.653) 1.717 0.003
Intercept (average) –6.868 –7.924 –7.052
PE, pre-eclampsia.
a BMI modelled non-linearly using (BMI/10)–2 for early-onset pre-eclampsia.
Note



































































TABLE 13 Parameter estimates for initial prediction models developed using second-trimester clinical characteristics to predict any-, early- or late-onset pre-eclampsia
Variable
Any-onset PE Early-onset PE Late-onset PE
OR (95% CI) Beta p-value OR (95% CI) Beta p-value OR (95% CI) Beta p-value
Age 0.983 (0.97 to 0.996) –0.017 0.013 0.985 (0.972 to 0.999) –0.015 0.034
SBP 1.011 (1.003 to 1.020) 0.011 0.010 1.011 (1.002 to 1.020) 0.011 0.012
DBP 1.021 (1.007 to 1.034) 0.020 0.003 1.060 (1.018 to 1.104) 0.059 0.006 1.013 (1.001 to 1.026) 0.013 0.035
BMI 1.065 (1.052 to 1.079) 0.063 < 0.001 1.072 (1.059 to 1.086) 0.070 < 0.001
Nulliparous 2.697 (1.905 to 3.820) 0.992 < 0.001 3.592 (2.469 to 5.225) 1.279 < 0.001
Previous PE 4.271 (2.794 to 6.528) 1.452 < 0.001 8.497 (4.579 to 15.767) 2.140 < 0.001 3.500 (2.144 to 5.713) 1.253 < 0.001
Renal disease 2.721 (1.323 to 5.596) 1.001 0.007 3.861 (1.074 to 13.878) 1.351 0.039 2.257 (1.101 to 4.625) 0.814 0.027
Hypertension 6.253 (4.859 to 8.047) 1.833 < 0.001 7.74 (6.020 to 9.953) 2.046 < 0.001
Autoimmune disease 2.817 (0.766 to 10.359) 1.036 0.118
Intercept (average) –8.260 –9.641 –8.475
PE, pre-eclampsia.
Note
















































































































































































































































































































































Following internal validation, the predictive performance of the models is summarised in Table 14.
The average (pooled) C-statistic for the models was close to 0.7, with considerable heterogeneity in the
C-statistic across individual data sets. C-statistics were slightly higher for second-trimester models
than for first-trimester models. The calibration slope was generally around 0.9 for models of any-onset
and late-onset pre-eclampsia but was greater than 1 for early-onset pre-eclampsia (1.001 and 1.105).
Again, there was large heterogeneity in the calibration slope across data sets for most models.
Average calibration-in-the-large was close to zero but, again, there was large heterogeneity across
data sets, suggesting that the baseline risk differs across the individual data sets and is not being fully
captured by the predictors included in the models.
To illustrate the heterogeneity in predictive performance across individual data sets, Appendix 17 provides
the forest plots of predictive performance measures for the second-trimester any-onset pre-eclampsia
model. It is evident that there is large variability around the average values; for example, the observed
calibration slope varies from 0.45 to 1.57 across data sets, and CIs often do not overlap.
Models including clinical characteristics and biochemical markers
Next, we examined whether or not biochemical markers should be included in the prediction models, in
addition to the clinical characteristics identified for each outcome in the previous section (seeModels
including clinical characteristics only). Therefore, the clinical characteristics were forced into the models and
only the biochemical markers were eligible for removal in the backwards elimination process. First-trimester
BMI was previously modelled as (BMI/10)–2 for early pre-eclampsia; however, this transformation was not
selected for any of the other clinical characteristic models and therefore may be a result of overfitting in data
for which we have the fewest events. Therefore, for comparability and consistency across models, we used
BMI rather than (BMI/10)–2 for early pre-eclampsia in the clinical plus biochemical marker models.
In the same way as for BMI in the clinical characteristics models, we considered non-normality for
the biochemical markers by developing prediction models with biochemical markers on their original
scale and compared this with models developed using natural logarithm-transformed biochemical
marker values. Comparisons of biochemical marker and ln(biochemical marker) models are given in
Appendix 18. For the first-trimester model for early pre-eclampsia, the model with better predictive
performance came from the data with log-transformed biochemical markers; however, all biochemical
markers were dropped from the model. Therefore, in this case, we selected the model that retained a
biochemical marker in the model (see Table 16).
Table 15 shows which biochemical markers were included in each model and if they were log-transformed.
PAPP-A was not retained in any of the models, whereas sFlt-1 was retained in all first-trimester prediction
models and the second-trimester model for early pre-eclampsia. PlGF was retained in all models except the
first-trimester model for early pre-eclampsia. Models included the original biochemical marker values apart
from the second-trimester model for early pre-eclampsia, which used ln(biochemical marker) values. For all
but the second-trimester model for early pre-eclampsia, biochemical markers were negatively associated with
the pre-eclampsia outcomes, so risk decreased with increasing biochemical marker values (Tables 16 and 17).
Table 18 shows the average predictive performance for the models, obtained through internal
validation using meta-analysis of the data set-specific performance statistics. Models with the clinical
characteristics identified in Models including clinical characteristics only were also refitted in the same
data so that it was possible to compare the predictive performance of models with and models without
the biochemical markers in the same data sets. For all models, the average predictive performance
improved with the addition of biochemical markers, and, for most models and performance statistics,
heterogeneity across data sets was reduced (lower I2 and τ2 values). The average calibration slope was
generally < 1 (between 0.857 and 0.961), except for the early-onset pre-eclampsia models, which had
calibration slopes of 1.038 and 1.079 for the first- and second-trimester models, respectively.
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TABLE 14 Average (pooled) predictive performance statistics for each clinical characteristics model, and estimates of heterogeneity (between-study variance, τ2; proportion of total
variability due to between-study variance, I2) in performance, as obtained from a meta-analysis of data set-specific performance statistics
Number of C-statistic Calibration slope Calibration-in-the-large




C-statistic) Estimate (95% CI) τ2 I2 Estimate (95% CI) τ2 I2
Any-onset pre-eclampsia
First-trimester models
11 29,187 1187 0.677 (0.612 to 0.736) 0.139 83.9 0.915 (0.603 to 1.226) 0.155 86.4 0.012 (–0.630 to 0.654) 0.881 98.7
Second-trimester models
9 29,153 1144 0.703 (0.648 to 0.753) 0.076 79.3 0.969 (0.664 to 1.273) 0.129 88.3 0.011 (–0.772 to 0.795) 1.003 99.0
Early-onset pre-eclampsia
First-trimester models
11 29,187 149 0.719 (0.590 to 0.820) 0.260 49.1 1.001 (0.795 to 1.206) 0.000 0.0 0.090 (–0.377 to 0.557) 0.318 77.9
Second-trimester models
9 29,153 152 0.723 (0.601 to 0.819) 0.223 56.4 1.105 (0.868 to 1.341) 0.000 0.0 0.037 (–0.465 to 0.539) 0.287 76.4
Late-onset pre-eclampsia
First-trimester models
11 29,187 1039 0.677 (0.615 to 0.733) 0.116 79.7 0.919 (0.621 to 1.217) 0.131 82.0 0.016 (–0.705 to 0.736) 1.105 98.8
Second-trimester models
















































































































































































































































































































































Models including clinical characteristics and ultrasound markers
When considered in addition to clinical characteristics, ultrasound markers were not retained in any
of the models fitted, whether using the original values or using the logarithm-transformed values.
Therefore, the models reverted to the clinical characteristic models, which were reported in more
detail and using more data sets in Models including clinical characteristics only.
Shrinkage and final models
Following model development and internal validation, shrinkage was applied to the beta coefficients
and the final model equations are given in Table 19, along with the average performance statistics from
meta-analysis across data sets for these models, including 95% CIs for the average performance and
95% prediction intervals for the performance of the model in a new but similar data set. Performance
of the models in the individual data sets can be found in Appendix 19.
After shrinkage and recalibration of the intercept, each model is, on average, perfectly calibrated
across data sets. However, as was observed for existing models in Chapter 5, large heterogeneity
remains in all of the performance statistics across data sets. The prediction intervals for potential
performance in new settings are generally very wide. For example, the prediction interval for the
calibration slope of model 4 ranges from 0.07 to 1.93. Therefore, although IPPIC models may predict
well on average across populations, they may not be as accurate in particular populations. Figure 13
presents the calibration plots for model 1 (first-trimester clinical characteristics for the prediction of
any pre-eclampsia) by data set. The model is fairly well calibrated for Baschat et al.;115 however, the
predictions are too high for pregnant women in the WHO cohort,175 but not high enough for those at
high risk in the POP cohort.161 Calibration plots for the other models (excluding for early pre-eclampsia,
which had too few events in individual data sets) are given in Appendix 20. Heterogeneity in calibration
performance could be reduced if, when applying the models in practice, model parameters (e.g. intercept)
could be recalibrated to each population and setting. This would require local data for recalibration and
model updating.
Decision curve analysis
Figures 14–17 are the decision curves in each data set for models predicting any pre-eclampsia. The
decision curves show the net benefit or harm across different probability thresholds of the model and
compared with the ‘treat-all’ and ‘treat-none’ strategies. Net benefit values are often best multiplied by
1000 to reveal the extra number of women who would be correctly treated per 1000 women who
used the model, with none treated incorrectly.
TABLE 15 Summary of biochemical markers retained in the models (alongside clinical characteristics) for any-, early- and
late-onset pre-eclampsia using first- or second-trimester measurements
Variable
Prediction from first-trimester predictors Prediction from second-trimester predictors
Any-onset PE Early-onset PE Late-onset PE Any-onset PE Early-onset PE Late-onset PE
sFlt-1 ✓ ✓ ✓ ✓ (ln)
PAPP-A
PlGF ✓ ✓ ✓ ✓ (ln) ✓
PE, pre-eclampsia.
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TABLE 16 Parameter estimates for initial prediction models using first-trimester clinical characteristics and biochemical markers to predict any-, early- or late-onset pre-eclampsia
Variable
Any-onset PE Early-onset PE Late-onset PE
OR (95% CI) Beta p-value OR (95% CI) Beta p-value OR (95% CI) Beta p-value
Age 0.977 (0.962 to 0.992) –0.023 0.003 0.995 (0.954 to 1.039) –0.005 0.831 0.976 (0.961 to 0.991) –0.025 0.002
SBP 1.016 (1.004 to 1.028) 0.016 0.011 1.055 (1.026 to 1.085) 0.053 < 0.001 1.009 (0.998 to 1.020) 0.009 0.113
DBP 0.996 (0.960 to 1.033) –0.004 0.836
BMI 1.042 (1.009 to 1.077) 0.041 0.015 0.993 (0.933 to 1.057) –0.007 0.831 1.052 (1.024 to 1.080) 0.051 < 0.001
Nulliparous 3.113 (1.816 to 5.337) 1.136 < 0.001 4.093 (2.258 to 7.418) 1.409 < 0.001
Previous PE 3.857 (2.252 to 6.607) 1.350 < 0.001 4.427 (2.002 to 9.789) 1.488 < 0.001 3.311 (1.745 to 6.283) 1.197 < 0.001
Renal disease 2.603 (1.376 to 4.925) 0.957 0.004 4.397 (1.494 to 12.942) 1.481 0.007 2.135 (1.088 to 4.190) 0.758 0.028
Hypertension 9.403 (7.113 to 12.430) 2.241 < 0.001 2.300 (1.034 to 5.117) 0.833 0.041 10.739 (8.039 to 14.346) 2.374 < 0.001
Diabetes 1.021 (0.401 to 2.605) 0.021 0.965
sFlt-1 0.9998 (0.9996 to 0.9999) –2.42 × 10–4 0.012 0.9995 (0.9989 to 1.0001) –5.15 × 10–4 0.079 0.9998 (0.9996 to 1.0000) –2 × 10–4 0.026






















































































































































































































































































































































TABLE 17 Parameter estimates for initial prediction models using second-trimester clinical characteristics and biochemical markers to predict any-, early- or late-onset pre-eclampsia
Variable
Any-onset PE Early-onset PE Late-onset PE
OR (95% CI) Beta p-value OR (95% CI) Beta p-value OR (95% CI) Beta p-value
Age 0.981 (0.966 to 0.996) –0.019 0.012 0.980 (0.965 to 0.996) –0.020 0.012
SBP 1.019 (1.009 to 1.030) 0.019 < 0.001 1.018 (1.008 to 1.029) 0.018 0.001
DBP 0.991 (0.979 to 1.004) –0.009 0.167 1.068 (1.039 to 1.096) 0.065 < 0.001 0.986 (0.973 to 0.999) –0.014 0.031
BMI 1.072 (1.057 to 1.088) 0.069 < 0.001 1.076 (1.060 to 1.093) 0.073 < 0.001
Nulliparous 8.156 (3.534 to 18.820) 2.099 < 0.001 12.673 (4.777 to 33.622) 2.539 < 0.001
Previous PE 6.237 (2.755 to 14.123) 1.831 < 0.001 10.594 (4.615 to 24.318) 2.360 < 0.001 5.664 (2.223 to 14.431) 1.734 < 0.001
Renal disease 4.150 (1.838 to 9.368) 1.423 0.001 23.285 (2.613 to 207.474) 3.148 0.005 3.680 (1.588 to 8.524) 1.303 0.002
Hypertension 11.034 (8.334 to 14.608) 2.401 < 0.001 11.380 (8.531 to 15.180) 2.432 < 0.001
Autoimmune disease 3.169 (0.397 to 25.315) 1.154 0.277
sFlt-1 or In(sFlt-1 + 0.5)a 1.581 (1.100 to 2.271) 0.458 0.013
PlGF or In(PlGF + 0.5)a 0.997 (0.996 to 0.998) –0.003 < 0.001 0.372 (0.277 to 0.500) –0.988 < 0.001 0.997 (0.996 to 0.998) –0.003 < 0.001
Intercept (average) –7.895 –9.343 –8.054
PE, pre-eclampsia.
a Biochemical markers modelled non-linearly using ln(biochemical marker + 0.5) for early-onset pre-eclampsia.
Note



































































TABLE 18 Average (pooled) predictive performance statistics for clinical characteristics and clinical and biochemical marker models, and estimates of heterogeneity in performance
(between-study variance, τ2; proportion of total variability due to between-study variance, I2), as derived from a meta-analysis of data set-specific performance estimates
Model
Number of C-statistic Calibration slope Calibration-in-the-large
Data




C-statistic) Estimate (95% CI) τ2 I2 Estimate (95% CI) τ2 I2
First-trimester predictors for
any pre-eclampsia (C)
4 20,132 795 0.675 (0.488 to 0.819) 0.212 92.1 0.870 (0.258 to 1.481) 0.123 89.3 –0.009 (–0.924 to 0.907) 0.318 97.8
First-trimester predictors for
any pre-eclampsia (C+B)
0.696 (0.516 to 0.832) 0.205 90.7 0.901 (0.355 to 1.447) 0.094 86.7 –0.004 (–0.939 to 0.931) 0.333 97.9
First-trimester predictors for
early pre-eclampsia (C)
4 20,132 103 0.749 (0.582 to 0.865) 0.066 28.6 1.047 (0.694 to 1.401) 0 0 0.025 (–1.175 to 1.226) 0.507 90.2
First-trimester predictors for
early pre-eclampsia (C+ B)
0.762 (0.576 to 0.883) 0.107 37.0 1.038 (0.666 to 1.410) 0 0 0.036 (–1.269 to 1.342) 0.610 91.7
First-trimester predictors for
late pre-eclampsia (C)
4 20,132 692 0.665 (0.476 to 0.814) 0.222 93.1 0.809 (0.213 to 1.404) 0.117 87.7 –0.010 (–0.901 to 0.881) 0.295 97.3
First-trimester predictors for
late pre-eclampsia (C+ B)
0.688 (0.505 to 0.827) 0.212 91.9 0.857 (0.338 to 1.376) 0.085 84.4 –0.005 (–0.932 to 0.922) 0.322 97.5
Second-trimester predictors
for any pre-eclampsia (C)
3 17,117 692 0.715 (0.488 to 0.868) 0.141 93.9 0.917 (0.194 to 1.641) 0.079 93.0 0.002 (–1.573 to 1.577) 0.395 98.7
Second-trimester predictors
for any pre-eclampsia (C+ B)
0.754 (0.526 to 0.894) 0.151 92.4 0.961 (0.358 to 1.564) 0.052 88.7 0.004 (–1.284 to 1.293) 0.262 98.0
Second-trimester predictors
for early pre-eclampsia (C)




0.830 (0.629 to 0.934) 0.041 17.4 1.079 (0.567 to 1.591) 0.011 26.0 0.099 (–0.972 to 1.169) 0.107 66.4
Second-trimester predictors
for late pre-eclampsia (C)
3 17,117 620 0.706 (0.437 to 0.881) 0.194 95.0 0.884 (0.152 to 1.615) 0.079 91.8 0.002 (–1.509 to 1.513) 0.363 98.4
Second-trimester predictors
for late pre-eclampsia (C+ B)
0.746 (0.493 to 0.898) 0.181 93.2 0.936 (0.355 to 1.517) 0.047 86.5 0.004 (–1.295 to 1.303) 0.266 97.8
C, clinical characteristics; C+ B, clinical characteristics and biochemical markers.
















































































































































































































































































































































TABLE 19 Final model equations for each outcome, predictor type and trimester of measurement after shrinkage to adjust for optimism (overfitting)
Model
number Predictors Model equation
Number of Average statistic (95% CI) [95% prediction interval]
Data





1 Clinical Logit(p)= –6.5297 – 0.0151 × age + 0.0156 ×
SBP + 0.0370 × BMI + 0.9287 × nulliparous+
1.2574 × previous PE + 1.5019 × renal disease +
1.5689 × hypertension + 0.3578 × diabetes












Logit(p)= –5.6061 – 0.0208 × age + 0.0142 ×
SBP + 0.0373 × BMI + 1.0232 × nulliparous+
1.2163 × previous PE + 0.8620 × renal disease +
2.0191 × hypertension + 0.0191 × diabetes –
0.000218 × sFlt-1 – 0.00478 × PlGF










1. 4 Clinical Logit(p)= –8.0909 – 0.0165 × age + 0.0108 ×
SBP + 0.0198 × DBP+ 0.0614 × BMI + 0.9616 ×
nulliparous+ 1.4068 × previous PE + 0.9700 ×
renal disease + 1.7763 × hypertension












Logit(p)= –7.6942 – 0.0186 × age + 0.0185 ×
SBP – 0.0083 × DBP + 0.0668 × BMI + 2.0169 ×
nulliparous + 1.7592 × previous PE + 1.3675 ×
renal disease + 2.3073 × hypertension –
0.00262 × PlGF











2 Clinical Logit(p)= –7.9161 – 0.0360 × age – 0.0176 ×
SBP + 0.0753 × DBP – 0.5937 × (BMI/10)–2 +
1.7440 × previous PE + 2.2795 × renal disease +
0.5486 × hypertension + 1.7185 × diabetes












Logit(p)= –10.3842 – 0.0048 × age+ 0.0555 ×
SBP – 0.0040 × DBP – 0.0069 × BMI + 1.5442 ×
previous PE + 1.5372 × renal disease + 0.8644 ×
hypertension – 0.000535 × sFlt-1












































































number Predictors Model equation
Number of Average statistic (95% CI) [95% prediction interval]
Data




5 Clinical Logit(p)= –10.1805 + 0.0647 × DBP+ 2.3643 ×
previous PE + 1.4929 × renal disease + 1.1445 ×
autoimmune disease












Logit(p)= –9.7075 + 0.0705 × DBP+ 2.5467 ×
previous PE + 3.3965 × renal disease + 1.2447 ×
autoimmune disease + 0.4942 × ln(sFlt-1 + 0.5) –
1.0661 × ln(PlGF + 0.5)











3 Clinical Logit(p)= –6.7280 – 0.0138 × age + 0.0150 ×
SBP + 0.0355 × BMI + 1.0363 × nulliparous+
1.1159 × previous PE + 1.2487 × renal disease +
1.6863 × hypertension












Logit(p)= –5.4124 – 0.0210 × age + 0.0076 ×
SBP + 0.0434 × BMI + 1.2077 × nulliparous+
1.0260 × previous PE + 0.6499 × renal disease +
2.0344 × hypertension – 0.000171 × sFlt-1 –
0.0051 × PlGF










6 Clinical Logit(p)= –8.0911 – 0.0137 × age + 0.0104 ×
SBP + 0.0124 × DBP+ 0.0647 × BMI + 1.1891 ×
nulliparous + 1.1650 × previous PE + 0.7569 ×
renal disease + 1.9032 × hypertension












Logit(p)= –7.7252 – 0.0189 × age + 0.0171 ×
SBP – 0.0136 × DBP + 0.0687 × BMI + 2.3770 ×
nulliparous + 1.6232 × previous PE + 1.2194 ×
renal disease + 2.2762 × hypertension –
0.00245 × PlGF


























































































































































































































































































































































































































































































FIGURE 13 Calibration plots for the final (shrunken) model predicting any-onset pre-eclampsia using first-trimester
clinical characteristics, in data sets (with > 100 events) used in the development and validation of the model. (a) SCOPE;42






































FIGURE 14 Decision curves for the final (shrunken) model predicting any pre-eclampsia using first-trimester clinical
characteristics, in data sets used in the development and validation of the model. (a) SCOPE;42 (b) Allen et al.;108
(c) Poston et al. 2015;149 (d) Baschat et al.;115 (e) Antsaklis et al.;110 (f) WHO;175 (g) NICH LR;159 (h) van Kuijk et al. 2014;166
(i) STORK G;135 (j) Vinter et al.;173 and (k) POP.161 Net benefit values are often best multiplied by 1000 to reveal the extra
number of women who would be correctly treated per 1000 women who used the model, with none treated incorrectly.
(continued )
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FIGURE 14 Decision curves for the final (shrunken) model predicting any pre-eclampsia using first-trimester clinical
characteristics, in data sets used in the development and validation of the model. (a) SCOPE;42 (b) Allen et al.;108
(c) Poston et al. 2015;149 (d) Baschat et al.;115 (e) Antsaklis et al.;110 (f) WHO;175 (g) NICH LR;159 (h) van Kuijk et al. 2014;166
(i) STORK G;135 (j) Vinter et al.;173 and (k) POP.161 Net benefit values are often best multiplied by 1000 to reveal the extra
number of women who would be correctly treated per 1000 women who used the model, with none treated incorrectly.
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FIGURE 15 Decision curves for the final (shrunken) model predicting any pre-eclampsia using second-trimester clinical
characteristics, in data sets used in the development and validation of the model. (a) SCOPE;42 (b) Poston et al. 2015;149
(c) Antsaklis et al.;110 (d) WHO;175 (e) NICH LR;159 (f) POUCH;131 (g) van Kuijk et al. 2014;166 (h) STORK G;135 and (i) POP.161
Net benefit values are often best multiplied by 1000 to reveal the extra number of women who would be correctly
treated per 1000 women who used the model, with none treated incorrectly.
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FIGURE 16 Decision curves for the final (shrunken) model predicting any pre-eclampsia using first-trimester clinical
characteristics and biochemical markers, in data sets used in the development and validation of the model. (a) SCOPE;42
(b) WHO;175 (c) POUCH;131 and (d) POP.161 Net benefit values are often best multiplied by 1000 to reveal the extra























































FIGURE 17 Decision curves for the final (shrunken) model predicting any pre-eclampsia using second-trimester clinical
characteristics and biochemical markers, in data sets used in the development and validation of the model. (a) SCOPE;42
(b) WHO;175 and (c) POP.161 Net benefit values are often best multiplied by 1000 to reveal the extra number of women
who would be correctly treated per 1000 women who used the model, with none treated incorrectly.
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Using first-trimester clinical characteristics (model 1; see Figure 14) shows some net benefit at
thresholds around 0.05 in the Poston et al. 2015,149 Baschat et al.,115 STORK G,135 Vinter et al.173 and
POP161 cohorts. The model shows little benefit or harm in SCOPE,42 Allen et al.,108 Antsaklis et al.,110
WHO175 and NICH LR.159 Using second-trimester clinical characteristics (model 4) shows some
improvement in net benefit in SCOPE161 but little improvement in the other data sets (see Figure 15).
In the data sets used for developing and validating models with first-trimester clinical characteristics
and biochemical markers (model 7), there may be greater net benefit in POP161 but little improvement
in the SCOPE42 or WHO175 cohorts (see Figure 16) compared with using clinical characteristics alone.
Using second-trimester clinical characteristics and biochemical markers (model 10) shows a slight
improvement in the SCOPE42 and POP161 cohorts (compared with first-trimester predictors), and the
addition of second-trimester biochemical markers has slightly greater net benefit than in models
including only second-trimester clinical characteristics (see Figure 17 ).
Decision curves for models predicting early-onset pre-eclampsia show no net benefit in most of the
data sets, and decision curves for models predicting late-onset pre-eclampsia are similar to those for
any-onset pre-eclampsia (see Appendix 21, Figures 38–45).
Summary
We used IPD from the IPPIC data sets to develop and validate new prediction models for early-onset,
late-onset and any-onset pre-eclampsia using clinical characteristics alone or with the addition of
biochemical markers. The IPPIC data sets used for model development and validation are heterogeneous,
with different case mix in different data sets (e.g. owing to different inclusion and exclusion criteria).
When the models were validated using an average intercept across data sets, the model performed
better in some IPPIC data sets than in others even if the average performance was good. The same was
observed in terms of net benefit in the individual data sets. In some data sets, there was potential for
net benefit at certain thresholds, whereas there was very little or no net benefit when the models were
applied in other data sets.
In summary, these prediction models have the potential to be useful in predicting pre-eclampsia
in some populations; however, additional predictors may be needed, or the models may need to be
tailored to improve the predictive performance across different settings and populations.
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Chapter 7 Predictive performance of
individual risk factors for pre-eclampsia
An unadjusted two-stage IPD meta-analysis of the prognostic effect of each candidate predictorprioritised in Chapter 4, Prioritisation of predictors of pre-eclampsia, was performed for each
outcome of early-onset, late-onset and any-onset pre-eclampsia, using complete cases of singleton
pregnancies in the IPPIC international data set. All analyses were carried out on raw values for
ultrasound and biochemical markers.
Any-onset pre-eclampsia
We investigated the prognostic value of individual clinical, biochemical and ultrasound markers for
predicting pre-eclampsia using a two-stage IPD meta-analysis. The analysis could not be performed for
the candidate factors PAPP-A, PlGF, sFlt-1, PCR and umbilical artery pulsatility index because the first-
stage logistic regression models could not be fitted owing to complete or quasi-complete separation.239
This happens when the outcome separates the predictor variable completely or partially, stopping the
model from fitting. The results of the two-stage IPD meta-analysis for any-onset pre-eclampsia and
each predictor variable are shown in Table 20.
TABLE 20 Two-stage IPD meta-analysis for any-onset pre-eclampsia
Predictor
Number




Age 71 1.06 0.97 to 1.17 0.58 to 1.94 95.96
Multiple current pregnancy 23 2.56 1.86 to 3.51 0.67 to 9.75 98.62
Previous pre-eclampsia 35 3.40 2.55 to 4.53 0.87 to 13.26 90.62
Parity 48 0.88 0.79 to 0.99 0.47 to 1.67 96.60
History of hypertension 49 4.76 3.56 to 6.35 0.69 to 32.93 98.39
History of renal disease 21 3.28 2.15 to 5.01 0.70 to 15.44 93.16
History of diabetes 34 2.89 2.15 to 3.88 0.64 to 12.95 95.62
History of autoimmune disease 16 1.94 1.19 to 3.17 0.49 to 7.69 75.43
Family history of pre-eclampsia 15 1.40 1.00 to 1.95 0.55 to 3.58 53.87
Previous SGA 11 1.22 0.82 to 1.82 0.53 to 2.83 48.18
Smoking during pregnancy 54 0.84 0.76 to 0.93 0.50 to 1.42 86.46
Spontaneous mode of conception 22 0.73 0.64 to 0.84 0.49 to 1.09 58.67
Cocaine, heroin or methamphetamine use 8 1.13 0.70 to 1.81 0.47 to 2.68 54.03
BMI 43 1.07 1.06 to 1.08 1.01 to 1.13 96.75
BMI trimester 1 48 1.08 1.06 to 1.09 1.00 to 1.16 93.33
BMI trimester 2 21 1.07 1.05 to 1.09 1.00 to 1.15 86.36
BMI trimester 3 11 1.09 1.06 to 1.14 0.98 to 1.22 87.89
SBP 19 1.60 1.42 to 1.80 0.99 to 2.58 89.98
continued
DOI: 10.3310/hta24720 Health Technology Assessment 2020 Vol. 24 No. 72
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Allotey et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
69
TABLE 20 Two-stage IPD meta-analysis for any-onset pre-eclampsia (continued )
Predictor
Number
of studies OR 95% CI
95% prediction
interval I2 (%)
SBP trimester 1 39 1.46 1.39 to 1.53 1.15 to 1.85 76.57
SBP trimester 2 28 1.55 1.46 to 1.64 1.24 to 1.94 73.11
SBP trimester 3 19 2.04 1.76 to 2.36 1.13 to 3.66 92.86
DBP 19 1.78 1.55 to 2.05 0.99 to 3.20 88.45
DBP trimester 1 39 1.70 1.57 to 1.85 1.19 to 2.45 79.61
DBP trimester 2 28 1.80 1.62 to 1.99 1.18 to 2.75 84.16
DBP trimester 3 18 2.59 2.04 to 3.29 1.06 to 6.30 94.44
MAP 25 2.00 1.75 to 2.30 1.08 to 3.71 89.06
MAP trimester 1 41 1.79 1.65 to 1.93 1.24 to 2.58 80.57
MAP trimester 2 29 1.92 1.74 to 2.11 1.27 to 2.89 83.52
MAP trimester 3 19 2.71 2.19 to 3.34 1.17 to 6.24 93.89
PCR 3 1.11 0.72 to 1.73 0.48 to 2.60 99.92
PCR trimester 1 1 0.75 0.34 to 1.67 N/A N/A
PCR trimester 2 1 0.98 0.93 to 1.03 N/A N/A
Urine dipstick 7 2.72 0.83 to 8.87 0.10 to 75.23 98.34
Urine dipstick trimester 1 6 2.27 1.52 to 3.38 1.20 to 4.29 27.67
Urine dipstick trimester 2 10 1.82 1.30 to 2.54 0.73 to 4.52 74.77
Urine dipstick trimester 3 6 3.46 1.83 to 6.55 0.74 to 16.18 92.92
Ultrasound markers
Uterine artery PI 11 3.11 1.86 to 5.18 0.71 to 13.66 74.32
Uterine artery PI trimester 1 12 1.67 1.18 to 2.38 0.64 to 4.37 70.27
Uterine artery PI trimester 2 13 4.18 3.25 to 5.38 2.27 to 7.70 47.16
Uterine artery PI trimester 3 3 3.99 0.02 to 688.38 0.00 to 37,752.95 75.04
Umbilical artery PI 5 1.08 0.44 to 2.65 0.44 to 2.65 0.00
Umbilical artery PI trimester 2 8 1.94 0.89 to 4.23 0.52 to 7.26 33.52
Umbilical artery PI trimester 3 5 1.60 0.48 to 5.38 0.21 to 12.31 37.99
Biochemical markers
PIGF trimester 1 17 0.22 0.09 to 0.50 0.01 to 4.34 85.44
PIGF trimester 2 16 0.66 0.53 to 0.83 0.34 to 1.29 87.27
PIGF trimester 3 12 0.59 0.45 to 0.77 0.25 to 1.36 96.78
sFlt-1 trimester 1 12 0.98 0.97 to 1.00 0.96 to 1.01 51.24
sFlt-1 trimester 2 13 1.02 0.99 to 1.04 0.96 to 1.08 89.91
sFlt-1 trimester 3 9 1.03 1.02 to 1.04 1.00 to 1.06 85.70
PAPP-A trimester 1 11 0.83 0.54 to 1.29 0.21 to 3.24 99.99
PAPP-A trimester 2 4 1.00 0.99 to 1.02 0.98 to 1.02 65.03
N/A, not applicable (only one study); PI, pulsatility index; SGA, small for gestational age.
Note
Continuous variables are 1-unit increments, except maternal age, SBP, DBP and MAP, which are 10-unit increments,
and PIGF, sFlt-1 and PAPP-A, which are 100-unit increments.
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The study estimates varied considerably in terms of heterogeneity, with most predictors showing
heterogeneity of ≥ 70%. Variation between the 95% CI for the mean effect and the 95% prediction
interval for the distribution of true effects was great for many predictors, which was expected given
the varying level of heterogeneity.
The strongest association with the outcome was observed for history of hypertension (OR 4.76, 95% CI
3.56 to 6.35; I2 = 98.39%), with a fivefold increase in the odds of pre-eclampsia in women with a
history of hypertension compared with women without a history of hypertension. Most predictors had
evidence of an association at the 5% level. However, maternal age, family history of pre-eclampsia,
PCR (for unspecified trimester estimates and trimester 1 and 2 estimates), urine dipstick (unspecified
trimester estimates), previous small for gestational age fetus, cocaine, heroin or methamphetamine use,
uterine artery pulsatility index (trimester 3), umbilical artery pulsatility index (for unspecified trimester
estimates and trimester 2 and 3 estimates), sFlt-1 (all trimesters estimates) and PAPP-A (all trimester
estimates) were not statistically significant at the 5% level (see Table 20).
Most statistically significant predictors had evidence of an increase in odds of pre-eclampsia over the
course of pregnancy with increasing values, except multiparity (OR 0.88, 95% CI 0.79 to 0.99; I2 = 96.6%),
smoking during pregnancy (OR 0.84, 95% CI 0.76 to 0.93; I2 = 86.46%), spontaneous mode of conception
(OR 0.73, 95% CI 0.64 to 0.84; I2 = 58.67%) and increasing levels of PIGF measured in the first (OR 0.22,
95% CI 0.09 to 0.50; I2 = 85.44), second (OR 0.66, 95% CI 0.53 to 0.83; I2 = 87.27%) and third trimester
(OR 0.59, 95% CI 0.45 to 0.77; I2 = 96.78%), which showed a decrease in the odds of pre-eclampsia,
thereby providing a possible protective effect.
Early-onset pre-eclampsia
Table 21 shows the results of the two-stage meta-analysis for early-onset (delivery at < 34 weeks’
gestation) pre-eclampsia and each predictor variable. Third-trimester predictors were not explored
because they do not predate the outcome. The two-stage IPD meta-analysis could not be performed
for the following predictors: previous pre-eclampsia, history of hypertension, history of renal disease,
TABLE 21 Two-stage IPD meta-analysis for early-onset pre-eclampsia
Predictor
Number




Age 64 1.21 1.01 to 1.44 0.45 to 3.22 89.83
Multiple current pregnancy 18 3.63 2.35 to 5.60 0.66 to 19.82 96.96
Parity 37 0.99 0.87 to 1.12 0.56 to 1.74 86.04
BMI 40 1.06 1.04 to 1.08 0.99 to 1.13 85.89
BMI trimester 1 41 1.07 1.05 to 1.09 0.99 to 1.15 73.36
BMI trimester 2 20 1.05 1.02 to 1.08 0.95 to 1.15 66.81
SBP 18 1.65 1.43 to 1.92 0.98 to 2.80 75.60
SBP trimester 1 31 1.50 1.39 to 1.63 1.11 to 2.05 57.89
SBP trimester 2 23 1.73 1.51 to 1.97 1.15 to 2.60 68.74
DBP 18 1.92 1.53 to 2.42 0.86 to 4.31 80.98
DBP trimester 1 30 1.85 1.61 to 2.12 1.10 to 3.10 71.92
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history of diabetes, history of autoimmune disease, family history of pre-eclampsia, PCR measured in
the first trimester, previous small for gestational age fetus, smoking during pregnancy, spontaneous
mode of conception, cocaine, heroin or methamphetamine use, umbilical artery pulsatility index
measured in the first trimester, PlGF, sFlt-1 and PAPP-A.239
Heterogeneity for predictors varied considerably, and ranged from 0% to 97% for PlGF. The strongest
association with the outcome was observed for uterine artery pulsatility index measured in the second
trimester (OR 14.73, 95% CI 8.12 to 26.72; I2 = 60.11%), which suggests an increase in the odds of
early-onset pre-eclampsia of about 15 times, with a unit increase in the mean uterine artery pulsatility
index. The confidence and prediction intervals for this were wide (95% prediction interval 3.10 to 69.96),
demonstrating the variability within the studies. Most predictors had evidence of an association at
the 5% level, but parity, PCR measured in the second trimester, urine dipstick (unspecified trimester
estimates and first trimester), sFlt-1 (first-trimester estimates) and PAPP-A (all trimester estimates)
TABLE 21 Two-stage IPD meta-analysis for early-onset pre-eclampsia (continued )
Predictor
Number
of studies OR 95% CI
95% prediction
interval I2 (%)
DBP trimester 2 23 2.15 1.79 to 2.59 1.23 to 3.76 69.28
MAP 24 2.18 1.83 to 2.60 1.11 to 4.30 74.08
MAP trimester 1 33 2.00 1.73 to 2.31 1.13 to 3.55 74.01
MAP trimester 2 24 2.25 1.89 to 2.69 1.28 to 3.97 70.79
PCR 3 1.00 1.00 to 1.01 1.00 to 1.01 0.00
PCR trimester 2 1 1.02 0.90 to 1.14 N/A N/A
Urine dipstick 5 3.30 0.31 to 35.27 0.01 to 922.24 96.69
Urine dipstick trimester 1 3 3.29 0.28 to 38.31 0.04 to 300.79 86.11
Urine dipstick trimester 2 8 3.20 1.79 to 5.72 0.93 to 10.94 67.54
Ultrasound markers
Uterine artery PI 11 6.27 2.70 to 14.58 0.82 to 48.23 54.17
Uterine artery PI trimester 1 11 2.14 1.24 to 3.67 0.56 to 8.24 50.70
Uterine artery PI trimester 2 13 14.73 8.12 to 26.72 3.10 to 69.96 60.11
Umbilical artery PI 5 5.44 3.27 to 9.06 3.27 to 9.06 0.00
Umbilical artery PI trimester 2 8 6.29 2.85 to 13.92 2.85 to 13.92 0.00
Biochemical markers
PIGF trimester 1 15 0.08 0.02 to 0.35 0.00 to 5.94 55.69
PIGF trimester 2 13 0.07 0.01 to 0.43 0.00 to 13.16 97.18
sFlt-1 trimester 1 10 0.99 0.97 to 1.01 0.97 to 1.01 0.21
sFlt-1 trimester 2 12 1.05 1.01 to 1.09 0.96 to 1.15 90.28
PAPP-A trimester 1 9 0.99 0.97 to 1.01 0.97 to 1.01 0.43
PAPP-A trimester 2 3 1.00 1.00 to 1.00 1.00 to 1.00 0.00
N/A, not applicable (only one study); PI, pulsatility index.
Note
Continuous variables are one-unit increments, except maternal age, SBP, DBP and MAP, which are 10-unit increments,
and PIGF, sFlt-1 and pregnancy-associated plasma protein A, which are 100-unit increments.
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were not statistically significant at the 5% level. All statistically significant predictors had evidence of
an increase in the odds of early pre-eclampsia with increasing values, except PlGF measured in the first
(OR 0.08, 95% CI 0.02 to 0.35; I2 = 55.69%) or the second trimester (OR 0.07, 95% CI 0.01 to 0.43;
I2 = 97.18%), which showed a decrease in the odds of pre-eclampsia with increasing levels.
Late-onset pre-eclampsia
The results of the two-stage meta-analysis for late-onset (delivery at ≥ 34 weeks’ gestation) pre-eclampsia
and each predictor variable are shown in Table 22. The two-stage IPD meta-analysis could not be
performed for the following predictors: previous pre-eclampsia, history of hypertension, history of
renal disease, history of diabetes, history of autoimmune disease, family history of pre-eclampsia, PCR
measured in the first trimester, previous small for gestational age fetus, smoking during pregnancy,
spontaneous mode of conception, cocaine, heroin or methamphetamine use, umbilical artery pulsatility
index measured in the first trimester, PlGF, sFlt-1, PAPP-A and PAPP-A measured in the third trimester.239
TABLE 22 Two-stage IPD meta-analysis for late-onset pre-eclampsia
Predictor Number of studies OR 95% CI 95% prediction interval I2 (%)
Maternal clinical characteristics
Age 68 1.04 0.94 to 1.14 0.60 to 1.81 94.66
Multiple current pregnancy 22 2.18 1.59 to 2.99 0.62 to 7.64 98.07
Parity 46 0.87 0.78 to 0.97 0.48 to 1.58 95.16
BMI 42 1.07 1.06 to 1.08 1.02 to 1.12 94.96
BMI trimester 1 45 1.07 1.06 to 1.09 1.00 to 1.15 92.31
BMI trimester 2 19 1.07 1.06 to 1.09 1.01 to 1.14 82.19
BMI trimester 3 10 1.09 1.06 to 1.13 0.99 to 1.21 82.31
SBP 19 1.44 1.29 to 1.61 0.94 to 2.22 87.60
SBP trimester 1 36 1.39 1.31 to 1.47 1.08 to 1.80 77.48
SBP trimester 2 26 1.43 1.33 to 1.54 1.09 to 1.88 76.58
SBP trimester 3 15 1.83 1.54 to 2.18 0.96 to 3.48 93.60
DBP 19 1.56 1.38 to 1.77 0.93 to 2.62 85.49
DBP trimester 1 36 1.58 1.44 to 1.73 1.09 to 2.30 79.70
DBP trimester 2 26 1.59 1.41 to 1.8 0.97 to 2.61 85.68
DBP trimester 3 15 2.20 1.68 to 2.88 0.84 to 5.78 95.00
MAP 25 1.74 1.51 to 2.01 0.94 to 3.22 88.77
MAP trimester 1 38 1.65 1.51 to 1.80 1.12 to 2.42 81.05
MAP trimester 2 27 1.70 1.51 to 1.92 1.02 to 2.85 86.86
MAP trimester 3 15 2.26 1.77 to 2.89 0.91 to 5.60 94.78
PCR 3 1.01 0.98 to 1.04 0.95 to 1.07 96.67
PCR trimester 1 1 0.75 0.34 to 1.67 N/A N/A
PCR trimester 2 1 0.97 0.92 to 1.03 N/A N/A
Urine dipstick 7 2.45 0.79 to 7.65 0.10 to 59.76 98.01
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There was considerable variation in the heterogeneity for predictors, and the strongest association
with the outcome was observed for uterine artery pulsatility index measured in the second trimester
(OR 2.95, 95% CI 2.31 to 3.76; I2 = 20.77%), which suggests that a 1-unit increase in the uterine
artery pulsatility index will lead to an approximate increase of three times in the odds of late-onset
pre-eclampsia. Most predictors assessed showed evidence of an association at the 5% level. However,
maternal age, PCR (for all trimester estimates), urine dipstick (unspecified trimester), third-trimester
uterine artery pulsatility index, umbilical artery pulsatility index (unspecified trimester and third trimester),
second-trimester sFlt-1 and PAPP-A (all trimesters estimates) were not statistically significant at the
5% level. All statistically significant predictors had evidence of an increase in odds of late-onset
pre-eclampsia except parity (OR 0.87, 95% CI 0.78 to 0.97; I2 = 95.16%), first-trimester (OR 0.33, 95% CI
0.16 to 0.68; I2 = 82.67%), second-trimester (OR 0.81, 95% CI 0.69 to 0.94; I2 = 76.39%) or third-trimester
(OR 0.68, 95% CI 0.57 to 0.81; I2 = 93.60%) measurement of PlGF and sFlt-1 measured in the first
trimester (OR 0.98, 95% CI 0.97 to 0.99; I2 = 37.07%), which showed a reduction in the odds of
late-onset pre-eclampsia.
Forest plots for each predictor assessed and for each outcome are presented in Report Supplementary
Material 1.
TABLE 22 Two-stage IPD meta-analysis for late-onset pre-eclampsia (continued )
Predictor Number of studies OR 95% CI 95% prediction interval I2 (%)
Urine dipstick trimester 1 5 1.85 1.48 to 2.32 1.48 to 2.32 0.00
Urine dipstick trimester 2 9 1.44 1.04 to 1.99 0.63 to 3.27 59.56
Urine dipstick trimester 3 5 2.73 1.47 to 5.04 0.72 to 10.34 81.85
Ultrasound markers
Uterine artery PI 11 2.19 1.36 to 3.54 0.59 to 8.12 64.30
Uterine artery PI trimester 1 12 1.61 1.09 to 2.39 0.54 to 4.83 71.53
Uterine artery PI trimester 2 12 2.95 2.31 to 3.76 1.94 to 4.48 20.77
Uterine artery PI trimester 3 3 3.98 0.04 to 403.56 0.00 to 11,096.61 67.65
Umbilical artery PI 5 0.91 0.05 to 15.46 0.00 to 375.27 88.83
Umbilical artery PI trimester 2 8 1.25 0.56 to 2.78 0.48 to 3.25 8.11
Umbilical artery PI trimester 3 5 0.91 0.26 to 3.25 0.11 to 7.36 32.31
Biochemical markers
PIGF trimester 1 17 0.33 0.16 to 0.68 0.03 to 3.93 82.67
PIGF trimester 2 16 0.81 0.69 to 0.94 0.52 to 1.25 76.39
PIGF trimester 3 12 0.68 0.57 to 0.81 0.38 to 1.20 93.60
sFlt-1 trimester 1 11 0.98 0.97 to 0.99 0.95 to 1.01 37.07
sFlt-1 trimester 2 13 1.00 0.99 to 1.00 0.99 to 1.01 8.29
sFlt-1 trimester 3 9 1.02 1.00 to 1.03 0.99 to 1.04 91.03
PAPP-A trimester 1 10 0.83 0.53 to 1.31 0.22 to 3.18 99.99
PAPP-A trimester 2 4 1.00 0.99 to 1.02 0.98 to 1.02 57.98
N/A, not applicable (only one study); PI, pulsatility index.
Note
Continuous variables are 1-unit increments, except maternal age, SBP, DBP and MAP, which are 10-unit increments,
and PIGF, sFlt-1 and PAPP-A, which are 100-unit increments.
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Summary
This unadjusted two-stage IPD meta-analysis of the prognostic effect of candidate predictors of early-,
late- and any-onset pre-eclampsia was limited to complete singleton records only and included all
78 studies in the IPPIC database, with missing data assumed to be missing completely at random.84
Most predictors had evidence of an association at the 5% level for each outcome. Increasing the values
of second-trimester measurement of uterine artery pulsatility index had the strongest statistically
significant association with early-onset (OR 14.73, 95% CI 8.12 to 26.72; I2 = 60.11%) or late-onset
(OR 2.95, 95% CI 2.31 to 3.76; I2 = 20.77%) pre-eclampsia. The predictor with the strongest statistically
significant association with any-onset pre-eclampsia was history of hypertension (OR 4.76, 95% CI
3.56 to 6.35; I2 = 98.39%). Smoking during pregnancy and spontaneous mode of conception were
associated with a reduction in odds of any-onset pre-eclampsia only; however, parity was associated
with reduced odds of late-onset and any-onset pre-eclampsia. Increases in PlGF measurements were
associated with a reduction in the odds of early-, late- and any-onset pre-eclampsia, whereas sFlt-1
was associated with a reduction in the odds of late-onset pre-eclampsia only. Conclusions drawn about
the association of predictors with outcomes should take into account the uncertainty resulting from
multiple testing type I errors. Further research should consider imputing for missing data to control for
the introduction of bias, and this would also allow associations to be adjusted for potential confounders,
giving a better evaluation of associations.
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Summary of the findings
Existing prediction models for any-, early- and late-onset pre-eclampsia IPD have poor to average
predictive performance when externally validated in the combined IPPIC-UK data sets. All models that
could be validated showed suboptimal predictive performance across data sets. The clinical utility of
the published models was poor.
Most of the IPPIC pre-eclampsia models showed good to average discrimination across data sets; all had
good to average calibration across data sets. The models varied in the predictive performance between
data sets. The clinical characteristics only and the clinical and biochemical first- and second-trimester
models to predict any pre-eclampsia showed consistent net benefit over a strategy of considering all
women to have pre-eclampsia for a wide range of probability thresholds beyond 5% in cohort of
nulliparous women with singleton pregnancies in the UK. Very few risk factors were associated with
pre-eclampsia, with significance in both the CIs and the prediction intervals including BMI, SBP and DBP
and MAP for any-, early- and late-onset pre-eclampsia; and urine dipstick, uterine artery pulsatility
index and umbilical artery pulsatility index for any- and early-onset pre-eclampsia.
Strengths and limitations
We used the largest data set to date to validate existing prediction models for pre-eclampsia, and to
further develop models when required. The IPPIC data set consists of information on predictor variables
at various trimesters. We used raw data to determine the presence or absence of pre-eclampsia and
the type of onset, ensuring the reliability of the findings. Our comprehensive search identified all published
models. By validating them in UK data sets, we were able to assess the extent of transportability of
existing models to women managed in the NHS. We assessed the quality of the data sets and studies
using robust tools. Rather than develop further models, we ensured that the performances of the
existing models were robustly evaluated. The models were validated not only using evidence synthesis,
but also within individual data sets. The large sample size provided us with sufficient events for the
rare but important outcome of early-onset pre-eclampsia. In addition to reporting the performances of
the models in terms of discrimination and calibration, we determined their clinical utility using decision
curve analysis.
Prior to the development of the IPPIC pre-eclampsia models, we prioritised the predictors for importance
to clinical practice by consensus to ensure face validity. We used multiple imputation to deal with missing
values for both predictors and outcomes to avoid the loss of useful information84,240 and explored complex
associations such as the non-linearity of predictor effects. We were able to report the association
between individual clinical, biochemical and ultrasound predictors, measured in the first, second or third
trimester, and rates of early-, late- and any-onset pre-eclampsia with very precise estimates. We pooled
data from a very large sample size using IPD meta-analysis, and explored a considerable number of risk
factors thought to be predictors of pre-eclampsia. We did not dichotomise any of the continuous predictive
factors and we also considered the predictive accuracy of these risk factors along with their association.
Our findings were limited by the variations in population mix, the definitions of the predictors in each
study and the outcomes reported. Some studies included only nulliparous women, some strictly included
low-risk pregnancies and some included all pregnancies. The prioritisation of predictors of pre-eclampsia
by members of the collaborative network who contributed data to the project could also be considered
a limitation in the identification of predictors to be considered for model development. It was possible
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that participants in the survey would rank predictors as important based on their particular research
interest, and this method could potentially hamper the identification of new candidate predictors.
However, we had a good representation of responses to the survey, and respondents were able to
suggest possible factors not already assessed in the survey to be considered as predictors. There was
also good consensus among respondents about the importance of predictors assessed, and no new
candidate predictors were identified. The individual UK data sets measured different sets of variables
(potential predictors) and measured them at different times (e.g. first, second or third trimester). Our
validation was carried out considering only UK data sets to reduce the heterogeneity in the outcome
definition and to allow existing models’ predictive performance to be assessed in the UK health-care
system context. However, this limited our ability to validate many of the existing prediction models and
meant that we could validate models across the studies only if all of them reported the same variables.
We were, therefore, also unable to validate all existing models in our IPD because of the unavailability
of predictors in the models in our UK IPD. It is possible that a significant predictor may not have been
evaluated if it was not provided across varied data sets. Some studies used data from the same cohort
of women to report various prediction models in multiple combinations. The sources of the data also
differed across data sets. Some were collected prospectively with the explicit purpose of predicting
pre-eclampsia, whereas others were routine registry data. All of the above accounted for the
heterogeneity observed in the performance of the models across the data sets. We validated the
performances of published models across only UK data sets, but included all data sets for model
development. It is likely that the transportability performances may have differed if all available data had
been included. Furthermore, some models, such as the North et al. model42 for any-onset pre-eclampsia,
the Poon 2009 model234 for early-onset pre-eclampsia and the Akolekar et al. model241 for late-onset
pre-eclampsia, could not be validated as the predictor variables in the models were not available in any
of the IPPIC-UK data sets.
To ensure that the relevant data were included in the analysis, we dealt with missing data by imputing
both within and between studies. We also made assumptions such as using early second-trimester
values of BMI and MAP if the first-trimester values were missing. Our analysis of the association of risk
factors and the different pre-eclampsia outcomes was limited to complete records only. Our assumption
that data missing were missing completely at random is unlikely to be true. Applying multilevel multiple
imputation would reduce this bias, and also allow estimates to be adjusted for potential confounders,
giving a better evaluation of associations. However, the complexity of modelling the missing data
mechanism would make this demanding (or impossible). We therefore present this as the most robustly
available assessment of risk factors for pre-eclampsia.
Comparison with existing evidence
Current guidelines such as those by the National Institute for Health and Care Excellence242 in the UK
and by the American College of Obstetricians and Gynecologists73 in the USA provide a list of risk
factors rather than a prediction model to determine an individual’s risk of pre-eclampsia. The predictive
performance of both approaches has been shown to be inferior to that of multivariable prediction
models.236,243,244 However, these models had not been externally validated in multiple data sets until
now, with resulting suboptimal predictive performance.
Until now, only a small fraction of the 131 pre-eclampsia prediction models identified have been
externally validated (11%, 15/131), and an even smaller proportion (4%, 5/131) have been evaluated
for their clinical utility.44,108,160,245,246 Studies reporting on the external validation of these models often
have not reported performance measures in terms of calibration, which has more value in assessing the
predictive performance of the model than discrimination estimates or detection rates.247 Some existing
models also used multiples of the mean to standardise biochemical and ultrasound markers, but this is
of limited use in real-world settings as the estimates of adjustment factors used to standardise these
DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
78
measurements to multiple of the mean values in the models are not always known in the population in
which the model is to be used. For some of the models that we could validate, the summary performance
measures have a lot of uncertainty (wide CIs), reflecting the small numbers of events and/or the
heterogeneity. Even with larger numbers of events, CIs can be wide, especially for calibration, so it is
possible that, for some of the models, miscalibration is due to chance. However, we must also look
at the broader picture emerging across all of the validations. For most models, the majority of summary
results for calibration, and the study-specific results for calibration, are suggestive of overfitting
(slopes < 1). This is something that the field needs to address as whole. In our IPPIC models, we have
examined overfitting in our model development, and adjusted for it.
Recently, the ASPRE trial34 showed that women at high risk of preterm pre-eclampsia who were
started on 150 mg of aspirin early in pregnancy had their risk lowered, and their high-risk status was
determined using a prediction model. However, a few questions need to be answered before this
approach is implemented. First, the extent to which the model over- or underpredicted women’s
pre-eclampsia risk is not reported in the study, because women assessed as being at low risk of
pre-eclampsia using the model were not followed up further. This is also shown by the significant
difference in the incidence of preterm pre-eclampsia between the placebo group and the population
used to develop the model. Second, it is likely that some women in the group categorised as ‘low risk’
using the model may have benefited from the intervention. In the absence of follow-up of this group
for pre-eclampsia outcomes, we cannot robustly confirm that they would not have benefited from the
intervention. Third, the clinical utility of the prediction model has not been assessed, limiting our ability
to recommend its routine use in clinical practice. We were unable to validate the exact model used
in the ASPRE trial because the multiple of the mean predictors were unavailable in our IPD data set.
The authors who developed this model recently validated it in three data sets with ‘appropriately
trained staff and quality control of measurement’.248 This showed that the model discriminated well,
with a large C-statistic in all three validation data sets. However, further independent validation of
this model is needed to evaluate its performance in ‘real-world’ settings.
Although some of the published models showed a promising ability to discriminate between women
who had a pre-eclampsia outcome and those who did not, calibration performance was generally poor
across the data sets and there was large heterogeneity in the calibration performance across different
IPPIC data sets. Although the CIs (e.g. for calibration slope) were sometimes very wide, a general
picture is that most models demonstrated overfitting at model development with predictions that
were too extreme compared with the observed risk in the data sets (calibration slope < 1). Model
predictions were also systematically too low or too high depending on the data set used to validate
the model (calibration-in-the-large ≠ 0). The models were validated in a rather heterogeneous group
of data sets with different eligibility criteria. These findings suggest that the differences between
women in the data sets were not adequately captured by the set of predictors included in the models.
There was also little difference in predictive performance when biochemical markers or ultrasound
markers were combined with maternal and clinical characteristics, compared with models with only
maternal and clinical characteristics. Some of the heterogeneity in predictive performance of the
models is likely to be due to different methods and timing of measurement, for example in blood
pressure and biochemical marker values. Going forward, standardisation of measurement methods,
for example across laboratories and hospitals, might reduce heterogeneity in calibration performance.
A related point is that prediction models in this field need to be clearer with regard to how and
exactly when included predictors should be measured.
For IPPIC models, summary predictive performance was promising, and net benefit was demonstrated
in some data sets across clinically relevant thresholds of predicted risk. However, large heterogeneity
remained in all performance statistics across data sets. Heterogeneity in calibration performance
could be reduced if, when applying the models in practice, model parameters (e.g. intercept) could
be recalibrated to each population and setting. This would require local data for recalibration and
model updating.
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Relevance to clinical practice
Existing models that were externally validated had poor calibration performance and their utility was
limited, with no model identified that can be recommended for clinical use. The IPPIC models showed
promising performance for predicting pre-eclampsia, in particular in both low- and middle-income
countries where only clinical characteristics may be available, and in high-income countries where
there is access to additional biochemical markers. However, on application, the predictive performance
of the models needs to be improved by recalibration to particular settings and populations; this
would require local data. Ultrasound markers did not add any additional information or improve the
performance of the prediction models beyond the clinical characteristic only models. This suggests a
lack of need for additional time or resources in carrying out these assessments for screening of women
at risk of pre-eclampsia. The thresholds of risk on which decision-making is based are likely to vary
with the planned intervention (aspirin or calcium), as well as following shared decision-making through
discussions between the clinician and the woman.
Relevance to research
Validation, including examination of calibration heterogeneity, is still required for the models we could not
validate. For these and the IPPIC models, we need validation in multiple large data sets across different
settings and populations to properly assess their transportability.249 The impact of using the models in
clinical practice needs to be evaluated beyond predicting pre-eclampsia, but also in the identification
of women with pre-eclampsia who are also most likely to have severe complications such as HELLP
syndrome, eclampsia, abruption or renal failure. The acceptability of the models to both women and
health-care professionals needs to be assessed, including elucidation of their preferred threshold
probability for treatment decisions. A decision-analytic model of resource implications, including the
cost utilities of consequences of decisions for various false-positive and false-negative cases, is also
needed. Updated models may be needed in local populations, for example using recalibration of the
IPPIC models in local data sets, to improve calibration performance. Furthermore, additional strong
predictors need to be identified to improve model performance and consistency. New cohorts need to
standardise the predictors and outcomes measured, including their timing and measurement methods,
to enable more homogenous data sets to be combined in IPD meta-analyses.
Conclusion
Among the 24 existing prediction models that could be validated in the IPD meta-analysis, generally
their predictive performance was poor across data sets. To address this, IPPIC models were developed
with adjustment for overfitting, which show good predictive performance on average across data sets
and may have net benefit in singleton nulliparous populations in the UK. However, heterogeneity
across settings is likely in calibration performance, and thus the models need to be recalibrated in local
settings and populations of application. Ultrasound markers did not improve the predictive performance
of the developed IPPIC clinical characteristic-only models. We did not identify any new predictors
for our model development that were not considered previously in existing models. Further work is
therefore needed to validate other models, identify new predictors and improve calibration performance
in all settings of intended use.
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Appendix 2 Search strategies
TABLE 23 Search strategies for the review of reviews
Set# Searched for
S1 MESH.EXACT(“Pre-Eclampsia”) OR MESH.EXACT(“Hypertension, Pregnancy-Induced”)
S2 (MESH.EXACT.EXPLODE(“Pregnancy”) OR MESH.EXACT.EXPLODE(“Pregnancy Trimesters”) OR MESH.EXACT
(“Pregnancy Complications”) OR MESH.EXACT(“Pregnancy Complications, Cardiovascular”) OR MESH.EXACT
(“Pregnant Women”)) and MESH.EXACT(“Hypertension”)
S3 (MESH.EXACT.EXPLODE(“Pregnancy”) OR MESH.EXACT.EXPLODE(“Pregnancy Trimesters”) OR MESH.EXACT
(“Pregnancy Complications”) OR MESH.EXACT(“Pregnancy Complications, Cardiovascular”) OR MESH.EXACT
(“Pregnant Women”)) and ti,ab(hypertens[*4])
S4 ti,ab(pregnan*) and MESH.EXACT(“Hypertension”)
S5 EMB.EXACT(“eclampsia and preeclampsia”) OR EMB.EXACT(“preeclampsia”) OR EMB.EXACT(“pregnancy
toxemia”) OR EMB.EXACT(“maternal hypertension”)
S6 (EMB.EXACT.EXPLODE(“pregnancy”) OR EMB.EXACT(“pregnancy complication”) OR EMB.EXACT(“pregnancy
disorder”) OR EMB.EXACT(“pregnant woman”)) and (EMB.EXACT(“essential hypertension”) OR EMB.EXACT
(“hypertension”))
S7 (EMB.EXACT.EXPLODE(“pregnancy”) OR EMB.EXACT(“pregnancy complication”) OR EMB.EXACT(“pregnancy
disorder”) OR EMB.EXACT(“pregnant woman”)) and ti,ab(hypertens[*4])
S8 ti,ab(pregnan*) and (EMB.EXACT(“essential hypertension”) OR EMB.EXACT(“hypertension”))
S9 ti,ab(preeclamp* or preclamp* or “pre eclamp*” or “pre clamp*”)
S10 ti,ab((pregnan* or eclamp*) near/3 (toxemi[*2] or toxaemi[*2] or toxicosis))
S11 ti,ab((edema or oedema) near/3 proteinuria near/3 hypertens[*4])
S12 ti,ab(“eph gestos[*2]” or “eph toxemi[*2]” or “eph toxaemi[*2]” or “eph complex” or “eph syndrome”)
S13 ti,ab(gestation* near/3 (hypertens[*4] or toxemi[*2] or toxaemi[*2] or toxicosis))
S14 ti,ab(maternal near/3 hypertens[*4])
S15 ti,ab(pregnan* near/5 hypertens[*4])
S16 rtype.exact(“Meta-Analysis”) or MESH.EXACT(“Meta-Analysis”) or EMB.EXACT(“meta analysis”) or EMB.EXACT
(“systematic review”)
S17 MESH.EXACT(“Meta-Analysis as Topic”) or EMB.EXACT(“meta analysis (topic)”) or EMB.EXACT(“systematic
review (topic)”)
S18 ti,ab(“meta analy[*3]” or metaanaly[*3] or “systematic review[*1]”)
S19 pub.exact(“Cochrane Database of Systematic Reviews” OR “Cochrane Database of Systemic Reviews” OR
“Cochrane Library” OR “Cochrane database of systematic reviews (Online)” OR “The Cochrane database of
systematic reviews” OR “The Cochrane library”)
S20 (s1 or s2 or s3 or s4 or s5 or s6 or s7 or s8 or s9 or s10 or s11 or s12 or s13 or s14 or s15) and (s16 or s17 or
s18 or s19)
S21 (s1 or s2 or s3 or s4 or s5 or s6 or s7 or s8 or s9 or s10 or s11 or s12 or s13 or s14 or s15) and (s16 or s17 or
s18 or s19) and human(yes)
S22 ((s1 or s2 or s3 or s4 or s5 or s6 or s7 or s8 or s9 or s10 or s11 or s12 or s13 or s14 or s15) and (s16 or s17
or s18 or s19)) not (human(yes) or animal(yes) or EMB.EXACT(“nonhuman”))
S23 s21 or s22
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TABLE 24 Search strategies for pre-eclampsia prediction models
Set# Searched for
#1 Validat*[tiab] OR Predict*[ti] OR Rule*[tiab]
#2 Predict*[tiab] AND (Outcome*[tiab] OR Risk*[tiab] OR Model*[tiab])
#3 (History[tiab] OR Variable*[tiab] OR Criteria[tiab] OR Scor*[tiab] OR Characteristic*[tiab] OR Finding*[tiab] OR
Factor*[tiab]) AND (Predict*[tiab] OR Model*[tiab] OR Decision*[tiab] OR Identif*[tiab] OR Prognos*[tiab])
#4 Decision*[tiab] AND (Model*[tiab] OR Clinical*[tiab] OR Logistic Model*[tiab])
#5 Prognostic[tiab] AND (History[tiab] OR Variable*[tiab] OR Criteria[tiab] OR Scor*[tiab] OR Characteristic*[tiab]
OR Finding*[tiab] OR Factor*[tiab] OR Model*[tiab])
#6 “risk score”[All fields] OR “prediction model”[All fields] OR “prediction rule”[All fields] OR “risk assessment”[All
fields] OR “algorithm”[All fields]
#7 # 1 OR #2 OR #3 OR #4 OR #5 OR #6
#8 (pregnan*[tiab] OR obstetric*[tiab] OR woman[tiab] OR women[tiab]) AND (preeclampsia[tiab] OR
pre-eclampsia [tiab])
#9 #7 AND #8
#10 #9 NOT (Animals[MeSH] NOT Humans[MeSH])
Reproduced from Snell et al.52 Open Access This article is licensed under a Creative Commons Attribution 4.0
International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format,
as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons
licence, and indicate if changes were made. The images or other third party material in this article are included in the
article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not
included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or
exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this
licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated in a credit line to the data.
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Appendix 3 Individual participant data
extracted on the IPPIC project
Candidate predictors Brief description Categories
Maternal clinical characteristics
Age ‘Age in years (continuous)’
Parity ‘Number of times giving birth before this pregnancy
(continuous)’
0 ‘No’ 1 ‘Yes’
‘Nulliparous (binary)’
Previous miscarriage ‘Number of previous miscarriages (continuous)’
‘Previous miscarriage (binary)’ 0 ‘No’ 1 ‘Yes’
‘Previous miscarriage trimester 1 (binary)’
‘Previous miscarriage trimester 2 (binary)’
Previous stillbirth ‘Previous stillbirth (binary)’ 0 ‘No’ 1 ‘Yes’
History of SGA birth ‘SGA in a previous pregnancy (binary)’ 0 ‘No’ 1 ‘Yes’
Previous pre-eclampsia ‘Previous history of any pre-eclampsia (binary)’ 0 ‘No’ 1 ‘Yes’
Previous early pre-eclampsia ‘Previous early pre-eclampsia (binary)’ 0 ‘No’ 1 ‘Yes’
Gestational age at previous
pre-eclampsia
‘Gestational age at previous pre-eclampsia (continuous)’
Previous any preterm delivery ‘Previous any preterm delivery (binary)’ 0 ‘No’ 1 ‘Yes’
Previous early preterm delivery ‘Previous early preterm delivery < 34 weeks (binary)’ 0 ‘No’ 1 ‘Yes’
Previous late preterm delivery ‘Previous late preterm delivery ≥ 34 weeks (binary)’ 0 ‘No’ 1 ‘Yes’
Gestational age at previous
preterm delivery
‘Gestational age at previous preterm delivery (continuous)’
Previous heritable
thrombophilia
‘History of heritable thrombophilia (binary)’ 0 ‘No’ 1 ‘Yes’
Previous autoimmune disease ‘History of systemic lupus, rheumatoid arthritis or
antiphospholipid syndrome (binary)’
0 ‘No’ 1 ‘Yes’
History of pre-eclampsia in
mother
‘Mother has a history of pre-eclampsia (binary)’ 0 ‘No’ 1 ‘Yes’
Family history of pre-eclampsia ‘Mother or sister has a history of pre-eclampsia (binary)’ 0 ‘No’ 1 ‘Yes’
Family history of cardiovascular
disease
‘Family history of cardiovascular disease (binary)’ 0 ‘No’ 1 ‘Yes’
History of renal disease ‘History of renal disease (binary)’ 0 ‘No’ 1 ‘Yes’
History of pre-existing diabetes ‘History of type 1, type 2 or gestational diabetes (binary)’ 0 ‘No’ 1 ‘Yes’
History of gestational diabetes
mellitus
‘Previous gestational diabetes mellitus (binary)’ 0 ‘No’ 1 ‘Yes’
Gestational diabetes in current
pregnancy
‘Gestational diabetes in current pregnancy trimester 1
(binary)’
0 ‘No’ 1 ‘Yes’
‘Gestational diabetes in current pregnancy trimester 1
(binary)’
0 ‘No’ 1 ‘Yes’
‘Gestational diabetes in current pregnancy trimester 2
(binary)’
0 ‘No’ 1 ‘Yes’
‘Gestational diabetes in current pregnancy trimester 3
(binary)’
0 ‘No’ 1 ‘Yes’
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Candidate predictors Brief description Categories
Early pregnancy bleeding ‘Early pregnancy bleeding in current pregnancy (binary)’ 0 ‘No’ 1 ‘Yes’
Chronic or pre-existing
hypertension
‘History of chronic, essential or pre-existing hypertension
(binary)’
0 ‘No’ 1 ‘Yes’
Smoking ‘Smoked during current pregnancy (binary)’ 0 ‘No’ 1 ‘Yes’
Number of cigarettes smoked
per day
‘Number of cigarettes smoked per day (continuous)’
Alcohol use ‘Drank Alcohol (binary)’ 0 ‘No’ 1 ‘Yes’
Substance misuse in current
pregnancy
‘Cocaine, heroin or methamphetamine use in current
pregnancy (binary)’
0 ‘No’ 1 ‘Yes’
Mode of conception ‘Spontaneous mode of conception (binary)’ 0 ‘No’ 1 ‘Yes’
Multiple pregnancy ‘Multiple pregnancy in current pregnancy (binary)’ 0 ‘No’ 1 ‘Yes’
Number of years between
pregnancies
‘Number of years between pregnancies (continuous)’
Maternal education ‘Highest level of maternal education attained (categorical)’ 1 ‘Primary’
2 ‘Secondary’
3 ‘Tertiary’
‘Maternal years in education primary school (continuous)’
New partner ‘New partner (binary)’ 0 ‘No’ 1 ‘Yes’
Healthy diet in pregnancy ‘On healthy diet in pregnancy (binary)’ 0 ‘No’ 1 ‘Yes’
Planned physical activity ‘Planned physical activity (categorical)’ 1 ‘Sedentary’
2 ‘Moderate’
3 ‘Severe’






BMI ‘BMI in kg/m2 (continuous)’
‘BMI in kg/m2 trimester 1 (continuous)’
‘BMI in kg/m2 trimester 2 (continuous)‘
‘BMI in kg/m2 trimester 3 (continuous)’
Height ‘Height in cm (continuous)’
Weight ‘Weight in kg (continuous)’
‘Weight in kg trimester 1 (continuous)’
‘Weight in kg trimester 2 (continuous)’
‘Weight in kg trimester 3 (continuous)’
SBP ‘SBP in mmHg (continuous)’
‘SBP in mmHg trimester 1 (continuous)’
‘SBP in mmHg trimester 2 (continuous)’
‘SBP in mmHg trimester 3 (continuous)’
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Candidate predictors Brief description Categories
DBP ‘DBP in mmHg (continuous)’
‘DBP in mmHg trimester 1 (continuous)’
‘DBP in mmHg trimester 2 (continuous)’
‘DBP in mmHg trimester 3 (continuous)’
MAP ‘MAP in mmHg (continuous)’
‘MAP in mmHg trimester 1 (continuous)’
‘MAP in mmHg trimester 2 (continuous)’
‘MAP in mmHg trimester 3 (continuous)’
Urine dipstick ‘Urine dipstick (categorical)’ 0 ‘0 or trace’ 1 ‘1+’
2 ‘≥ 2+’
‘Urine dipstick trimester 1 (categorical)’
‘Urine dipstick trimester 2 (categorical)’
‘Urine dipstick trimester 3 (categorical)’
24-hour protein ‘24-hour protein in g/24hr (continuous)’
‘24-hour protein in g/24hr trimester 1 (continuous)’
‘24-hour protein in g/24hr trimester 2 (continuous)’
‘24-hour protein in g/24hr trimester 3 (continuous)’
PCR ‘PCR in mg/mmol of creatinine (continuous)’
‘PCR in mg/mmol of creatinine trimester 1 (continuous)’
‘PCR in mg/mmol of creatinine trimester 2 (continuous)’
‘PCR in mg/mmol of creatinine trimester 3 (continuous)’
Ultrasound markers
Unilateral notching ‘Unilateral notching (binary)’ 0 ‘No’ 1 ‘Yes’
‘Unilateral notching trimester 1 (binary)’
‘Unilateral notching trimester 2 (binary)’
‘Unilateral notching trimester 3 (binary)’
Bilateral notching ‘Bilateral notching (binary)’ 0 ‘No’ 1 ‘Yes’
‘Bilateral notching trimester 1 (binary)’
‘Bilateral notching trimester 2 (binary)’
‘Bilateral notching trimester 3 (binary)’
Uterine artery PI ‘Uterine artery PI (continuous)’
‘Uterine artery PI trimester 1 (continuous)’
‘Uterine artery PI trimester 2 (continuous)’
‘Uterine artery PI trimester 3 (continuous)’
Umbilical artery PI ‘Umbilical artery PI (continuous)’
‘Umbilical artery PI trimester 1 (continuous)’
‘Umbilical artery PI trimester 2 (continuous)’
‘Umbilical artery PI trimester 3 (continuous)’
Uterine artery PI MoM ‘Uterine artery PI MoM (continuous)’
‘Uterine artery PI MoM trimester 1 (continuous)’
‘Uterine artery PI MoM trimester 2 (continuous)’
‘Uterine artery PI MoM trimester 3 (continuous)’
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Candidate predictors Brief description Categories
Umbilical artery PI MoM ‘Umbilical artery PI MoM (continuous)’
‘Umbilical artery PI MoM trimester 1 (continuous)’
‘Umbilical artery PI MoM trimester 2 (continuous)’
‘Umbilical artery PI MoM trimester 3 (continuous)’
Uterine artery RI ‘Uterine artery RI (continuous)’
‘Uterine artery RI trimester 1 (continuous)’
‘Uterine artery RI trimester 2 (continuous)’
‘Uterine artery RI trimester 3 (continuous)’
Umbilical artery RI ‘Umbilical artery RI (continuous)’
‘Umbilical artery RI trimester 1 (continuous)’
‘Umbilical artery RI trimester 2 (continuous)’
‘Umbilical artery RI trimester 3 (continuous)’
Uterine artery RI MoM ‘Uterine artery RI MoM (continuous)’
‘Uterine artery RI MoM trimester 1 (continuous)’
‘Uterine artery RI MoM trimester 2 (continuous)’
‘Uterine artery RI MoM trimester 3 (continuous)’
Umbilical artery RI MoM ‘Umbilical artery RI MoM (continuous)’
‘Umbilical artery RI MoM trimester 1 (continuous)’
‘Umbilical artery RI MoM trimester 2 (continuous)’
‘Umbilical artery RI MoM trimester 3 (continuous)’
Abdominal circumference ‘Abdominal circumference (continuous)’
‘Abdominal circumference trimester 2 (continuous)’
‘Abdominal circumference trimester 3 (continuous)’
Abdominal circumference
centile
‘Abdominal circumference centile (continuous)’
‘Abdominal circumference centile trimester 2 (continuous)’
‘Abdominal circumference centile trimester 3 (continuous)’
CRL ‘Crown–rump length in mm (continuous)’
‘Crown–rump length in mm trimester 1 (continuous)’
‘Crown–rump length in mm trimester 2 (continuous)’
Expected fetal weight ‘Expected fetal weight in grams (continuous)’
‘Expected fetal weight in grams trimester 1 (continuous)’
‘Expected fetal weight in grams trimester 2 (continuous)’
‘Expected fetal weight in grams trimester 3 (continuous)’
Expected fetal weight centile ‘Expected fetal weight centile (continuous)’
‘Expected fetal weight centile trimester 1 (continuous)’
‘Expected fetal weight centile trimester 2 (continuous)’
‘Expected fetal weight centile trimester 3 (continuous)’
Biochemical markers
PAPP-A ‘PAPP-A (continuous)’
‘PAPP-A trimester 1 (continuous)’
‘PAPP-A trimester 2 (continuous)’
‘PAPP-A trimester 3 (continuous)’
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Candidate predictors Brief description Categories
PlGF ‘PlGF (continuous)’
‘PlGF trimester 1 (continuous)’
‘PlGF trimester 2 (continuous)’
‘PlGF trimester 3 (continuous)’
sFlt-1 ‘sFlt-1 (continuous)’
‘sFlt-1 trimester 1 (continuous)’
‘sFlt-1 trimester 2 (continuous)’
‘sFlt-1 trimester 3 (continuous)’
sENG ‘sENG (continuous)’
‘sENG trimester 1 (continuous)’
‘sENG trimester 2 (continuous)’
‘sENG trimester 3 (continuous)’
CRP ‘CRP (continuous)’
‘CRP trimester 1 (continuous)’
‘CRP trimester 2 (continuous)’
‘CRP trimester 3 (continuous)’
Hypertriglyceridaemia ‘Hypertriglyceridaemia (continuous)’
‘Hypertriglyceridaemia trimester 1 (continuous)’
‘Hypertriglyceridaemia trimester 2 (continuous)’
‘Hypertriglyceridaemia trimester 3 (continuous)’
PAI-1 polymorphism ‘PAI-1 polymorphism (continuous)’
‘PAI-1 polymorphism trimester 1 (continuous)’
‘PAI-1 polymorphism trimester 2 (continuous)’
‘PAI-1 polymorphism trimester 3 (continuous)’
Human chorionic gonadotropin ‘hCG (continuous)’
‘hCG trimester 1 (continuous)’
‘hCG trimester 2 (continuous)’
‘hCG trimester 3 (continuous)’
AFP ‘AFP (continuous)’
‘AFP trimester 1 (continuous)’
‘AFP trimester 2 (continuous)’
‘AFP trimester 3 (continuous)’
PAPP-A MoM ‘PAPP-A MoM (continuous)’
‘PAPP-A MoM trimester 1 (continuous)’
‘PAPP-A MoM trimester 2 (continuous)’
‘PAPP-A MoM trimester 3 (continuous)’
PlGF MoM ‘PlGF MoM (continuous)’
‘PlGF MoM trimester 1 (continuous)’
‘PlGF MoM trimester 2 (continuous)’
‘PlGF MoM trimester 3 (continuous)’
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Candidate predictors Brief description Categories
sFlt-1 MoM ‘sFlt-1 MoM (continuous)’
‘sFlt-1 MoM trimester 1 (continuous)’
‘sFlt-1 MoM trimester 2 (continuous)’
‘sFlt-1 MoM trimester 3 (continuous)’
sENG MoM ‘sENG MoM (continuous)’
‘sENG MoM trimester 1 (continuous)’
‘sENG MoM trimester 2 (continuous)’
‘sENG MoM trimester 3 (continuous)’
CRP MoM ‘CRP MoM (continuous)’
‘CRP MoM trimester 1 (continuous)’
‘CRP MoM trimester 2 (continuous)’
‘CRP MoM trimester 3 (continuous)’
Hypertriglyceridaemia MoM ‘Hypertriglyceridaemia MoM (continuous)’
‘Hypertriglyceridaemia MoM trimester 1 (continuous)’
‘Hypertriglyceridaemia MoM trimester 2 (continuous)’
‘Hypertriglyceridaemia MoM trimester 3 (continuous)’
PAI-1 polymorphism MoM ‘PAI-1 polymorphism MoM (continuous)’
‘PAI-1 polymorphism MoM trimester 1 (continuous)’
‘PAI-1 polymorphism MoM trimester 2 (continuous)’




‘hCG MoM trimester 1 (continuous)’
‘hCG MoM trimester 2 (continuous)’
‘hCG MoM trimester 3 (continuous)’
AFP MoM ‘AFP MoM (continuous)’
‘AFP MoM trimester 1 (continuous)’
‘AFP MoM trimester 2 (continuous)’
‘AFP MoM trimester 3 (continuous)’
Primary outcome
Any-onset pre-eclampsia ‘Any-onset pre-eclampsia (binary)’ 0 ‘No’ 1 ‘Yes’
Early-onset pre-eclampsia ‘Early-onset pre-eclampsia < 34 weeks (binary)’ 0 ‘No’ 1 ‘Yes’
Late-onset pre-eclampsia ‘Late-onset pre-eclampsia ≥ 34 weeks (binary)’ 0 ‘No’ 1 ‘Yes’
Superimposed pre-eclampsia ‘Superimposed pre-eclampsia (binary)’ 0 ‘No’ 1 ‘Yes’
Gestational age at diagnosis ‘Gestational age in weeks of diagnosis of pre-eclampsia
(continuous)’
SBP ‘SBP in mmHg (continuous)’
‘SBP in mmHg trimester 2 (continuous)’
‘SBP in mmHg trimester 3 (continuous)’
Gestational age of
measurement
‘Gestational age in weeks of measurement of SBP
(continuous)’
DBP ‘DBP in mmHg (continuous)’
‘DBP in mmHg trimester 2 (continuous)’
‘DBP in mmHg trimester 3 (continuous)’
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Candidate predictors Brief description Categories
Gestational age at
measurement
‘Gestational age in weeks of measurement of DBP
(continuous)’
PCR ‘PCR in mg/mmol of creatinine (continuous)’
‘PCR in mg/mmol of creatinine trimester 2 (continuous)’
‘PCR in mg/mmol of creatinine trimester 3 (continuous)’
24-hour protein ‘24-hour protein in g/24hr (continuous)’
‘24-hour protein in g/24hr trimester 2 (continuous)’
‘24-hour protein in g/24hr trimester 3 (continuous)’
Urine dipstick ‘Urine dipstick (categorical)’ 0 ‘0 or trace’ 1 ‘1+’
2 ‘≥ 2+’
‘Urine dipstick trimester 2 (categorical)’
‘Urine dipstick trimester 3 (categorical)’
Gestational age of
measurement
‘Gestational age in weeks of measurement of urine dipstick
(continuous)’
Birthweight ‘Birth weight in grams (continuous)’
‘Birth weight in grams trimester 2 (continuous)’
‘Birth weight in grams trimester 3 (continuous)’
Birthweight centile ‘Birth weight centile (continuous)’
‘Birth weight centile trimester 2 (continuous)’
‘Birth weight centile trimester 3 (continuous)’
Gestational age at delivery ‘Gestational age at delivery in weeks (continuous)’







Eclampsia ‘Eclampsia (binary)’ 0 ‘No’ 1 ‘Yes’
HELLP syndrome ‘HELLP syndrome (binary)’ 0 ‘No’ 1 ‘Yes’
Placental abruption ‘Placental abruption (binary)’ 0 ‘No’ 1 ‘Yes’
Hepatic failure ‘Hepatic failure (binary)’ 0 ‘No’ 1 ‘Yes’
Renal failure ‘Renal failure (binary)’ 0 ‘No’ 1 ‘Yes’
Cortical blindness ‘Cortical blindness (binary)’ 0 ‘No’ 1 ‘Yes’
Pulmonary oedema ‘Pulmonary oedema (binary)’ 0 ‘No’ 1 ‘Yes’
Postpartum haemorrhage ‘Postpartum haemorrhage (binary)’ 0 ‘No’ 1 ‘Yes’
Disseminated intravascular
coagulation
‘Disseminated intravascular coagulation (binary)’ 0 ‘No’ 1 ‘Yes’
Preterm delivery ‘Preterm delivery (binary)’ 0 ‘No’ 1 ‘Yes’
‘Preterm delivery < 34 weeks (binary)’
‘Preterm delivery ≥ 34 weeks (binary)’
Admission to high-dependency
unit
‘Admission to high-dependency unit (binary)’ 0 ‘No’ 1 ‘Yes’
Maternal death ‘Maternal death (binary)’ 0 ‘No’ 1 ‘Yes’
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Candidate predictors Brief description Categories
Caesarean section ‘Caesarean section (binary)’ 0 ‘No’ 1 ‘Yes’
Stillbirth ‘Stillbirth (binary)’ 0 ‘No’ 1 ‘Yes’
‘Stillbirth trimester 2 (binary)’
‘Stillbirth trimester 3 (binary)’
Neonatal death ‘Neonatal death (binary)’ 0 ‘No’ 1 ‘Yes’
Hypoxic-ischaemic
encephalopathy
‘Hypoxic ischaemic encephalopathy (binary)’ 0 ‘No’ 1 ‘Yes’
Respiratory distress syndrome ‘Respiratory distress syndrome (binary)’ 0 ‘No’ 1 ‘Yes’
Septicaemia ‘Septicaemia (binary)’ 0 ‘No’ 1 ‘Yes’
Admission to neonatal unit ‘Admission to neonatal unit (binary)’ 0 ‘No’ 1 ‘Yes’
Treatment
Aspirin ‘Aspirin use (binary)’ 0 ‘No’ 1 ‘Yes’
‘Aspirin dose in mg (continuous)’
‘Aspirin use in trimester 1 (binary)’ 0 ‘No’ 1 ‘Yes’
‘Aspirin use in mg trimester 1 (continuous)’
‘Aspirin use in trimester 2 (binary)’ 0 ‘No’ 1 ‘Yes’
‘Aspirin use in mg trimester 2 (continuous)’
‘Aspirin use in trimester 3 (binary)’ 0 ‘No’ 1 ‘Yes’
‘Aspirin use in mg trimester 3 (continuous)’
Calcium supplement ‘Calcium supplement (binary)’ 0 ‘No’ 1 ‘Yes’
Vitamin supplement ‘Vitamin supplement (binary)’ 0 ‘No’ 1 ‘Yes’
AFP, alpha-fetoprotein; CRL, crown–rump length; CRP, C-reactive protein; hCG, human chorionic gonadotropin;
MoM, multiple of the mean; PAI-1, plasminogen activator inhibitor-1; PI, pulsatility index; RI, resistance index;
sENG, soluble endoglin.
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Appendix 4 Participant summary from data
sets contributing to the IPPIC project
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Study/data set






























5061 (89.9) 65 (1.2) 304 (5.4) 24 (0.4) 0 (0) 174 (3.1) 5628 (100) 0 (0) 278 (4.9) 44 (0.8) 234 (4.2)




398 (38.2) 108 (10.4) 495 (47.5) 0 (0) 12 (1.2) 30 (2.9) 584 (55.9) 17 (1.6) 14 (1.3) 1 (0.1) 13 (1.2)




11,769 (97.4) 127 (1.1) 113 (0.9) 0 (0) 0 (0) 76 (0.6) 5704 (45.3) 0 (0) 297 (2.2) 37 (0.3) 260 (1.9)




215 (68) 91 (28.8) 6 (1.9) 3 (0.9) 0 (0) 1 (0.3) 202 (63.9) 56 (17.7) 35 (12.4) 6 (2.1) 29 (10.2)




449 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 291 (65) 0 (0) 10 (4.9) 0 (0) 10 (4.8)




881 (72.5) 193 (15.9) 85 (7) 0 (0) 0 (0) 57 (4.7) 206 (16.9) 0 (0) 22 (1.8) 2 (0.2) 20 (1.7)




– – – – – – – 657 (27.1) 371 (15.3) 144 (5.9) 227 (9.4)




954 (61.4) 395 (25.4) 97 (6.2) 0 (0) 0 (0) 108 (6.9) 674 (43.4) 69 (4.5) 54 (3.6) 5 (0.3) 49 (3.3)
Khan137 222 222 – 25.3 [6.6],
18–46.1
– – – – – – 146 (65.8) 0 (0) 27 (12.2) 11 (5) 16 (7.2)




33,257 (62.1) 7820 (14.6) 10388 (19.4) 5 (0) 1528 (2.9) 555 (1) 29318 (53.8) 0 (0) 1492 (2.7) 152 (0.3) 1340 (2.5)
PARIS112 35,955 34,609 23.6 (6.1),
11–48
– – – – – – – 19793 (57.5) 6086 (18.5) 2928 (8.8) 498 (1.5) 2403 (7.2)




– – – – – – 65206 (47.7) 0 (0) 5194 (3.7) 1329 (1) 3865 (2.8)




4443 (42.4) 212 (2) 5380 (51.4) 0 (0) 158 (1.5) 278 (2.7) 5034 (39.6) 0 (0) 334 (2.7) 0 (0) 0 (0)
Velauthar39 1208 1206 – 23.9 [6],
13.8–46.6
402 (35.3) 90 (7.9) 565 (49.6) 0 (0) 0 (0) 82 (7.2) 598 (52.2) 0 (0) 26 (2.3) 3 (0.3) 23 (2.1)




3900 (92.6) 25 (0.6) 91 (2.2) 0 (0) 1 (0) 195 (4.6) 4212 (100) 0 (0) 273 (6.5) 10 (0.2) 263 (6.3)




775 (45.5) 803 (47.1) 88 (5.2) 27 (1.6) 0 (0) 11 (0.6) 736 (43.2) 92 (5.4) 106 (6.2) 21 (1.2) 85 (5)



































































– – – – – – 322 (48.1) 15 (2.2) 28 (4.1) 3 (0.4) 25 (3.7)
Giguère126 7866 7693 – 23 [5.9],
13.9–58.3
6422 (96.9) 37 (0.6) 23 (0.3) 47 (0.7) 47 (0.7) 49 (0.7) 3631 (47.2) 0 (0) 142 (1.8) 13 (0.2) 129 (1.6)




3282 (82.6) 397 (10) 112 (2.8) 65 (1.6) 0 (0) 116 (2.9) 751 (20.1) 0 (0) 271 (12.1) 19 (0.8) 252 (11.3)




3229 (97.2) 49 (1.5) 32 (1) 0 (0) 0 (0) 11 (0.3) 3328 (100) 0 (0) 32 (1.4) 13 (0.6) 19 (0.8)
Llurba140 11,668 11,668 30.2 (5.9),
14–51
– 10,415 (90.6) 125 (1.1) 4 (0) 794 (6.9) 0 (0) 163 (1.4) – 51 (0.4) 411 (3.5) 69 (0.6) 218 (1.9)




2222 (30.6) 756 (10.4) 1443 (19.9) 0 (0) 0 (0) 2846 (39.2) 6710 (92.3) 432 (5.9) 142 (1.9) 18 (0.2) 124 (1.7)




1765 (96.6) 3 (0.2) 31 (1.7) 5 (0.3) 0 (0) 24 (1.3) 1193 (56.3) 0 (0) 159 (7.5) 3 (0.1) 156 (7.4)




– – – – – – 193 (60.5) 2 (0.6) 11 (3.4) 1 (0.3) 10 (3.1)




2498 (99.7) 4 (0.2) 4 (0.2) 0 (0) 0 (0) 0 (0) 1653 (66) 189 (7.5) 1440 (57.5) 260 (10.4) 1180 (47.1)




160 (68.4) 17 (7.3) 3 (1.3) 37 (15.8) 0 (0) 17 (7.3) 117 (50.2) 38 (15.3) 103 (41.4) 33 (13.3) 70 (28.1)




4800 (58.8) 2117 (26) 484 (5.9) 0 (0) 0 (0) 756 (9.3) 4745 (55.7) 0 (0) 194 (2.3) 24 (0.3) 170 (2)




612 (33.1) 1079 (58.4) 2 (0.1) 148 (8) 0 (0) 7 (0.4) 430 (23.3) 76 (5.9) 485 (19.4) 108 (4.3) 377 (15.1)




548 (17.7) 1515 (48.9) 2 (0.1) 1010 (32.6) 0 (0) 22 (0.7) 3097 (100) 0 (0) 163 (5.5) 13 (0.4) 150 (5)
Placental Health
Study176




593 (71.4) 29 (3.5) 66 (7.9) 28 (3.4) 0 (0) 115 (13.8) 856 (100) 0 (0) 69 (8.1) 3 (0.4) 66 (7.7)




2018 (66.8) 743 (24.6) 57 (1.9) 160 (5.3) 0 (0) 41 (1.4) 1293 (42.8) 106 (3.5) 44 (3.2) 12 (0.9) 32 (2.3)




– – – – – – 0 (0) 407 (100) 106 (26) 24 (5.9) 82 (20.1)




















































































































































































































































































































































































735 (61.3) 325 (27.1) 94 (7.8) 23 (1.9) 22 (1.8) 1 (0.1) 518 (43.2) 64 (5.3) 102 (8.7) 20 (1.7) 82 (7)
PREDO127 1082 1082 – 25.8 [9.9],
17.2–55
1082 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 247 (22.8) 96 (8.9) 20 (1.9) 75 (6.9)




203 (74.4) 41 (15) 29 (10.6) 0 (0) 0 (0) 0 (0) 108 (39.6) 56 (20.5) 12 (4.4) 3 (1.1) 9 (3.3)




589 (98.3) 0 (0) 1 (0.2) 1 (0.2) 4 (0.7) 4 (0.7) 559 (93.3) 33 (5.5) 27 (4.5) 1 (0.2) 26 (4.3)




503 (93.3) 15 (2.8) 12 (2.2) 0 (0) 0 (0) 9 (1.7) 267 (49.5) 26 (4.6) 94 (17.2) 20 (3.6) 74 (13.5)




1777 (94.9) 3 (0.2) 1 (0.1) 1 (0.1) 4 (0.2) 87 (4.6) 1877 (100) 0 (0) 103 (5.5) 6 (0.3) 97 (5.2)
Vollebregt174 308 308 – 22.9 [4.3],
17.7–41.2
264 (85.7) 4 (1.3) 14 (4.5) 20 (6.5) 0 (0) 6 (1.9) 256 (83.1) 38 (12.3) 21 (6.8) 7 (2.3) 14 (4.6)








1509 (0.4) 22,880 (5.6) 3548 (0.9) 19,323 (4.8)




2111 (88.1) 24 (1) 191 (8) 4 (0.2) 7 (0.3) 60 (2.5) – – 76 (3.2) 8 (0.3) 68 (2.9)
Danish National Birth
Cohort136




– – – – – – 0 (0) – 2144 (2.5) 196 (0.2) 1948 (2.3)




0 (0) 0 (0) 2223 (100) 0 (0) 0 (0) 0 (0) 664 (42.7) 3 (0.1) 97 (6.1) 8 (0.5) 80 (5)
Ohkuchi148 288 288 28.7 (4),
18–42
– 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 288 (100) 146 (50.7) 9 (3.2) 9 (3.1) 1 (0.3) 8 (2.8)




93 (38.3) 123 (50.6) 4 (1.6) 0 (0) 0 (0) 23 (9.5) 46 (18.9) 46 (18.9) 58 (23.8) 32 (13.1) 26 (10.7)




– – – – – – 557 (100) 0 (0) 23 (4.1) 2 (0.4) 18 (3.2)




539 (96.8) 2 (0.4) 10 (1.8) 0 (0) 6 (1.1) 0 (0) 1244 (100) 0 (0) 109 (8.8) 0 (0) 0 (0)




222 (92.5) 5 (2.1) 13 (5.4) 0 (0) 0 (0) 0 (0) 132 (55) 0 (0) 73 (30.4) 41 (17.1) 32 (13.3)































































Vatten170 736 736 27.9 (5.3),
17–43
– – – – – – – 373 (51) 0 (0) 344 (46.7) 154 (20.9) 190 (25.8)




304 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 160 (52.6) 1 (0.3) 19 (6.3) 2 (0.7) 17 (5.6)
BORN Ontorio104 281,466 276,329 – 23.8 [6.9],
9.8–144
– – – – – – 116,602
(43.7)
0 (0) 2903 (1) 336 (0.1) 2379 (0.8)




0 (0) 1010 (100) 0 (0) 0 (0) 0 (0) 0 (0) – 34 (3.3) 16 (2) 0 (0) 9 (1.1)




– – – – – – 48,457 (43.9) 0 (0) 4225 (3.7) 414 (0.4) 3785 (3.4)
Huang132 141,698 141,698 30.8 (5.1),
13.1–53.3
– 89,350 (66.1) 8708 (6.4) 35,293
(26.1)
0 (0) 0 (0) 1760 (1.3) 57,879 (49.1) 0 (0) 1036 (0.7) 0 (0) 0 (0)




– – – – – – 16,809 (40) 391 (0.9) 359 (0.8) 93 (0.2) 266 (0.6)
Goffinet129 3317 3317 28.8 (5.2),
15.4–47.2
– – – – – – – 1485 (46.3) 0 (0) 33 (1.2) 1 (0) 32 (1.2)
Rang152 42 42 29.6 (3.7),
22–39
– 13,752 (32.7) 19,602
(46.6)
2379 (5.7) 0 (0) 0 (0) 6303 (15) 21 (50) 21 (50) 6 (14.3) 2 (4.8) 4 (9.5)
Cameroni117 173 173 34.5 (4.5),
21–48
– 152 (87.9) 0 (0) 0 (0) 0 (0) 0 (0) 21 (12.1) 74 (42.8) 22 (12.7) 17 (9.8) 1 (0.6) 16 (9.2)
Conserva123 53 53 33.2 (6),
24–43
– 53 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 34 (64.2) 5 (9.4) 3 (5.7) 0 (0) 3 (5.7)




172 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 119 (69.2) 52 (30.4) 58 (33.7) 3 (1.7) 55 (32)
Ferrazzani158 54 54 32.5 (5),
21–42
– 54 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 54 (100) 10 (19.6) 5 (9.8) 5 (9.8)
Figueiró-Filho125 81 81 30 (6.2),
18–46
– 59 (72.8) 4 (4.9) 0 (0) 0 (0) 17 (21) 1 (1.2) 0 (0) 81 (100) 30 (44.1) 11 (16.4) 18 (26.9)




171 (88.6) 11 (5.7) 6 (3.1) 0 (0) 0 (0) 5 (2.6) 205 (100) 0 (0) 54 (26.3) 21 (10.3) 32 (15.7)




– – – – – – – – 10,159 (1.9) 471 (0.1) 9574 (1.8)




















































































































































































































































































































































































Trogstad164 37,738 37,738 28.1 (4.5),
17–48
– 37,738 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 37738 (100) 4722 (12.6) 321 (0.9) 4085 (11)
Salim156 97 97 30.3 (5.8),
18–45
– – – – – – – – – 5 (5.2) 2 (2.1) 3 (3.1)
Van Oostwaard
2012168




288 (84) 46 (13.4) 4 (1.2) 0 (0) 3 (0.9) 2 (0.6) 0 (0) 208 (48.9) 22 (11.6) 4 (2.1) 18 (9.5)
Van Oostwaard
2014169




360 (71.9) 119 (23.8) 17 (3.4) 0 (0) 3 (0.6) 2 (0.4) 0 (0) 224 (35.1) 30 (9.9) 5 (1.6) 25 (8.2)




1061 (65.5) 502 (31) 0 (0) 0 (0) 0 (0) 57 (3.5) – – 8 (0.5) 0 (0) 8 (0.5)
Brown 2007116 2785 2702 29.5 (5),
15–46
– – – – – – – 1192 (44.1) 0 (0) 781 (28) 79 (2.8) 702 (25.2)
Gurgel Alves 2014130 500 500 – – – – – – – – – – 31 (12.2) 8 (3.1) 23 (9.1)




– – – – – – – 45 (6.1) 55 (7.5) 11 (1.5) 44 (6)




431 (75.3) 21 (3.7) 96 (16.8) 0 (0) 24 (4.2) 0 (0) 251 (43.7) 40 (7) 29 (5.1) 3 (0.5) 26 (4.5)




128 (18.2) 20 (2.8) 556 (79) 0 (0) 0 (0) 0 (0) 360 (49.1) 39 (5.3) 55 (7.5) 11 (1.5) 44 (6)
































Appendix 5 Detailed study characteristics of
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2004–8 Low risk Healthy nulliparous women
with singleton pregnancies
Recognised as high risk of pre-
eclampsia, small for gestational
age fetus or spontaneous preterm
birth owing to underlying
medical condition such as
chronic hypertension requiring
antihypertensive drugs, diabetes,
renal disease, systemic lupus
erythematosus, antiphospholipid
syndrome, sickle cell disease or
HIV. Previous cervical knife cone
biopsy, three or more abortions
or miscarriages, current ruptured
membranes, known major fetal
anomaly or abnormal karyotype,
and interventions that can alter
the course of pregnancy such as
aspirin or cervical suture
Allen108 Observational Prospective
cohort
UK 2010–14 Any pregnancy All pregnant women attending
an inner London hospital
between 11 and 14 weeks’
gestation




UK 1991–2 Any pregnancy All pregnant women resident
in Avon, UK
None
Chappell121 Randomised Trial UK NI High risk Pregnant women with an
abnormal doppler waveform
in either uterine artery at
18–22 weeks’ gestation or
pre-eclampsia in a previous
pregnancy that led to preterm
delivery, eclampsia or HELLP
syndrome
Heparin or warfarin treatment,















































low risk] Inclusion criteria Exclusion criteria
EMPOWaR122 Randomised Trial UK 2011–14 High risk Women at least 16 years of
age at recruitment, between
12 and 16 weeks’ gestation
and with a BMI of 30 kg/m2
Non-white women and those
with: history of diabetes, systemic
disease at the time of enrolment
(requiring either regular drugs
or systemic corticosteroids
treatment in the past 3 months),
previous delivery of a baby
smaller than the third centile for
weight, history of pre-eclampsia
with delivery before 32 weeks’
gestation, known hypersensitivity
to metformin hydrochloride or
any of the excipients. Known liver
or renal failure, acute disorders
at the time of trial entry with
the potential to change renal
function, such as dehydration
sufficient to require intravenous
infusion, severe infection, shock,
intravascular administration of
iodinated contrast agents, or
acute or chronic diseases that
might cause tissue hypoxia
(e.g. cardiac or respiratory failure,
recent myocardial infarction,
hepatic insufficiency, acute
alcohol intoxication or alcoholism);




UK 2011–13 Any pregnancy Pregnant asymptomatic
women with a high risk of
spontaneous preterm birth,
such as previous history of
spontaneous preterm delivery,
late miscarriage, invasive

































































































































































































































































































































































low risk] Inclusion criteria Exclusion criteria
Poston
2006150
Randomised Trial UK 2003–5 High risk Gestational age of
14–21 weeks plus one or
more of the following risk
factors: history of pre-
eclampsia necessitating




DBP of ≥ 90mmHg before
20 weeks’ gestation in current
pregnancy, history of diabetes,
antiphospholipid syndrome;
chronic renal disease, multiple
pregnancy; abnormal uterine
artery Doppler waveform,




supplements containing doses of
vitamin C of 200mg or more or
of vitamin E of ≥ 40 IU daily.
Women treated with warfarin
Poston
2015149
Randomised Trial UK 2009–14 High risk Women aged > 16 years with
a BMI of ≥ 30 kg/m2 and a
singleton pregnancy
Any underlying disorders, including
a pre-pregnancy diagnosis of
essential hypertension, diabetes,
renal disease, systemic lupus
erythematosus, antiphospholipid
syndrome, sickle cell disease,
thalassaemia, coeliac disease,
thyroid disease, and current
psychosis; or if on metformin
Khan137 Randomised Trial UK NI High risk Women identified to be




Women with underlying conditions
thought likely to compromise
renal function, such as diabetes or
renal disease
St George’s163 Observational Prospective
registry
















































low risk] Inclusion criteria Exclusion criteria
PARIS112 IPD MA of 31
randomised
trials
Trial 33 countries 1985–2005 Varied Varied (dependent on
individual study)




UK 1986–2015 Any pregnancy Data from every pregnancy























USA 2007–10 Any pregnancy All pregnant women attending






Canada 2006–8 Low risk Nulliparous women with
singleton pregnancies
presenting for Down syndrome
screening at 11–13 weeks





Chile NI Any pregnancy All pregnant women attending





Canada 2005–10 Any pregnancy Women at least 18 years old
and with a gestational age of
at least 10 weeks at their first
prenatal visit with no chronic
hepatic or renal diseases
Pregnancies with major fetal
abnormalities and those ending
in termination, miscarriage or





































































































































































































































































































































































low risk] Inclusion criteria Exclusion criteria
Antsaklis110 Observational Prospective
cohort
Greece 1997–8 Low risk All nulliparous women Women with multiple pregnancies,
renal disease, cardiovascular
disease and fetal anomalies
Llurba140 Observational Prospective
cohort











2006–9 High risk Women with risk factors for
pre-eclampsia








Spain 2000–1 Any pregnancy Women attending routine







Finland 2008–11 Any pregnancy Nulliparous or multiparous
women with a singleton
pregnancy with or without
pre-eclampsia on admission
to hospital
Multiple pregnancy, maternal age




Spain NI Any pregnancy Singleton pregnancies Multigestation, antiphospholipid
antibody syndrome, systemic
lupus erythematosus or any other
autoimmune disease, as well as
chronic corticosteroid or
nonsteroidal anti-inflammatory
drug use, except low-dose aspirin
(< 150mg/day)
Generation R134 Observational Prospective
birth cohort
Netherlands 2002–6 Any pregnancy Resident mothers delivering















































low risk] Inclusion criteria Exclusion criteria
NICHD HR32 Randomised Trial USA 1991–5 High risk Women with pre-gestational,
insulin-treated diabetes
mellitus, women with chronic
hypertension, women with
multifetal gestations, and
women who had had
preeclampsia in a previous
pregnancy
Women with multifetal gestation
if they also had chronic
hypertension, renal disease,
diabetes, history of pre-eclampsia
and current proteinuria
NICHD LR159 Randomised Trial USA NI (early
1990s)
Low risk Healthy nulliparous women Women with chronic
hypertension, renal disease,






Canada 2012–13 Low risk Healthy nulliparous women
with singleton pregnancies
Chronic hypertension, use of
unfractionated or low molecular-
weight heparin, pre-gestational
diabetes mellitus, major fetal
abnormalities, ruptured
membranes, vaginal bleeding from
13 0/7 weeks of gestation for
greater than 1 day, or a short
cervical length on ultrasonography
before 20 weeks of gestation
(< 2 cm long)
POUCH131 Observational Prospective
cohort
USA 1998–2004 Any pregnancy Women with a singleton
pregnancy at 16–27 weeks’
gestation, no known
chromosomal abnormality,
maternal age of at least





















































































































































































































































































































































































Women who had diabetes,










Finland 2005–9 Any pregnancy Pregnant women with known
risk factor for pre-eclampsia
and intrauterine growth
restriction and those without,
attending clinics for their first
ultrasound screening between
12 and 14 weeks’ gestation
Asthma diagnosed by a physician,
allergy to ASA, tobacco smoking
during pregnancy, previous peptic
ulcer, previous placental ablation,
inflammatory bowel diseases
(Crohn’s disease, ulcerative colitis),
rheumatoid arthritis, haemophilia
or thrombophilia (previous venous
or pulmonary thrombosis and/or
coagulation abnormality),
gestational weeks+ days < 12+ 0
or > 14+ 0 or multiple pregnancy
Prefumo151 Observational Prospective
cohort
Italy 2001–5 Any pregnancy Women attending routine
antenatal care
Known medical condition (e.g.
diabetes mellitus, connective tissue
disease, essential hypertension) or
a history of recurrent miscarriage
Skråstad160 Observational Prospective
cohort
Norway 2010–12 High risk Nulliparous and high-risk
parous women with one or
more previous pre-eclampsia
pregnancies






Germany NI Any pregnancy Singleton pregnancies Multigestation, antiphospholipid
antibody syndrome, systemic
lupus erythematosus or any other
autoimmune disease, as well as
chronic corticosteroid or
nonsteroidal anti-inflammatory















































low risk] Inclusion criteria Exclusion criteria
Rumbold155 Randomised Trial Australia 2001–5 Low risk Nulliparous women with a
singleton pregnancy between
14 and 22 weeks’ gestation
and normal blood pressure
Known multiple pregnancy,










Netherlands 2004–6 High risk Healthy nulliparous women
at low risk and women with
elevated risk for pre-eclampsia









DOMInO143 Randomised Trial Australia 2005–8 Any pregnancy Singleton pregnancies at less
than 21 weeks’ gestation
Already taking a prenatal
supplement with DHA, their fetus
had a known major abnormality,
had a bleeding disorder in which
tuna oil was contraindicated,
were taking anticoagulant
therapy, had a documented
history of drug or alcohol abuse,


















































































































































































































































































































































































low risk] Inclusion criteria Exclusion criteria
Lecarpentier139 Observational Retrospective
cohort




women with proteinuria at
< 20 weeks’ gestation, women
considered as having chronic
hypertension but without any
treatment at first prenatal visit,
women transferred from other
maternities, pregnancies
complicated by fetal malformations
TEST146 Randomised Trial Ireland 2014–16 Low risk Nulliparous women between
11–14 weeks’ gestation and





Canada 1989–91 Low risk Nulliparous women attending
hospital for routine blood




hypertension) or renal disease or




Norway NI Low risk Women with singleton
pregnancies
NI
STORK G135 Observational Prospective
cohort
Norway 2008–10 Any pregnancy Healthy pregnant women Women with diabetes or diseases





Norway 1992–4 Any pregnancy Women attending
antenatal care
None
Vinter173 Randomised Trial Denmark 2007–10 High risk Women aged between
18–40 years with a
pre-pregnancy weight of
between 30 and 45 kg/m2
Women with chronic medical
disorders (hypertension, diabetes,






















































Canada 2012–14 Any pregnancy Women giving birth during







Ghana 2012–14 Any pregnancy Women < 17 weeks pregnant,

















France 1996–2005 Any pregnancy Women giving birth during
the data period in that region
None
Goffinet129 Randomised Trial France 1994–7 Low risk All women attending routine
antenatal visit before
24 weeks
Any indications for uterine
artery Doppler, such as chronic
hypertension, diabetes, previous
fetal death, intrauterine growth
restriction, hypertensive disorders




Netherlands NI High risk Women with a history of
early-onset pre-eclampsia in a
previous pregnancy or women






Italy NI High risk Singleton pregnancies at







































































































































































































































































































































































Italy 2001–8 High risk Women with previous adverse
pregnancy outcomes
Multiple gestation; a previous
uneventful pregnancy; a previous
pregnancy treated with low-
molecular-weight heparin or
unfractionated heparin; patients
with clinical immune disease and
acquired thrombophilia − lupus-like
anticoagulant or APL syndrome;
patients with positive antinuclear,
antimitochondria, anti-smooth
muscle antibodies; postnatal or
postmortem diagnosis of
congenital fetal anomaly or fetal
infection; women of non-Caucasian
ethnicity; alcohol or illicit drug use;
early pregnancy loss was not




Italy 2001–6 High risk Previous singleton pregnancies
complicated by pre-eclampsia




































































low risk] Inclusion criteria Exclusion criteria
Langenveld138 Observational Retrospective
cohort





before 34 weeks of gestation








Denmark 1978–2007 Any pregnancy Singleton deliveries of women
with first delivery aged
> 15 years and second
delivery aged < 50 years
Cardiovascular diagnosis and
type 1 or type 2 diabetes
Mbah145 Observational Prospective
registry
USA 1989–2005 Any pregnancy Women with first and second
singleton pregnancies within










Israel 2000–6 High risk Previous pregnancy with
antepartum complications at
≥ 23 weeks’ gestation
Women who had a previous
pregnancy with antepartum
complications that could be
attributed to multiple gestations,










Netherlands 2000–2 High risk Women with a hypertensive
disorder in the index
pregnancy and delivery at





































































































































































































































































































































































Netherlands 2000–2 High risk Women with a hypertensive
disorder in the index





USA 1959–65 Any pregnancy Women attending prenatal
care
None
Brown 2007116 Observational Retrospective
cohort














Brazil 2009–14 Any pregnancy Women with singleton
pregnancies attending for first-
trimester ultrasound scans
Prior maternal renal disease,
major fetal malformations or
chromosomal abnormalities,
miscarriage
Costa 2017107 Observational Prospective
cohort
Australia 2012–15 Any pregnancy Women attending for their
second-trimester morphology





Brazil 2009–14 Any pregnancy Singleton pregnancies of
women attending routine
ultrasound screening
Kidney disease diagnosis in
their history or on ultrasound
examination, major fetal
malformations or chromosomal
abnormalities, and fetuses with
crown–rump length of > 84mm
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APPENDIX 6






























SCOPE42 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
















Chappell121 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 316 (100) 316 (100) 316 (100) 0 (0) 0 (0) 0 (0) 316 (100) 316 (100)
EMPOWaR122 0 (0) 0 (0) 1 (0.2) 0 (0) 449 (100) 449 (100) 449 (100) 0 (0) 0 (0) 449 (100) 0 (0) 0 (0) 449 (100)
POPPY106 0 (0) 0 (0) 0 (0) 1010
(83.1)








1216 (100) 1216 (100)
Poston 2006150 2422
(100)
22 (1.1) 2422 (100) 0 (0) 0 (0) 2422 (100) 2422
(100)
0 (0) 0 (0) 0 (0) 2422
(100)
2422 (100) 2422 (100)
Poston 2015149 0 (0) 0 (0) 0 (0) 7 (0.5) 0 (0) 1554 (100) 61 (3.9) 0 (0) 0 (0) 0 (0) 0 (0) 1554 (100) 4 (0.3)
Khan137 222 (100) 222 (100) 0 (0) 76 (34.2) 222 (100) 222 (100) 222 (100) 0 (0) 0 (0) 222 (100) 0 (0) 222 (100) 222 (100)
St George’s163 1086 (2) 0 (0) 104 (0.2) 25,326
(46.4)





























19 (0) 7 (0) 72,684
(53.2)










405 (3.1) 405 (3.1) 8178
(62.3)









Velauthar39 67 (5.6) 1208
(100.2)




62 (5.1) 62 (5.1) 62 (5.1) 1208 (100) 1208 (100)
POP161 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1704
(100)
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Baschat115 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 893 (100) 893 (100) 0 (0) 0 (0) 0 (0) 0 (0) 893 (100) 893 (100)
Audibert113 682 (100) 3 (0.4) 12 (1.8) 0 (0) 0 (0) 0 (0) 682 (100) 682 (100) 0 (0) 0 (0) 0 (0) 682 (100) 682 (100)




5553 (70.6) 5515 (70.1) 7866
(100)
426 (5.4) 313 (4) 256 (3.3) 872 (11.1) 6307
(80.2)
7866 (100)
Giguère126 63 (1.6) 72 (1.8) 302 (7.5) 3284
(81.4)




281 (7) 244 (6) 281 (7) 92 (2.3)
Goetzinger128 7 (0.2) 11 (0.3) 0 (0) 0 (0) 0 (0) 3328 (100) 3328
(100)
0 (0) 0 (0) 0 (0) 6 (0.2) 3328 (100) 3328 (100)













Llurba140 6 (0.1) 1 (0) 0 (0) 0 (0) 2 (0) 2 (0) 7315
(100)
0 (0) 1 (0) 1 (0) 2 (0) 7315 (100) 7315 (100)




198 (9.2) 197 (9.1) 2 (0.1) 2161 (100) 2161 (100)
Andersen109 319 (100) 0 (0) 0 (0) 0 (0) 0 (0) 319 (100) 319 (100) 319 (100) 319 (100) 0 (0) 0 (0) 0 (0) 319 (100)
Arenas111 0 (0) 1 (0) 0 (0) 0 (0) 0 (0) 2506 (100) 2506
(100)
0 (0) 0 (0) 0 (0) 2506
(100)
2506 (100) 2506 (100)
FINNPEC133 1 (0.4) 0 (0) 3 (1.3) 5 (2.1) 0 (0) 253 (100) 253 (100) 7 (2.8) 3 (1.2) 8 (3.2) 1 (0.4) 253 (100) 253 (100)
Galindo171 478 (5.5) 2 (0) 108 (1.3) 3938
(45.6)




1397 (16) 1253 (14.4) 1112
(12.7)
0 (0) 592 (6.8)
Generation R134 0 (0) 19 (1) 0 (0) 1250
(67.6)




0 (0) 0 (0) 0 (0) 2539 (100) 2539 (100)
NICHD HR32 0 (0) 99 (3.2) 0 (0) 0 (0) 0 (0) 3134 (100) 3134
(100)
0 (0) 0 (0) 0 (0) 6 (0.2) 3134 (100) 3134 (100)
NICHD LR159 25 (2.9) 0 (0) 0 (0) 0 (0) 0 (0) 36 (4.2) 856 (100) 856 (100) 0 (0) 0 (0) 0 (0) 856 (100) 1 (0.1)
Placental Health
Study176




0 (0) 1 (0) 6 (0.2) 7 (0.2) 3019 (100)
POUCH131 407 (100) 0 (0) 0 (0) 0 (0) 407 (100) 407 (100) 407 (100) 407 (100) 407 (100) 0 (0) 407 (100) 407 (100) 407 (100)
van Kuijk
2011167
230 (100) 0 (0) 0 (0) 2 (0.9) 0 (0) 230 (100) 230 (100) 0 (0) 0 (0) 0 (0) 230 (100) 230 (100) 20 (8.7)
van Kuijk
2014166
0 (0) 1 (0.1) 1 (0.1) 0 (0) 1200 (100) 1200 (100) 1200
(100)
7 (0.6) 0 (0) 0 (0) 9 (0.8) 11 (0.9) 5 (0.4)

























48 (0.9) 51 (0.9) 48 (0.9) 5 (0.1) 5 (0.1) 5 (0.1)






114 (10.9) 0 (0) 1045
(100)





























0 (0) 316 (100) 33 (10.4) 33 (10.4) 33 (10.4) 33 (10.4) 92 (29.1) 316 (100) 316 (100) 316 (100) 316 (100) 143 (45.3) 238 (75.3) 33 (10.4) 33 (10.4) 33 (10.4)























12 (1) 12 (1) 12 (1)
0 (0) 2422
(100)












0 (0) 0 (0) 0 (0)
0 (0) 1554
(100)










47 (3) 47 (3) 47 (3)




































































































955 (7.2) 1289 (9.7) 1289 (9.7)
0 (0) 1208
(100)
67 (5.5) 69 (5.7) 69 (5.7) 69 (5.7) 1208
(100)








93 (7.7) 93 (7.7) 93 (7.7)
0 (0) 1704
(100)






704 (41.3) 704 (41.3) 1704
(100)
0 (0) 0 (0) 0 (0)
0 (0) 893 (100) 0 (0) 893 (100) 893 (100) 893 (100) 893 (100) 893 (100) 28 (3.1) 893 (100) 4 (0.4) 362 (40.5) 893 (100) 0 (0) 0 (0) 0 (0)




































































985 (29.6) 985 (29.6) 985 (29.6)




















0 (0) 0 (0) 0 (0)
0 (0) 7315
(100)



































47 (2.2) 47 (2.2) 47 (2.2)
0 (0) 319 (100) 0 (0) 319 (100) 319 (100) 319 (100) 319 (100) 319 (100) 2 (0.6) 2 (0.6) 319 (100) 319 (100) 319 (100) 0 (0) 0 (0) 0 (0)
0 (0) 2506
(100)








1930 (77) 1929 (77) 0 (0) 0 (0) 0 (0)
0 (0) 253 (100) 15 (5.9) 2 (0.8) 2 (0.8) 2 (0.8) 253 (100) 253 (100) 253 (100) 78 (30.8) 253 (100) 3 (1.2) 3 (1.2) 4 (1.6) 4 (1.6) 4 (1.6)
0 (0) 8727
(100)










635 (7.3) 635 (7.3) 255 (2.9) 10 (0.1) 245 (2.8)
0 (0) 2539
(100)












36 (1.4) 36 (1.4) 36 (1.4)
0 (0) 3134
(100)












150 (4.8) 150 (4.8) 150 (4.8)

























0 (0) 407 (100) 0 (0) 407 (100) 407 (100) 407 (100) 407 (100) 407 (100) 407 (100) 407 (100) 407 (100) 407 (100) 407 (100) 0 (0) 0 (0) 0 (0)
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 230 (100) 230 (100) 230 (100) 230 (100) 230 (100) 230 (100) 230 (100) 13 (5.7) 13 (5.7) 13 (5.7)








697 (58.1) 889 (74.1) 23 (1.9) 23 (1.9) 23 (1.9)
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APPENDIX 6






























Odibo147 0 (0) 1082
(100)
0 (0) 0 (0) 0 (0) 1082 (100) 1082
(100)
0 (0) 0 (0) 0 (0) 1082
(100)
1082 (100) 125 (11.6)
PREDO127 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 273 (100) 273 (100) 0 (0) 0 (0) 0 (0) 0 (0) 273 (100) 273 (100)
Prefumo151 0 (0) 0 (0) 0 (0) 0 (0) 599 (100) 599 (100) 599 (100) 599 (100) 599 (100) 0 (0) 0 (0) 599 (100) 0 (0)
Skråstad160 3 (0.6) 0 (0) 3 (0.6) 0 (0) 235 (41.5) 0 (0) 566 (100) 2 (0.4) 2 (0.4) 2 (0.4) 21 (3.7) 566 (100) 566 (100)
Verlohren172 4 (0.2) 0 (0) 0 (0) 0 (0) 1877 (100) 0 (0) 1877
(100)
0 (0) 0 (0) 0 (0) 39 (2.1) 1877 (100) 39 (2.1)
Rumbold155 0 (0) 308 (100) 0 (0) 0 (0) 308 (100) 308 (100) 308 (100) 2 (0.6) 2 (0.6) 2 (0.6) 308 (100) 308 (100) 308 (100)
Vollebregt174 0 (0) 1147 (0.3) 1586 (0.4) 0 (0) 0 (0) 406,286 (100) 406,286
(100)





JSOG105 2 (0.1) 0 (0) 2399 (100) 2399
(100)






2399 (100) 3 (0.1) 2399 (100) 3 (0.1)
DOMInO143 86,082
(100)
0 (0) 0 (0) 86,082
(100)
0 (0) 86,082 (100) 86,082
(100)









1 (0) 18 (0.8) 1264
(56.1)
2252 (100) 2252 (100)
Indonesian
Cohort157
0 (0) 288 (100) 0 (0) 4 (1.4) 288 (100) 288 (100) 288 (100) 288 (100) 288 (100) 288 (100) 288 (100) 288 (100) 288 (100)
Ohkuchi148 0 (0) 0 (0) 0 (0) 0 (0) 244 (100) 244 (100) 244 (100) 0 (0) 0 (0) 0 (0) 0 (0) 244 (100) 244 (100)
Lecarpentier139 557 (100) 0 (0) 0 (0) 0 (0) 0 (0) 557 (100) 557 (100) 0 (0) 557 (100) 0 (0) 0 (0) 557 (100) 0 (0)
TEST146 1244
(100)
0 (0) 0 (0) 0 (0) 1244 (100) 1244 (100) 1244
(100)
0 (0) 0 (0) 0 (0) 1244
(100)
1244 (100) 1244 (100)
Massé144 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 240 (100) 240 (100) 0 (0) 0 (0) 0 (0) 0 (0) 240 (100) 240 (100)
Staff162 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 823 (100) 823 (100) 0 (0) 0 (0) 0 (0) 0 (0) 823 (100) 0 (0)
STORK G135 736 (100) 736 (100) 4 (0.5) 363 (49.3) 736 (100) 736 (100) 736 (100) 736 (100) 736 (100) 736 (100) 736 (100) 736 (100) 736 (100)


























1016 (100) 1016 (100)
Ghana Cohort165 112,758
(100)






496 (0.4) 0 (0) 496 (0.4) 18,757
(16.6)
0 (0) 0 (0)





























112 (3.4) 0 (0) 0 (0) 3317 (100) 3317
(100)
0 (0) 0 (0) 592 (17.8) 3317
(100)
3317 (100) 3317 (100)
Goffinet129 42 (100) 42 (100) 0 (0) 0 (0) 42 (100) 42 (100) 42 (100) 42 (100) 42 (100) 0 (0) 0 (0) 42 (100) 42 (100)
Rang152 0 (0) 173 (100) 0 (0) 0 (0) 173 (100) 173 (100) 173 (100) 173 (100) 173 (100) 0 (0) 173 (100) 173 (100) 173 (100)
Cameroni
2011117
0 (0) 53 (100) 0 (0) 0 (0) 0 (0) 0 (0) 53 (100) 0 (0) 0 (0) 0 (0) 53 (100) 53 (100) 53 (100)
Conserva
2012123
0 (0) 2 (1.2) 0 (0) 1 (0.6) 0 (0) 0 (0) 172 (100) 0 (0) 0 (0) 0 (0) 23 (13.4) 172 (100) 172 (100)
Facchinetti124 0 (0) 54 (100) 0 (0) 0 (0) 0 (0) 54 (100) 54 (100) 0 (0) 0 (0) 0 (0) 54 (100) 54 (100) 54 (100)
Ferrazzani158 0 (0) 81 (100) 0 (0) 0 (0) 0 (0) 0 (0) 81 (100) 81 (100) 0 (0) 0 (0) 81 (100) 81 (100) 81 (100)






































































661 (61.1) 976 (90.2) 976 (90.2) 0 (0) 1 (0.1) 1 (0.1)
0 (0) 273 (100) 60 (22) 273 (100) 273 (100) 273 (100) 273 (100) 273 (100) 62 (22.7) 273 (100) 273 (100) 273 (100) 273 (100) 0 (0) 0 (0) 0 (0)
0 (0) 599 (100) 0 (0) 0 (0) 0 (0) 0 (0) 599 (100) 599 (100) 98 (16.4) 599 (100) 0 (0) 0 (0) 599 (100) 0 (0) 0 (0) 0 (0)
0 (0) 0 (0) 12 (2.1) 3 (0.5) 3 (0.5) 3 (0.5) 28 (4.9) 566 (100) 477 (84.3) 166 (29.3) 566 (100) 103 (18.2) 103 (18.2) 18 (3.2) 18 (3.2) 18 (3.2)












0 (0) 0 (0) 0 (0)









































































0 (0) 0 (0) 0 (0)














655 (29.1) 664 (29.5) 664 (29.5)
0 (0) 288 (100) 288 (100) 288 (100) 288 (100) 288 (100) 288 (100) 288 (100) 288 (100) 288 (100) 288 (100) 288 (100) 288 (100) 0 (0) 0 (0) 0 (0)
0 (0) 244 (100) 20 (8.2) 33 (13.5) 33 (13.5) 33 (13.5) 244 (100) 244 (100) 244 (100) 244 (100) 244 (100) 244 (100) 244 (100) 0 (0) 0 (0) 0 (0)
0 (0) 557 (100) 1 (0.2) 0 (0) 0 (0) 0 (0) 557 (100) 557 (100) 3 (0.5) 557 (100) 0 (0) 0 (0) 557 (100) 0 (0) 0 (0) 0 (0)
0 (0) 1244
(100)














0 (0) 109 (8.8) 109 (8.8)
0 (0) 240 (100) 0 (0) 0 (0) 0 (0) 0 (0) 240 (100) 240 (100) 240 (100) 240 (100) 240 (100) 29 (12.1) 8 (3.3) 0 (0) 0 (0) 0 (0)
0 (0) 0 (0) 3 (0.4) 15 (1.8) 15 (1.8) 15 (1.8) 823 (100) 823 (100) 823 (100) 71 (8.6) 823 (100) 823 (100) 823 (100) 0 (0) 0 (0) 0 (0)
0 (0) 736 (100) 736 (100) 736 (100) 736 (100) 736 (100) 736 (100) 736 (100) 736 (100) 736 (100) 736 (100) 17 (2.3) 56 (7.6) 0 (0) 0 (0) 0 (0)

























0 (0) 188 (0.1) 188 (0.1)
0 (0) 1016
(100)






71 (7) 71 (7) 1016
(100)


















































0 (0) 1036 (0.7) 1036 (0.7)







































602 (18.1) 602 (18.1) 602 (18.1)
0 (0) 42 (100) 42 (100) 0 (0) 0 (0) 0 (0) 42 (100) 42 (100) 0 (0) 42 (100) 42 (100) 42 (100) 42 (100) 0 (0) 0 (0) 0 (0)
0 (0) 0 (0) 173 (100) 173 (100) 173 (100) 173 (100) 173 (100) 173 (100) 173 (100) 173 (100) 173 (100) 173 (100) 173 (100) 0 (0) 0 (0) 0 (0)
0 (0) 0 (0) 53 (100) 53 (100) 53 (100) 53 (100) 53 (100) 53 (100) 53 (100) 53 (100) 53 (100) 53 (100) 53 (100) 0 (0) 0 (0) 0 (0)
0 (0) 172 (100) 90 (52.3) 172 (100) 172 (100) 172 (100) 172 (100) 172 (100) 172 (100) 172 (100) 172 (100) 172 (100) 172 (100) 0 (0) 0 (0) 0 (0)
0 (0) 54 (100) 54 (100) 3 (5.6) 3 (5.6) 3 (5.6) 54 (100) 54 (100) 54 (100) 54 (100) 54 (100) 54 (100) 54 (100) 3 (5.6) 3 (5.6) 3 (5.6)
0 (0) 0 (0) 81 (100) 81 (100) 81 (100) 81 (100) 81 (100) 81 (100) 81 (100) 81 (100) 81 (100) 81 (100) 81 (100) 13 (16) 14 (17.3) 14 (17.3)
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APPENDIX 6






























Mbah145 0 (0) 37,738
(100)
0 (0) 0 (0) 37,738 (100) 37,738 (100) 37,738
(100)





Trogstad164 97 (100) 97 (100) 97 (100) 97 (100) 97 (100) 97 (100) 97 (100) 97 (100) 97 (100) 97 (100) 97 (100) 97 (100) 97 (100)
Salim156 82 (19.3) 232 (54.6) 0 (0) 0 (0) 278 (65.4) 278 (65.4) 425 (100) 278 (65.4) 278 (65.4) 273 (64.2) 242 (56.9) 425 (100) 425 (100)
van Oostwaard
2012168
138 (21.6) 329 (51.5) 0 (0) 0 (0) 407 (63.7) 407 (63.7) 639 (100) 408 (63.8) 406 (63.5) 404 (63.2) 350 (54.8) 639 (100) 639 (100)
van Oostwaard
2014169
19 (1.2) 19 (1.2) 1639 (100) 1639
(100)
1639 (100) 33 (2) 1639
(100)
30 (1.8) 19 (1.2) 17 (1) 26 (1.6) 1639 (100) 1639 (100)
Zhang178 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 4212 (100) 4212
(100)











0 (0) 0 (0) 1368
(49.1)
2785 (100) 2785 (100)
Gurgel Alves130 500 (100) 500 (100) 500 (100) 500 (100) 500 (100) 500 (100) 500 (100) 500 (100) 500 (100) 0 (0) 500 (100) 500 (100) 500 (100)
Rocha153 733 (100) 0 (0) 733 (100) 0 (0) 733 (100) 733 (100) 733 (100) 0 (0) 733 (100) 733 (100) 733 (100) 733 (100) 733 (100)
Costa 2017107 2 (0.3) 0 (0) 0 (0) 0 (0) 574 (100) 0 (0) 574 (100) 574 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Rocha154 29 (4) 0 (0) 0 (0) 0 (0) 733 (100) 733 (100) 733 (100) 0 (0) 0 (0) 0 (0) 0 (0) 733 (100) 733 (100)
JSOG, Japan Society of Obstetrics and Gynecology; PE, pre-eclampsia; PI, pulsatility index; SGA, small for gestational age.









































299 (0.8) 615 (1.6) 615 (1.6)
0 (0) 97 (100) 97 (100) 97 (100) 97 (100) 97 (100) 97 (100) 97 (100) 97 (100) 97 (100) 97 (100) 97 (100) 97 (100) 0 (0) 0 (0) 0 (0)
0 (0) 0 (0) 265 (62.4) 251 (59.1) 247 (58.1) 251 (59.1) 425 (100) 425 (100) 425 (100) 425 (100) 425 (100) 425 (100) 425 (100) 235 (55.3) 235 (55.3) 235 (55.3)
0 (0) 0 (0) 388 (60.7) 373 (58.4) 373 (58.4) 373 (58.4) 639 (100) 639 (100) 639 (100) 639 (100) 639 (100) 639 (100) 639 (100) 335 (52.4) 335 (52.4) 335 (52.4)




















0 (0) 0 (0) 0 (0)
0 (0) 4212
(100)























0 (0) 0 (0) 0 (0)
0 (0) 500 (100) 500 (100) 500 (100) 500 (100) 500 (100) 500 (100) 500 (100) 7 (1.4) 500 (100) 500 (100) 500 (100) 500 (100) 246 (49.2) 246 (49.2) 246 (49.2)
0 (0) 733 (100) 0 (0) 733 (100) 733 (100) 0 (0) 733 (100) 733 (100) 733 (100) 733 (100) 733 (100) 733 (100) 733 (100) 0 (0) 0 (0) 0 (0)
0 (0) 0 (0) 0 (0) 574 (100) 574 (100) 0 (0) 574 (100) 574 (100) 32 (5.6) 574 (100) 574 (100) 574 (100) 574 (100) 0 (0) 0 (0) 0 (0)
0 (0) 733 (100) 0 (0) 733 (100) 733 (100) 0 (0) 733 (100) 733 (100) 733 (100) 733 (100) 733 (100) 733 (100) 733 (100) 0 (0) 0 (0) 0 (0)
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Appendix 7 International Prediction of
Pregnancy Complications Collaborators
pre-eclampsia predictors prioritisation survey
Please rank each variable according to its level of importance as 
a predictor of pre-eclampsia





























Family history of 
cardiovascular 
disease
History of renal 
disease
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diabetes (GDM) in 
current 
pregnancy
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plasma protein A 
(PAPP-A)
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5. Please suggest any other predictor not listed which you think might be important
to consider.
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Appendix 8 Risk-of-bias assessment of data
sets on the IPPIC project











development study Risk Rationale of rating
SCOPE42 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Allen108 Yes Yes N/A Low Responses to relevant
signalling questions are yes
ALSPAC103 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Chappell121 Yes No N/A High Selected high-risk population
EMPOWaR122 Yes No N/A High Selected high-risk population
POPPY106 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Poston 2006150 Yes No N/A High Selected high-risk population
Poston 2015149 Yes No N/A High Selected high-risk population
Khan137 Yes No N/A High Selected high-risk population
St George’s163 Yes Yes N/A Low Responses to relevant




Yes Probably no N/A High Likely to be a mix of high-
and low-risk population
AMND114 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Born in
Bradford177
Yes Yes N/A Low Responses to relevant
signalling questions are yes
Velauthar39 Yes Yes N/A Low Responses to relevant
signalling questions are yes
POP161 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Baschat115 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Audibert113 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Caradeux118 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Giguère126 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Goetzinger128 Yes Yes N/A Low Responses to relevant
signalling questions are yes
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development study Risk Rationale of rating
Antsaklis110 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Llurba140 Yes Yes N/A Low Responses to relevant
signalling questions are yes
WHO175 Yes No N/A High Selected high-risk population
Andersen109 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Arenas111 Yes Yes N/A Low Responses to relevant
signalling questions are yes
FINNPEC133 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Galindo171 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Generation R134 Yes Yes N/A Low Responses to relevant
signalling questions are yes
NICHD HR32 Yes No N/A High Selected high-risk population
NICHD LR159 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Placental Health
Study176
Yes Yes N/A Low Responses to relevant
signalling questions are yes
POUCH131 Yes Yes N/A Low Responses to relevant
signalling questions are yes
van Kuijk
2011167
Yes No N/A High Selected high-risk population
van Kuijk
2014166
Yes No N/A High Selected high-risk population
Odibo147 Yes Yes N/A Low Responses to relevant
signalling questions are yes
PREDO127 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Prefumo151 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Skråstad160 Yes No N/A High Selected high-risk population
Verlohren172 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Rumbold155 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Vollebregt174 Yes No N/A High Selected high-risk population
JSOG105 Yes Yes N/A Low Responses to relevant
signalling questions are yes
DOMInO143 Yes Yes N/A Low Responses to relevant
signalling questions are yes
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development study Risk Rationale of rating
Danish Birth
Cohort136
Yes Yes N/A Low Responses to relevant
signalling questions are yes
Indonesian
Cohort157
Yes Yes N/A Low Responses to relevant
signalling questions are yes
Ohkuchi148 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Lecarpentier139 Yes No N/A High Selected high-risk population
TEST146 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Massé144 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Staff162 Yes Yes N/A Low Responses to relevant
signalling questions are yes
STORK G135 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Vatten170 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Vinter173 Yes No N/A High Selected high-risk population
BORN Ontorio104 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Ghana Cohort165 Yes Yes N/A Low Responses to relevant
signalling questions are yes
MoBa142 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Huang132 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Carbillion119 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Goffinet129 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Rang152 Yes No N/A High Selected high-risk population
Cameroni117 Yes No N/A High Selected high-risk population
Conserva123 Yes No N/A High Selected high-risk population
Facchinetti124 Yes No N/A High Selected high-risk population
Ferrazzani158 Yes No N/A High Selected high-risk population
Figueiro-Filho125 Yes No N/A High Selected high-risk population
Langenveld138 Yes No N/A High Selected high-risk population
Lykke141 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Mbah145 Yes Yes N/A Low Responses to relevant
signalling questions are yes
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development study Risk Rationale of rating
Trogstad164 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Salim156 Yes No N/A High Selected high-risk population
van Oostwaard
2012168
Yes No N/A High Selected high-risk population
van Oostwaard
2014169
Yes No N/A High Selected high-risk population
Zhang178 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Brown116 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Gurgel Alves130 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Rocha153 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Costa 2017107 Yes Yes N/A Low Responses to relevant
signalling questions are yes
Rocha154 Yes Yes N/A Low Responses to relevant
signalling questions are yes
JSOG, Japan Society of Obstetrics and Gynecology; N/A, not applicable.






















is to be used Risk Rationale of rating
SCOPE42 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Allen108 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
ALSPAC103 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Chappell121 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
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is to be used Risk Rationale of rating
POPPY106 NI N/A NI Yes Unclear No information to
make assessment
Poston 2006150 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Poston 2015149 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Khan137 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes






Probably no N/A Probably yes Yes High Definition of
predictor may differ
across studies





Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Velauthar39 NI N/A NI Yes Unclear No information to
make assessment
POP161 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Baschat115 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Audibert113 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Caradeux118 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Giguère126 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Goetzinger128 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
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is to be used Risk Rationale of rating
Llurba140 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
WHO175 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Andersen109 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Arenas111 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
FINNPEC133 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Galindo171 Yes N/A Probably yes Yes Low Responses to
relevant signalling
questions are yes
Generation R134 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
NICHD HR32 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes





Yes N/A Probably yes Yes Low Responses to
relevant signalling
questions are yes










Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Odibo147 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
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is to be used Risk Rationale of rating
Prefumo151 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Skråstad160 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Verlohren172 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Rumbold155 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Vollebregt174 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
JSOG105 NI N/A NI Yes Unclear No information to
make assessment










Yes N/A Probably yes Yes Low Responses to
relevant signalling
questions are yes
Ohkuchi148 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Lecarpentier139 Yes N/A Probably yes Yes Low Responses to
relevant signalling
questions are yes
TEST146 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Massé144 Probably yes N/A Probably yes Yes Low Responses to
relevant signalling
questions are yes
Staff162 Yes N/A Probably yes Yes Low Responses to
relevant signalling
questions are yes
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is to be used Risk Rationale of rating
Vatten170 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Vinter173 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
BORN Ontorio104 Yes N/A Probably yes Yes Low Responses to
relevant signalling
questions are yes
Ghana Cohort165 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
MoBa142 Probably yes N/A Probably yes Yes Low Responses to
relevant signalling
questions are yes
Huang132 Probably yes N/A Probably yes Yes Low Responses to
relevant signalling
questions are yes
Carbillion119 Probably yes N/A NI Yes Unclear No information to
make assessment
Goffinet129 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Rang152 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Cameroni117 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Conserva123 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Facchinetti124 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Ferrazzani158 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Figueiró-Filho125 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Langenveld138 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
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is to be used Risk Rationale of rating
Mbah145 Probably yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Trogstad164 Probably yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes










Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Zhang178 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Brown 2007116 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Gurgel Alves130 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Rocha153 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Costa 2017107 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
Rocha154 Yes N/A Yes Yes Low Responses to
relevant signalling
questions are yes
JSOG, Japan Society of Obstetrics and Gynecology; N/A, not applicable; NI, no information.
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need to be known
for diagnosis
Allen108 NI NI Probably no Probably yes N/A Probably no Probably yes Unclear No information to
make assessment
ALSPAC103 NI NI Probably no Probably yes N/A Probably no Probably yes Unclear No information to
make assessment




need to be known
for diagnosis
EMPOWaR122 NI NI Probably no Probably yes N/A Probably no Probably yes Unclear No information to
make assessment
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NI NI Probably no Probably yes N/A Probably no Probably yes Unclear No information to
make assessment
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Yes Yes No Yes N/A No Yes Unclear No information to
make assessment
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need to be known
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JSOG105 NI NI Probably no Probably yes N/A Probably no Probably yes Unclear No information to
make assessment
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Massé144 NI NI Probably no Probably yes N/A Probably no Probably yes Unclear No information to
make assessment














































































STORK G135 NI NI Probably no Probably yes N/A Probably no Probably yes Unclear No information to
make assessment
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Huang132 NI NI Probably no Probably yes N/A Probably no Probably yes Unclear No information to
make assessment
Carbillion119 NI NI Probably no Probably yes N/A Probably no Probably yes Unclear No information to
make assessment
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Appendix 9 Prediction models and equations
identified from the literature search















C+ B First trimester LP: –8.72 + 0.157 (if nulliparous) + 0.341
(if history of hypertension)+ 0.635
(if history of PE) + 0.064 (MAP) – 0.186
(PAPP-A, Ln MoM)
Yes
North, 201142 C 15 weeks’
gestation
LP1: –6.8855 – 0.0393 (age, years)+
0.0659 (MAP)+ 0.0483 (BMI)+ 0.6861
(if family history of PE)+ 0.6232
(if family history CHD) – 0.3881
(woman’s birthweight, kg)+ 0.7129
(if vaginal bleeding ≥ 5 days) – 0.8033
(if one miscarriage ≤ 10 weeks, same
partner) – 0.9070 (if ≥ 12 months to
conceive) – 0.3733 (if high fruit intake at
15 weeks) – 0.508 (if alcohol consumed
in first trimester) – 0.063 (number of





C+U LP2: –9.1113+ 0.0634 (MAP)+ 0.0485
(BMI)+ 0.6539 (if family history of
PE)+ 0.6093 (if family history of CHD)
– 0.3787 (participant’s birthweight, kg)
+ 0.6493 (if vaginal bleeding ≥ 5 days)
+ 0.5008 (if months in sexual relationship
≤ 6 months)+ 0.5084 (if bilateral
notches)+ 2.0802 (mean Ut RI) – 0.8248
(one miscarriage ≤ 10 weeks, same
partner) – 0.8983 (≥ 12 months to
conceive) – 0.4389 (high fruit intake at






Odibo, 2011147 C+ B First trimester LP1: –3.389 – 0.716 (PAPP-A, MoM)+
0.05 (BMI) + 0.319 (if black ethnicity) +
1.57 (if history of chronic hypertension)
Yes
C+ B LP2: –2.607 – 0.502 (PP13, MoM) +
0.759 (if pre-gestational diabetic) + 0.777






C+U LP3: –3.895 – 0.593 (mean uterine
artery PI) + 0.944 (if pre-gestational
diabetes) + 0.059 (BMI) + 1.532
(if history of chronic hypertension)
Yes
C+ B+U LP4: –1.308 – 0.574 (PP13, MoM) –
0.502 (PAPP-A, MoM) – 0.643
(mean uterine artery PI) + 0.799
(if pre-gestational diabetic) + 0.664
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Seed, 2011 C Second
trimester
LP: –1.2422 + 0.4061 (if chronic
hypertension) + 0.5071 (if DBP > 70) –
0.3846 (if DBP > 90) + 0.8890 (if SBP
> 120) + 0.7040 (if previous PE) – 0.4043
(if on folates) + 0.8311 (if mother is








C+ B First trimester LP: –3.25+ 0.51 (if PAPP-A
< 10th centile)+ 0.93 (if BMI > 25)+
0.94 (if chronic hypertension)+
0.97 (if diabetes)+ 0.61 (if African
American ethnicity)
Yes
Emonts, 2008 C Post pregnancy LP: –3.72 + 0.030 (age, years) – 0.50
(parity) + 0.15 (gestation) + 1.89
(if chronic hypertension in patient’s
mother) + 0.14 (BMI)+ 0.079





Poon, 2008233 C First trimester LP: –6.311 + 1.299 (if African Caribbean
ethnicity) + 0.092 (BMI)+ 0.855
(if woman’s mother had PE) – 1.481
(if parous without previous PE)




C First trimester LP: –6.253 + 1.432 (if African Caribbean
ethnicity) + 1.465 (if mixed ethnicity) +
0.084 (BMI) + 0.81 (if patient’s mother
had PE) – 1.539 (if parous without
previous PE) + 1.049 (if parous with
previous PE)
Yes
Yu, 2005238 C+U Second
trimester
LP: 1.8552 + 5.9228 (mean uterine
artery PI)–2 – 14.4474 (mean uterine
artery PI)–1 – 0.5478 (if smoker) + 0.6719
(bilateral notch) + 0.0372 (age)+ 0.4949
(if black ethnicity) + 1.5033 (if history
of PE) – 1.2217 (if previous term live
birth) + 0.0367 (BMI)
Yes
Kenny, 2014 C+ B +U First trimester LP: −12.200−0.655 (high fruit intake)
+ 0.054 (BMI) + 0.065 (MAP) + 2.569
(mean uterine artery RI)−0.311 (PlGF








C First trimester LP: 0.74 – 1.016 prior infertility +






Teixeira, 2014 C + B First trimester LP: –5.723 + 0.870 (if chronic
hypertension) + 1.428 (if diabetic) –
0.787 (if multiparous) + 3.952 (if history
of PE) + 0.039 × (maternal age)+
6.159 × (maternal weight MoM, log)+
0.027 × (CRL) + (–0.483) × NT+ 0.766 ×






















C First trimester LP1: –5.177 + 2.383 (if black ethnicity) –
1.105 (if nulliparous) + 3.543 (if parous
with previous PE)+ 2.229 (if chronic
hypertension)+ 2.201 (if renal disease) a
priori risk= exp(LP1)/(1 + exp(LP1))
Yes
C+U LP2: –21.99 + 12.25 (a priori risk,
log10)+ 11.516 (MAP, MoM) + 3.784





C+ B+U LP3: 21.515 + 12.884 (a priori risk,
log10)+ 11.219 (MAP, MoM) + 3.325
(mean uterine PI, MoM) – 7.346







C First trimester LP: –5.803 + 0.302 (if history of





C+ B+U First trimester LP: –6.942 + 0.074 (BMI)+ 1.878
(if smoker) + 2.1116 (lowest uterine








C First trimester LP1: –7.703 + 0.086 (BMI)+ 1.708
(if chronic hypertension)+ 4.033 (if renal
disease)+ 1.931 (if parous with previous
PE) + 0.005 (if parous with no previous
PE) a priori risk= exp(LP1)/(1 + exp(LP1))
Yes
C+U LP2: –0.32+ 2.681 (a priori risk, Ln)+
13.12 (mean uterine artery PI, Ln MoM)





Kuc, 2013230 C First trimester LP: –6.790 – 0.119 (maternal height, cm)
+ 4.8565 (maternal weight, Ln)+ 1.845
(if nulliparous)+ 0.086 (maternal age,
years)+ 1.353 (if smoker)
Yes
Odibo, 2011 C+ B+U First trimester LP: –4.678 – 0.443 (PP13, MoM) – 0.009
(PAPP-A, MoM) + 0.347 (mean uterine






Seed, 2011 C Second
trimester
LP: –2.693+ 1.735 (if SBP > 140)+
1.004 (if on antihypertensive therapy) –
0.9790 (if previous PE in most recent
pregnancy) + 2.121 (if previous PE with
delivery < 34 weeks)+ 1.285 (if mother





Poon, 2010 (1) C + B First trimester LP1: 3.022 + 2.652 (maternal factor-
derived a priori risk for early-PE, Ln) –
6.056 (PlGF, Ln MoM) + 3.103 (inhibin-A,





C+ B LP2: 2.547 + 2.518 (combined a priori
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C First trimester LP: –5.674 + 1.267 (if black ethnicity) +
2.193 (if history of chronic hypertension)
– 1.184 (if parous without previous PE)
+ 1.362 (if parous with previous PE)
+ 1.537 (if conceived with ovulation
induction)
Yes
Poon, 2009 (1) C + B First trimester LP: –8.776 + 14.177 (uterine artery PI,
Ln MoM)+ 42.960 (MAP, Ln MoM) –
2.249 (PAPP-A, Ln MoM) – 3.529
(PlGF, Ln MoM) + 0.120 (BMI) – 1.472





Poon, 2009 (2) C +U First trimester LP: –3.657 + 1.592 (maternal factor-
derived a priori risk for early PE, Ln) +
31.396 (MAP, Ln MoM)+ 13.322







C+ B First trimester LP: –6.413 – 3.612 (PAPP-A, Ln MoM)+
1.803 (if history of chronic hypertension)+
1.564 (if black ethnicity) – 1.005 (if parous
without previous PE)+ 1.491 (if parous
with previous PE)
Yes
Akolekar, 2008 C+ B +U First trimester LP: –5.620 – 4.717 (PlGF, Ln MoM) –
1.865 (PAPP-A, Ln MoM) + 14.519
(uterine artery PI, MoM) + 5.471
(if history of chronic hypertension)+










LP: –11.4487+ 31.2443 (uterine artery PI,
Ln MoM) + 40.1105 (MAP, Ln MoM) +





Plasencia, 2008 C+U First trimester LP: –6.546 + 3.769 (if chronic
hypertension) + 15.692







C First trimester LP: –6.431 + 1.680 (if African Caribbean
ethnicity) + 1.889 (if mixed ethnicity) +
2.822 (if parous with previous PE)
Yes
Yu, 2005238 U Second
trimester
LP: –9.81223 + 2.10910 (mean uterine
artery PI)3 – 1.79921 (mean uterine
artery PI)3 + 1.059463 (if bilateral notch)
Yes
APPENDIX 9













Wright, 2015236 C First trimester LP: mean gestational age at delivery
with PE= 54.3637 – 0.0206886
(age, years – 35, if age ≥ 35)+ 0.11711
(height, cm – 164) – 2.6786
(if Afro-Caribbean ethnicity) – 1.129
(if South Asian ethnicity) – 7.2897 (if
chronic hypertension) – 3.0519 (if systemic
lupus erythematosus or antiphospholipid
syndrome) – 1.6327 (if conception by in
vitro fertilisation) – 8.1667 (if parous with
previous PE)+ 0.0271988 (if parous with
previous PE, previous gestation in
weeks – 24)2 – 4.335 (if parous with no
previous PE) – 4.15137651 (if parous
with no previous PE, interval between
pregnancies in years)–1+ 9.21473572
(if parous with no previous PE, interval
between pregnancies in years)–0.5
– 0.0694096 (if no chronic hypertension,
weight in kg – 69) – 1.7154 (if no chronic
hypertension and family history of PE)
– 3.3899 (if no chronic hypertension and
diabetes mellitus type 1 or 2)
Yes
Kenny, 2014 C+ B+U First trimester LP: −14.164 + 0.075 (MAP) + 6.1782
(mean uterine artery RI)+ 0.649
(interleukin-1 receptor antagonist/PlGF);
early-onset PE: −34.347 + 0.109





Teixeira, 2014 C First trimester LP: –4.951+ 1.519 (if chronic
hypertension) – 1.201 (if multiparous)+






Keikkala, 2013 C + B First trimester LP: 1.75 – 3.27 (%hCG-H MoM)
–3.63 (PAPP-AMoM)+ 1.49 [parity






Myers, 2013 C Second
trimester
LP1: –8.4093 + 0.9037 (fertility
treatment) + 0.7999 (any sister





C+ B LP2: –7.7769 + 0.7307 (fertility






C+U LP3: –13.5946 + 0.8402 (fertility
treatment) + 0.1039 (MAP) + 7.0938





C+ B+U LP4: –12.5382 + 0.1078 (MAP)
–1.5658 (PlGF MoM) + 6.1087





C+ B+U LP5: –10.4272 + 0.0994 (MAP)
–1.1787 (PlGF MoM) + 0.0344 (endoglin
20-week) + 0.5285 (20-week bilateral
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C First trimester LP1: –5.873 – 0.462 (if white ethnicity) +
0.109 (BMI) – 0.825 (if nulliparous) +
2.726 (if parous with previous PE) +
1.956 (if chronic hypertension) – 0.575
(if smoker) a priori risk= exp(LP1)/
(1 + exp(LP1))
Yes
C+U LP2: –14.315 + 8.864 (a priori risk,
log10)+ 7.429 (MAP, MoM)+ 2.447





C+ B +U LP3: 25.921 + 9.652 (a priori risk,
log10)+ 6.89 (MAP, MoM) + 2.343
(mean uterine artery PI, MoM) – 5.618







C+ B +U First trimester LP: –5.584 + 0.137 (BMI)+ 0.822
(lowest uterine artery PI, Ln MoM) –







C First trimester LP1: 6.135 + 2.124 (if previous PE)+
1.571 (if chronic hypertension)+ 0.958
(if diabetes) + 1.416 (if thrombophilic
condition) – 0.487 (if multiparous) +
0.093 (BMI) a priori risk= exp(LP1)/
(1 + exp(LP1))
Yes
C+ B LP2: 0.328 + 2.205 (a priori risk, Ln) –





Kuc, 2013230 C First trimester LP: –14.374 + 2.300 (maternal weight,
Ln) + 1.303 (if nulliparous) + 0.068
(maternal age, years)
Yes
Poon, 2010 (1) C + B First trimester LP1: 3.810 + 2.898 (maternal factor-
derived a priori risk for late PE, Ln) –
3.171 (PlGF, Ln MoM)+ 3.792 (activin-A,
Ln MoM)+ 2.013 (MMP-9, Ln MoM) +





LP2: 3.490 + 2.717 (combined a priori
risk for late PE, Ln) – 2.966 (PlGF, Ln
MoM) + 3.937 (activin-A, Ln MoM) +







C First trimester LP: –7.860 + 0.034 (age, years)+ 0.096
(BMI) + 1.089 (if black ethnicity) + 0.980
(if Indian or Pakistani ethnicity) + 1.196
(if mixed ethnicity) + 1.070 (if woman’s
mother had PE) – 1.413 (if parous

















Poon, 2009 (1) C + B+U First trimester LP: –5.324+ 2.233 (uterine artery PI, Ln)+
23.134 (MAP, Ln MoM) – 2.408 (PlGF, Ln
MoM) + 0.123 (BMI) + 1.019 (if black
ethnicity) + 2.028 (if mixed ethnicity) +
1.298 (if family history of PE) – 1.443





Poon, 2009 (2) C +U First trimester LP: –0.468 + 2.272 (maternal factor-
derived a priori risk for late PE, Ln) +
21.147 (MAP, Ln MoM) + 3.537 (lowest







C+ B First trimester LP: –6.652 – 0.884 (PAPP-A, Ln MoM) +
1.127 (if family history of PE) + 1.222
(if black ethnicity) + 0.936 (if Indian or
Pakistani ethnicity) + 1.335 (if mixed
ethnicity) + 0.084 (BMI) – 1.255
(if parous without previous PE) + 0.818
(if parous with previous PE)
Yes
Akolekar, 2008 C+ B+U First trimester LP: –5.136 – 2.400 (PlGF, Ln MoM) +
2.641 (uterine artery PI, Ln MoM) +
0.108 (BMI)+ 1.441 (if patient’s mother
had PE)+ 1.366 (if black ethnicity) +
1.083 (if Indian or Pakistani ethnicity) +
1.549 (if mixed ethnicity) – 1.281










LP: –7.4924 + 6.2361 (uterine artery PI,
Ln MoM) + 23.1953 (MAP, Ln MoM)+
0.6003 (if African Caribbean ethnicity) +






Plasencia, 2008 C+U First trimester LP: –6.140 + 0.082 (BMI)+ 0.813
(if African Caribbean ethnicity) – 1.234
(if parous with no previous PE)+ 0.922
(if parous with a previous PE) + 1.049
(if patient’s mother had PE) + 2.198







C First trimester LP: –6.585 + 1.368 (if African Caribbean
ethnicity) + 1.311 (if mixed ethnicity)
+ 0.091 (BMI) + 0.960 (if patient’s
mother had PE) – 1.663 (if parous
without previous PE)
Yes
Yu, 2005238 C+U Second
trimester
LP: 0.7901 + 5.1473 (mean uterine
artery PI)–2 – 12.5152 (mean uterine
artery PI)–1 – 0.5575 (if smoker) + 0.5333
(if bilateral notch) + 0.0328 (age) +
0.4958 (if black ethnicity) + 1.5109
(if history of PE) + 1.1556 (if previous
term live birth) + 0.0378 (BMI)
Yes
Kenny, 2014 C+ B+U First trimester LP: −9.504 − 0.577 high fruit intake +
0.058 MAP + 0.058 BMI + 0.550 tissue
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Teixeira, 2014 C + B First trimester LP: –8.248+ 0.050 (if chronic
hypertension)+ 1.649 (if diabetic) –
0.623 (if multiparous)+ 3.668 (if history
of PE)+ 5.834 × (maternal weight MoM,
log)+ 0.036 × (CRL)+ (–0.592) ×NT+





CHD, coronary heart disease; CRL, crown–rump length; hCG, human chorionic gonadotropin; hCG-H, hyperglycosylated
human chronic gonadotropin; MoM, multiple of the mean; PE, pre-eclampsia; PI, pulsatility index; PP13, placental
protein 13; RI, resistance index; SGA, small for gestational age.
a For logistic regression, logit(p) = LP where the LP= α + β1 × x1 + β2 × x2 + . . ., and absolute predicted probabilities (p)
can be obtained using the transformation p = eLP/(1+ eLP). The model for ‘mean gestational age at delivery with PE’
assumes a normal distribution with the predicted mean gestational age and SD 6.8833. The risk of delivery with
PE is then calculated as the area under the normal curve between 24 weeks and either 42 weeks for any-onset PE
(model 3) or 34 weeks for early-onset PE (model 14). For more detail, see Wright et al.236
Note
Ln and log10 indicate that a variable was modelled on the natural logarithm scale or logarithm with base 10
scale, respectively.
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Appendix 10 Patient characteristics of
IPPIC-UK individual participant data sets
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White 554 (84) 398 (38) 11,769 (97) 215 (68) 449 (100) NR 954 (61) 33,257 (62) NR 402 (35) 3900 (93)
Black 49 (7) 108 (10) 127 (1) 91 (29) 0 (0) 395 (25) 7820 (15) 90 (8) 25 (< 1)
Asian 47 (7) 495 (47) 113 (< 1) 6 (2) 0 (0) 97 (6) 10,388 (19) 565 (50) 91 (2)
Hispanic 1 (< 1) 0 (0) 0 (0) 3 (< 1) 0 (0) 0 (0) 5 (< 1) 0 (0) 0 (0)
Mixed 0 (0) 12 (1) 0 (0) 0 (0) 0 (0) 0 (0) 1528 (3) 0 (0) 1 (< 1)
Other 7 (1) 30 (3) 76 (< 1) 1 (< 1) 0 (0) 108 (7) 555 (1) 82 (7) 195 (5)
Nulliparous, n (%) 658 (100) 584 (56) 5704 (45) 202 (64) 291 (65) NR 674 (43) 29,319 (54) 65,206 (48) 598 (52) 4212 (100)
Previous PE, n (%) 0 (0) 17 (2) NR 56 (18) 0 (0) 657 (27) 69 (4) NR NR NR 0 (0)
Outcome, n (%)
Any-onset PE 32 (5) 14 (1) 288 (2) 35 (12) 10 (5) 371 (15) 54 (4) 1487 (3) 4970 (4) 26 (2) 273 (6)
Early-onset PE 6 (1) 1 (< 1) 37 (< 1) 6 (2) 0 (0) 144 (6) 5 (< 1) 151 (< 1) 1237 (< 1) 3 (< 1) 10 (< 1)
Late-onset PE 26 (4) 13 (1) 251 (2) 29 (10) 10 (5) 227 (9) 49 (3) 1336 (2) 3733 (3) 23 (2) 263 (6)
NR, not recorded; PE, pre-eclampsia.
Note

































Appendix 11 Number and proportion missing
(or not recorded) for each predictor in each
data set used for external validation
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Variable




























Maternal age 0 (0) 1 (< 1) 1353 (9) 0 (0) 0 (0) 22 (< 1) 0 (0) 0 (0) 19 (< 1) 1145 (100) 0 (0)
Ethnicity 0 (0) 2 (< 1) 2259 (16) 0 (0) 0 (0) 2422 (100) 0 (0) 1082 (2) 136,635 (100) 6 (< 1) 0 (0)
Nulliparous 0 (0) 0 (0) 1745 (12) 0 (0) 1 (< 1) 2422 (100) 0 (0) 104 (< 1) 6 (< 1) 0 (0) 0 (0)
Parity and
previous PE
0 (0) 0 (0) 14,344 (100) 0 (0) 1 (< 1) 2422 (100) 8 (< 1) 54,635 (100) 136,635 (100) 1145 (100) 0 (0)
Family history
of PE
0 (0) 6 (< 1) 14,344 (100) 316 (100) 449 (100) 2422 (100) 61 (4) 54,635 (100) 136,635 (100) 1145 (100) 4212 (100)
Family history of
PE in mother
0 (0) 6 (< 1) 14,344 (100) 316 (100) 449 (100) 2422 (100) 101 (6) 54,635 (100) 136,635 (100) 1145 (100) 4212 (100)
Spontaneous
conception
0 (0) 0 (0) 2167 (15) 316 (100) 449 (100) 2422 (100) 4 (< 1) 1427 (3) 136,635 (100) 1145 (100) 0 (0)
History of
hypertension
0 (0) 0 (0) 2307 (16) 0 (0) 449 (100) 0 (0) 0 (0) 0 (0) 0 (0) 1 (< 1) 0 (0)
History of renal
disease
0 (0) 0 (0) 2060 (14) 316 (100) 0 (0) 0 (0) 0 (0) 54,635 (100) 0 (0) 1145 (100) 0 (0)
History of
diabetes




0 (0) 1045 (100) 14,344 (100) 316 (100) 449 (100) 2422 (100) 1554 (100) 54,635 (100) 136,635 (100) 1145 (100) 4212 (100)
Smoker 0 (0) 0 (0) 1972 (14) 0 (0) 0 (0) 2422 (100) 0 (0) 4053 (7) 2902 (2) 1 (< 1) 0 (0)
Maternal height 0 (0) 0 (0) 8769 (61) 316 (100) 0 (0) 0 (0) 0 (0) 8454 (15) 3867 (3) 5 (< 1) 6 (< 1)
Maternal weight
(trimester 1)
0 (0) 5 (< 1) 9190 (64) 316 (100) 152 (34) 0 (0) 0 (0) 7992 (15) 23,926 (18) 6 (< 1) 146 (3)
Trimester 1 BMI 0 (0) 5 (< 1) 2409 (17) 33 (10) 152 (34) 0 (0) 0 (0) 9151 (17) 25,650 (19) 6 (< 1) 152 (4)





























































Trimester 1 MAP 0 (0) 5 (< 1) 3618 (25) 316 (100) 152 (34) 0 (0) 1536 (99) 54,635 (100) 136,635 (100) 8 (< 1) 280 (7)
Trimester 1
PAPP-A (MoM)
658 (100) 119 (11) 14,344 (100) 316 (100) 449 (100) 2422 (100) 1554 (100) 30,919 (57) 136,635 (100) 1145 (100) 171 (4)
Trimester 1
PAPP-A
658 (100) 119 (11) 14,344 (100) 316 (100) 449 (100) 2422 (100) 526 (34) 54,635 (100) 136,635 (100) 1145 (100) 134 (3)
Trimester 1 UtPI 658 (100) 1045 (100) 14,344 (100) 316 (100) 449 (100) 2422 (100) 1554 (100) 32,595 (60) 136,635 (100) 2 (< 1) 4212 (100)
Trimester 2 UtPI 658 (100) 1045 (100) 14,344 (100) 316 (100) 449 (100) 2257 (93) 1554 (100) 28,109 (51) 136,635 (100) 1145 (100) 133 (3)
Trimester 2
bilateral notching
3 (< 1) 1040 (100) 14,344 (100) 316 (100) 449 (100) 27 (1) 1554 (100) 21,596 (40) 136,635 (100) 1145 (100) 133 (3)
Outcome
Any-onset PE 4 (< 1) 0 (0) 832 (5) 33 (10) 246 (55) 0 (0) 47 (3) 0 (0) 0 (0) 32 (3) 5 (< 1)
Early-onset PE 4 (< 1) 0 (0) 832 (5) 33 (10) 78 (17) 0 (0) 47 (3) 0 (0) 0 (0) 32 (3) 5 (< 1)
Late-onset PE 4 (< 1) 0 (0) 832 (5) 33 (10) 239 (53) 0 (0) 47 (3) 0 (0) 0 (0) 32 (3) 5 (< 1)


















































































































































































































































































































































Appendix 12 Summary of linear predictor
and predicted probability values from
external validation
DOI: 10.3310/hta24720 Health Technology Assessment 2020 Vol. 24 No. 72
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Allotey et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
189
















First-trimester any-onset pre-eclampsia models
1 Plasencia
et al., 2007231
C SCOPE UK42 658 33 (5.0) –4.186 –4.408 to –3.868 –4.865 to –1.052 0.015 0.012 to 0.020 0.008 to 0.259
Allen et al.108 1045 14 (1.3) –4.508 –5.576 to –4.139 –6.464 to –1.023 0.011 0.004 to 0.016 0.002 to 0.264
Poston et al.
2015149
1554 56 (3.6) –3.488 –4.531 to –2.943 –5.269 to 0.337 0.03 0.011 to 0.050 0.005 to 0.584
2 Poon et al.,
2008233
C SCOPE UK42 658 33 (5.0) –4.047 –4.290 to –3.700 –4.790 to –0.884 0.017 0.014 to 0.024 0.008 to 0.292
Allen et al.108 1045 14 (1.3) –4.406 –5.386 to –4.002 –6.337 to –0.885 0.012 0.005 to 0.018 0.002 to 0.292
Poston et al.
2015149
1554 56 (3.6) –3.292 –4.220 to –2.700 –5.028 to 0.691 0.036 0.014 to 0.063 0.007 to 0.666
3 Wright et al.,
2015236
C SCOPE UK42 658 33 (5.0) –3.272 –3.513 to –2.929 –4.179 to –0.758 0.037 0.029 to 0.051 0.015 to 0.319
Allen et al.108 584 8 (1.4) –3.093 –3.436 to –2.729 –4.182 to –0.962 0.043 0.031 to 0.061 0.015 to 0.277
Poston et al.
2015149
674 36 (5.3) –2.084 –2.300 to –1.710 –3.090 to –0.437 0.111 0.091 to 0.153 0.044 to 0.393
4 Baschat
et al., 2014115
C+ B Allen et al.108 1045 14 (1.3) –3.041 –3.440 to –2.615 –4.705 to 0.283 0.046 0.031 to 0.068 0.009 to 0.570
POP161 4212 273 (6.5) –3.549 –3.885 to –3.107 –5.801 to 0.185 0.028 0.020 to 0.043 0.003 to 0.546
5 Goetzinger
et al., 2010128
C+ B Allen et al.108 1045 14 (1.3) –3.25 –3.250 to –2.320 –3.250 to –0.260 0.037 0.037 to 0.089 0.037 to 0.435
Poston et al.
2015149
1554 56 (3.6) –2.32 –2.320 to –1.710 –2.320 to –1.200 0.089 0.089 to 0.153 0.089 to 0.231
POP161 4212 273 (6.5) –3.25 –3.250 to –2.320 –3.250 to 0.100 0.037 0.037 to 0.089 0.037 to 0.525
6 Odibo et al.,
2011147
C+ B Allen et al.108 1045 14 (1.3) –2.92 –3.223 to –2.614 –5.367 to –0.301 0.051 0.038 to 0.068 0.005 to 0.425
St George’s163 54,635 1487 (2.7) –2.866 –3.200 to –2.573 –36.527 to 0.882 0.054 0.039 to 0.071 0.000 to 0.707
POP161 4212 273 (6.5) –2.874 –3.287 to –2.517 –21.418 to 0.230 0.053 0.036 to 0.075 0.000 to 0.557




















































First-trimester early-onset pre-eclampsia models
8 Baschat
et al., 2014115
C SCOPE UK42 658 6 (0.9) –5.070 –5.114 to –5.019 –5.234 to –4.069 0.006 0.006 to 0.007 0.005 to 0.017
ALSPAC103 14,344 40 (0.3) –5.013 –5.076 to –4.949 –5.362 to –3.502 0.007 0.006 to 0.007 0.005 to 0.029
Poston et al.
2006150
2422 144 (6.0) –4.891 –5.013 to –4.151 –5.297 to –3.631 0.007 0.007 to 0.016 0.005 to 0.026
Velauthar
et al.39
1145 4 (0.3) –5.029 –5.090 to –4.975 –5.272 to –3.867 0.007 0.006 to 0.007 0.005 to 0.020
POP161 4212 10 (0.2) –5.059 –5.108 to –4.992 –5.361 to –3.761 0.006 0.006 to 0.007 0.005 to 0.023
9 Crovetto
et al., 2015229
C SCOPE UK42 658 6 (0.9) –6.282 –6.282 to –6.282 –6.282 to –1.670 0.002 0.002 to 0.002 0.002 to 0.158
Poston et al.
2015149
1554 6 (0.4) –5.177 –6.282 to –3.899 –6.282 to 0.749 0.006 0.002 to 0.020 0.002 to 0.679
POP161 4212 10 (0.2) –6.282 –6.282 to –6.282 –6.282 to –1.670 0.002 0.002 to 0.002 0.002 to 0.158
10 Kuc et al.,
2013230
C SCOPE UK42 658 6 (0.9) –1.679 –2.24 to –0.955 –4.285 to 2.445 0.157 0.096 to 0.278 0.014 to 0.920
ALSPAC103 14,344 40 (0.3) –3.339 –4.242 to –2.413 –8.414 to 2.483 0.034 0.014 to 0.082 0.000 to 0.919
Poston et al.
2015149
1554 6 (0.4) –0.543 –1.413 to 0.373 –3.744 to 3.982 0.367 0.196 to 0.592 0.023 to 0.982
St George’s163 54,635 151 (0.3) –2.351 –3.236 to –1.488 –11.455 to 7.092 0.087 0.038 to 0.184 0.000 to 0.999
AMND114 136,635 1237 (0.9) –2.304 –3.223 to –1.371 –7.660 to 4.857 0.091 0.038 to 0.202 0.000 to 0.992
POP161 4212 10 (0.2) –1.599 –2.268 to –0.842 –4.585 to 3.497 0.168 0.094 to 0.301 0.010 to 0.970
11 Plasencia
et al., 2007231
C SCOPE UK42 658 6 (0.9) –6.431 –6.431 to –6.431 –6.431 to –4.751 0.002 0.002 to 0.002 0.002 to 0.009
Chappell
et al.121
316 7 (2.1) –6.431 –6.431 to –4.751 –6.431 to –1.929 0.002 0.002 to 0.009 0.002 to 0.127
Poston et al.
2015149
1554 6 (0.4) –6.431 –6.431 to –4.751 –6.431 to –1.929 0.002 0.002 to 0.009 0.002 to 0.127


































































































































































































































































































































































12 Poon et al.,
2010232
C SCOPE UK42 658 6 (0.9) –5.674 –5.674 to –5.674 –5.674 to –2.214 0.003 0.003 to 0.003 0.003 to 0.099
Poston et al.
2015149
1554 6 (0.4) –4.137 –5.321 to –4.054 –6.858 to –1.508 0.016 0.005 to 0.017 0.001 to 0.181
POP161 4212 10 (0.2) –4.137 –4.137 to –4.137 –5.674 to –0.677 0.016 0.016 to 0.016 0.003 to 0.337
13 Scazzocchio
et al., 2013235
C SCOPE UK42 658 6 (0.9) –5.631 –5.832 to –5.397 –6.282 to –3.145 0.004 0.003 to 0.005 0.002 to 0.041
Poston et al.
2015149
1554 6 (0.4) –4.662 –4.877 to –4.333 –5.127 to –0.099 0.009 0.008 to 0.013 0.006 to 0.475
POP161 4212 10 (0.2) –5.617 –5.822 to –5.303 –6.448 to 1.688 0.004 0.003 to 0.005 0.002 to 0.844
14 Wright et al.,
2015236
C SCOPE UK42 658 6 (0.9) –6.461 –6.804 to –5.972 –7.744 to –2.932 0.002 0.001 to 0.003 0.000 to 0.051
Poston et al.
2015149
674 6 (0.4) –4.761 –5.069 to –4.231 –6.201 to –2.521 0.008 0.006 to 0.014 0.002 to 0.074
15 Poon et al.,
2009234
C+ B POP161 4212 10 (0.2) –6.321 –7.824 to –4.693 –18.294 to 3.971 0.002 0.000 to 0.009 0.000 to 0.981
First-trimester late-onset pre-eclampsia models
16 Crovetto
et al., 2015229
C SCOPE UK42 658 26 (4.0) –4.504 –4.789 to –4.149 –5.703 to –1.592 0.011 0.008 to 0.016 0.003 to 0.169
Allen et al.108 1045 13 (1.2) –3.914 –4.494 to –3.298 –5.654 to 1.509 0.020 0.011 to 0.036 0.003 to 0.819
Chappell
et al.121
316 32 (10.0) –4.084 –4.648 to –2.645 –5.903 to 2.098 0.017 0.009 to 0.066 0.003 to 0.891
Poston et al.
2015149
1554 51 (3.3) –2.658 –3.207 to –2.114 –4.468 to 3.007 0.066 0.039 to 0.108 0.011 to 0.953
















































17 Kuc et al.,
2013230
C SCOPE UK42 658 26 (4.0) –1.464 –1.871 to –1.062 –3.016 to 0.191 0.188 0.133 to 0.257 0.047 to 0.548
Allen et al.108 1045 13 (1.2) –2.104 –2.653 to –1.526 –4.520 to 0.558 0.109 0.066 to 0.179 0.011 to 0.636
ALSPAC103 14,344 266 (1.9) –2.698 –3.226 to –2.070 –5.045 to 0.134 0.063 0.038 to 0.112 0.006 to 0.533
EMPOWaR122 449 28 (6.3) –0.801 –1.395 to –0.281 –3.032 to 1.118 0.310 0.199 to 0.430 0.047 to 0.751
Poston et al.
2015149
1554 51 (3.3) –1.286 –1.801 to –0.641 –3.074 to 1.077 0.217 0.142 to 0.345 0.044 to 0.746
St George’s163 54,635 1336 (2.4) –1.992 –2.562 to –1.437 –4.741 to 1.303 0.120 0.072 to 0.192 0.009 to 0.786
AMND114 136,635 3733 (2.7) –2.238 –2.791 to –1.652 –4.987 to 1.023 0.096 0.058 to 0.161 0.007 to 0.735
POP161 4212 263 (6.2) –1.367 –1.723 to –1.011 –3.233 to 0.874 0.203 0.151 to 0.267 0.038 to 0.705
18 Plasencia
et al., 2007231
C SCOPE UK42 658 26 (4.0) –4.346 –4.586 to –4.001 –5.081 to –1.134 0.013 0.010 to 0.018 0.006 to 0.243
Allen et al.108 1045 13 (1.2) –4.702 –5.848 to –4.318 –6.809 to –1.020 0.009 0.003 to 0.013 0.001 to 0.265
Poston et al.
2015149
1554 51 (3.3) –3.636 –4.715 to –3.103 –5.514 to 0.141 0.026 0.009 to 0.043 0.004 to 0.535
19 Poon et al.,
2010232
C SCOPE UK42 658 26 (4.0) –4.460 –4.746 to –3.925 –5.459 to –1.342 0.011 0.009 to 0.019 0.004 to 0.207
Allen et al.108 1045 13 (1.2) –4.542 –5.007 to –3.860 –6.748 to –1.142 0.011 0.007 to 0.021 0.001 to 0.242
Poston et al.
2015149
1554 51 (3.3) –3.656 –4.321 to –2.968 –5.612 to 0.285 0.025 0.013 to 0.049 0.004 to 0.571
20 Scazzocchio
et al., 2013235
C SCOPE UK42 658 26 (4.0) –3.894 –4.111 to –3.641 –4.598 to –1.482 0.020 0.016 to 0.026 0.010 to 0.185
21 Poon et al.,
2009234


































































































































































































































































































































































Second-trimester any-onset pre-eclampsia models
22 Yu et al.,
2005238
C+U POP161 4212 273 (6.5) –4.470 –4.806 to –3.860 –6.206 to 65.058 0.011 0.008 to 0.021 0.002 to 1.000
Second-trimester early-onset pre-eclampsia models
23 Yu et al.,
2005238
C+U POP161 4212 10 (0.2) –9.601 –9.694 to –9.412 –9.809 to 0.374 0.000 0.000 to 0.000 0.000 to 0.591
Second-trimester late-onset pre-eclampsia models
24 Yu et al.,
2005238
C+U POP161 4212 263 (6.2) –4.488 –4.789 to –3.967 –6.145 to 56.090 0.011 0.008 to 0.019 0.002 to 1.000
C, clinical characteristics; C+ B, clinical and biochemical markers; C+U, clinical characteristics and ultrasound markers.
a For imputed data, the estimates are the average across imputations (pooled using Rubin’s rules).
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FIGURE 18 Median (dot) and range (bar) of values for (a) LP and (b) predicted probabilities across validation data sets
for each model being externally validated. This figure contains information from several sources.115,128,147,229–236,238
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Appendix 13 Predictive performance
statistics for models in the individual
IPPIC-UK data sets
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Performance statistic (95% CI)
C-statistic Calibration slope Calibration-in-the-large
First-trimester any-onset pre-eclampsia models
1 Plasencia et al.,
2007231
C SCOPE UK42 658 33 (5.0) 0.636 (0.532 to 0.729) 0.521 (0.025 to 1.017) 0.865 (0.502 to 1.228)
Allen et al.108 1045 14 (1.3) 0.782 (0.638 to 0.880) 1.110 (0.600 to 1.619) –0.117 (–0.651 to 0.417)
Poston et al.
2015149
1554 56 (3.6) 0.692 (0.617 to 0.758) 0.580 (0.346 to 0.813) –0.326 (–0.610 to –0.042)
2 Poon et al., 2008233 C SCOPE UK42 658 33 (5.0) 0.637 (0.532 to 0.730) 0.546 (0.051 to 1.040) 0.731 (0.368 to 1.093)
Allen et al.108 1045 14 (1.3) 0.782 (0.638 to 0.880) 1.155 (0.622 to 1.689) –0.209 (–0.743 to 0.324)
Poston et al.
2015149
1554 56 (3.6) 0.694 (0.620 to 0.759) 0.597 (0.357 to 0.837) –0.518 (–0.801 to –0.234)
3 Wright et al.,
2015236
C SCOPE UK42 658 33 (5.0) 0.647 (0.552 to 0.732) 0.638 (0.097 to 1.179) 1.880 (1.519 to 2.240)
Allen et al.108 584 8 (1.4) 0.680 (0.453 to 0.845) 0.840 (–0.100 to 1.781) 0.367 (–0.334 to 1.069)
Poston et al.
2015149
674 36 (5.3) 0.592 (0.497 to 0.681) 0.560 (–0.067 to 1.187) 0.544 (0.200 to 0.888)
4 Baschat et al.,
2014115
C+ B Allen et al.108 1045 14 (1.3) 0.758 (0.620 to 0.857) 1.246 (0.667 to 1.824) –1.543 (–2.074 to –1.011)
POP161 4212 273 (6.5) 0.704 (0.670 to 0.737) 1.237 (1.034 to 1.439) 0.658 (0.533 to 0.782)
5 Goetzinger et al.,
2010128
C+ B Allen et al.108 1045 14 (1.3) 0.670 (0.502 to 0.804) 0.910 (0.092 to 1.729) –1.691 (–2.221 to –1.162)
Poston et al.
2015149
1554 56 (3.6) 0.521 (0.451 to 0.590) 0.409 (–0.567 to 1.386) –1.206 (–1.480 to –0.933)
POP161 4212 273 (6.5) 0.764 (0.730 to 0.795) 1.706 (1.499 to 1.913) –0.070 (–0.195 to 0.054)
6 Odibo et al., 2011147 C+ B Allen et al.108 1045 14 (1.3) 0.660 (0.491 to 0.796) 0.847 (–0.022 to 1.716) –1.512 (–2.041 to –0.982)
St George’s163 54,635 1487 (2.7) 0.672 (0.654 to 0.690) 0.962 (0.885 to 1.039) –0.897 (–0.950 to –0.845)
POP161 4212 273 (6.5) 0.779 (0.744 to 0.812) 1.490 (1.329 to 1.651) –0.033 (–0.159 to 0.094)
7 Odibo et al., 2011147 C+U Velauthar
et al.39









































Performance statistic (95% CI)
C-statistic Calibration slope Calibration-in-the-large
First-trimester early-onset pre-eclampsia models
8 Baschat et al.,
2014115
C SCOPE UK42 658 6 (0.9) 0.513 (0.291 to 0.73) 0.212 (–8.468 to 8.892) 0.399 (–0.407 to 1.205)
ALSPAC103 14,344 40 (0.3) 0.706 (0.600 to 0.794) 2.070 (1.234 to 2.905) –1.029 (–1.352 to –0.705)
Poston et al.
2006150
2422 144 (6.0) 0.672 (0.626 to 0.716) 1.281 (0.898 to 1.664) 1.797 (1.628 to 1.967)
Velauthar
et al.39
1145 4 (0.3) 0.698 (0.434 to 0.876) 1.639 (–4.040 to 7.319) –0.755 (–1.875 to 0.365)
POP161 4212 10 (0.2) 0.739 (0.494 to 0.891) 3.403 (2.017 to 4.789) –1.054 (–1.674 to –0.433)
9 Crovetto et al.,
2015229
C SCOPE UK42 658 6 (0.9) 0.464 (0.428 to 0.500) NE 1.039 (0.218 to 1.861)
Poston et al.
2015149
1554 6 (0.4) 0.596 (0.278 to 0.850) 0.264 (–0.216 to 0.743) –2.484 (–3.401 to –1.567)
POP161 4212 10 (0.2) 0.721 (0.532 to 0.855) 0.996 (0.596 to 1.395) –0.317 (–0.943 to 0.309)
10 Kuc et al., 2013230 C SCOPE UK42 658 6 (0.9) 0.762 (0.520 to 0.905) 0.682 (0.050 to 1.314) –3.709 (–4.530 to –2.889)
ALSPAC103 14,344 40 (0.3) 0.664 (0.484 to 0.812) 0.442 (–0.025 to 0.909) –3.458 (–3.786 to –3.130)
Poston et al.
2015149
1554 6 (0.4) 0.519 (0.323 to 0.710) 0.010 (–0.705 to 0.726) –5.978 (–6.861 to –5.094)
St George’s163 54,635 151 (0.3) 0.635 (0.587 to 0.679) 0.343 (0.227 to 0.460) –4.510 (–4.674 to –4.347)
AMND114 136,635 1237 (0.9) 0.681 (0.665 to 0.696) 0.470 (0.430 to 0.511) –3.387 (–3.445 to –3.330)
POP161 4212 10 (0.2) 0.656 (0.518 to 0.772) 0.450 (–0.069 to 0.969) –5.191 (–5.815 to –4.567)
11 Plasencia et al.,
2007231
C SCOPE UK42 658 6 (0.9) 0.465 (0.429 to 0.501) NE 1.500 (0.691 to 2.309)
Chappell et al.121 316 7 (2.1) 0.706 (0.463 to 0.872) 0.510 (0.013 to 1.007) 0.462 (–0.402 to 1.327)
Poston et al.
2015149
1554 6 (0.4) 0.667 (0.391 to 0.863) 0.517 (–0.135 to 1.170) –0.478 (–1.367 to 0.411)

























































































































































































































































































































































Performance statistic (95% CI)
C-statistic Calibration slope Calibration-in-the-large
12 Poon et al., 2010232 C SCOPE UK42 658 6 (0.9) 0.524 (0.355 to 0.687) 0.236 (–1.154 to 1.627) 0.648 (–0.163 to 1.458)
Poston et al.
2015149
1554 6 (0.4) 0.745 (0.512 to 0.892) 0.846 (0.004 to 1.688) –1.667 (–2.548 to –0.787)
POP161 4212 10 (0.2) 0.687 (0.455 to 0.852) 1.176 (0.617 to 1.734) –2.228 (–2.849 to –1.606)
13 Scazzocchio et al.,
2013235
C SCOPE UK42 658 6 (0.9) 0.728 (0.448 to 0.898) 1.131 (–0.130 to 2.392) 0.788 (–0.020 to 1.596)
ALSPAC103 1554 6 (0.4) 0.612 (0.333 to 0.834) 0.586 (–0.376 to 1.548) –1.434 (–2.316 to –0.551)
Poston et al.
2006150
4212 10 (0.2) 0.844 (0.640 to 0.943) 0.746 (0.449 to 1.042) –1.439 (–2.092 to –0.787)




658 6 (0.9) 0.763 (0.614 to 0.867) 0.907 (–0.027 to 1.842) 1.396 (0.585 to 2.207)
POP161 674 6 (0.4) 0.591 (0.207 to 0.890) 0.958 (–0.727 to 2.642) –0.906 (–2.048 to 0.236)
15 Poon et al., 2009234 C+ B SCOPE UK42 4212 10 (0.2) 0.741 (0.507 to 0.888) 0.452 (0.210 to 0.693) –2.671 (–3.35 to –1.991)
First-trimester late-onset pre-eclampsia models
16 Crovetto et al.,
2015229
C SCOPE UK42 658 26 (4.0) 0.569 (0.448 to 0.683) 0.379 (–0.231 to 0.988) 1.074 (0.675 to 1.472)
Allen et al.108 1045 13 (1.2) 0.544 (0.352 to 0.723) 0.516 (0.108 to 0.924) –1.205 (–1.779 to –0.630)
Chappell et al.121 316 32 (10.0) 0.696 (0.586 to 0.788) 0.345 (0.152 to 0.538) 0.037 (–0.451 to 0.525)
Poston et al.
2015149
1554 51 (3.3) 0.504 (0.412 to 0.596) 0.210 (–0.035 to 0.456) –1.502 (–1.812 to –1.192)
POP161 4212 263 (6.2) 0.781 (0.745 to 0.813) 1.248 (1.120 to 1.376) 1.309 (1.177 to 1.441)
17 Kuc et al., 2013230 C SCOPE UK42 658 26 (4.0) 0.544 (0.421 to 0.663) 0.224 (–0.445 to 0.893) –1.867 (–2.262 to –1.471)
Allen et al.108 1045 13 (1.2) 0.583 (0.425 to 0.726) 0.340 (–0.356 to 1.036) –2.570 (–3.119 to –2.020)
ALSPAC103 14,344 266 (1.9) 0.657 (0.616 to 0.696) 0.761 (0.550 to 0.973) –1.574 (–1.699 to –1.448)
EMPOWaR122 449 28 (6.3) 0.337 (0.162 to 0.558) –0.755 (–1.808 to 0.299) –2.127 (–2.795 to –1.459)
Poston et al.
2015149









































Performance statistic (95% CI)
C-statistic Calibration slope Calibration-in-the-large
St George’s163 54,635 1336 (2.4) 0.636 (0.621 to 0.651) 0.632 (0.560 to 0.704) –1.970 (–2.025 to –1.915)
AMND114 136,635 3733 (2.7) 0.844 (0.640 to 0.943) 0.746 (0.449 to 1.042) –1.439 (–2.092 to –0.787)
POP161 4212 263 (6.2) 0.599 (0.561 to 0.636) 0.673 (0.452 to 0.894) –1.487 (–1.613 to –1.361)
18 Plasencia et al.,
2007231
C SCOPE UK42 658 26 (4.0) 0.627 (0.509 to 0.732) 0.523 (–0.003 to 1.049) 0.778 (0.377 to 1.178)
Allen et al.108 1045 13 (1.2) 0.751 (0.600 to 0.858) 1.008 (0.459 to 1.556) 0.043 (–0.510 to 0.596)
Poston et al.
2015149
1554 51 (3.3) 0.673 (0.596 to 0.742) 0.523 (0.264 to 0.782) –0.204 (–0.498 to 0.090)
19 Poon et al., 2010232 C SCOPE UK42 658 26 (4.0) 0.570 (0.405 to 0.682) 0.369 (–0.199 to 0.937) 0.909 (0.511 to 1.308)
Allen et al.108 1045 13 (1.2) 0.716 (0.556 to 0.836) 0.913 (0.312 to 1.514) –0.289 (–0.841 to 0.262)
Poston et al.
2015149
1554 51 (3.3) 0.666 (0.591 to 0.734) 0.541 (0.280 to 0.802) –0.271 (–0.566 to 0.025)
20 Scazzocchio et al.,
2013235
C SCOPE UK42 658 26 (4.0) 0.597 (0.478 to 0.705) 0.562 (–0.168 to 1.291) 0.524 (0.128 to 0.920)
21 Poon et al., 2009234 C+ B Allen et al.108 1045 13 (1.2) 0.684 (0.550 to 0.792) 0.799 (0.257 to 1.341) –0.349 (–0.902 to 0.205)
Second-trimester any-onset pre-eclampsia models
22 Yu et al., 2005238 C+U POP161 4212 273 (6.5) 0.610 (0.574 to 0.645) 0.075 (0.007 to 0.144) NE
Second-trimester early-onset pre-eclampsia models
23 Yu et al., 2005238 C+U POP161 4212 10 (0.2) 0.908 (0.826 to 0.954) 0.557 (0.293 to 0.821) 2.473 (1.716 to 3.229)
Second-trimester late-onset pre-eclampsia models
24 Yu et al., 2005238 C+U POP161 4212 263 (6.2) 0.607 (0.570 to 0.642) 0.077 (0.005 to 0.148) NE
C, clinical characteristics; C+ B, clinical and biochemical markers; C+U, clinical characteristics and ultrasound markers; NE, not estimable due to perfect prediction (same predicted
probability for all individuals that had the event).


















































































































































































































































































































































Appendix 14 Decision curves for prediction
models of early-onset pre-eclampsia in
(a) SCOPE UK,42 (b) Poston et al. 2015149 and
(c) POP161
Threshold probability
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Appendix 15 Imputation checking for
model development
Imputation checking for clinical characteristics models
Trimester 1 predictors
BMI values were not imputed reliably in POUCH, illustrated by the distribution of imputed values
getting wider in later imputations, particularly for transformations of BMI.
Mean ± SD
Mean




































































































































FIGURE 19 Median and range of BMI values in imputed data set for cohorts included in the development of models with
trimester 1 clinical characteristics. (continued )
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FIGURE 19 Median and range of BMI values in imputed data set for cohorts included in the development of models with






















































































FIGURE 20 Median and range of ln(BMI) values in imputed data set for cohorts included in the development of models
with trimester 1 clinical characteristics. (continued )
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FIGURE 20 Median and range of ln(BMI) values in imputed data set for cohorts included in the development of models
with trimester 1 clinical characteristics.
Mean ± SD
Mean




























































FIGURE 21 Median and range of (BMI/10)–2 values in imputed data set for cohorts included in the development of
models with trimester 1 clinical characteristics. (continued )
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FIGURE 21 Median and range of (BMI/10)–2 values in imputed data set for cohorts included in the development of
models with trimester 1 clinical characteristics.
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Trimester 2 predictors
SBP, DBP and BMI values were not imputed reliably in Allen, Baschat and Vinter, as illustrated by
extreme imputed values for later imputations (particularly for Allen and Vinter).
Mean ± SD
Mean







































































































































FIGURE 22 Median and range of DBP values in imputed data set for cohorts included in the development of models with
trimester 2 clinical characteristics. (continued )
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FIGURE 22 Median and range of DBP values in imputed data set for cohorts included in the development of models with
trimester 2 clinical characteristics.
Mean ± SD
Mean



























































































FIGURE 23 Median and range of SBP values in imputed data set for cohorts included in the development of models with
trimester 2 clinical characteristics. (continued )
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FIGURE 23 Median and range of SBP values in imputed data set for cohorts included in the development of models with
trimester 2 clinical characteristics.
Mean ± SD
Mean































FIGURE 24 Median and range of BMI values in imputed data set for cohorts included in the development of models with
trimester 2 clinical characteristics. (continued )
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(i) Van Kuijk 2014166



































































FIGURE 24 Median and range of BMI values in imputed data set for cohorts included in the development of models with
trimester 2 clinical characteristics.
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I) Mean ± SD
Mean
(d) Baschat115

































































(i) Van Kuijk 2014166



























FIGURE 25 Median and range of ln(BMI) values in imputed data set for cohorts included in the development of models
with trimester 2 clinical characteristics. (continued )
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FIGURE 25 Median and range of ln(BMI) values in imputed data set for cohorts included in the development of models
with trimester 2 clinical characteristics.
Mean ± SD
Mean






























































































FIGURE 26 Median and range of (BMI/10)–2 values in imputed data set for cohorts included in the development of
models with trimester 2 clinical characteristics. (continued )
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Imputation checking for clinical characteristics and biochemical
markers models
Trimester 2 biomarkers
POUCH was excluded because of the unreliable imputation of PAPP-A, although the range of imputed
values in POP was also concerning in later imputations.


































































































FIGURE 26 Median and range of (BMI/10)–2 values in imputed data set for cohorts included in the development of
models with trimester 2 clinical characteristics.
Mean ± SD
Mean
































FIGURE 27 Median and range of ln(PAPP-A) values in imputed data set for cohorts included in the development of
models with trimester 2 clinical characteristics. (continued )
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FIGURE 27 Median and range of ln(PAPP-A) values in imputed data set for cohorts included in the development of
models with trimester 2 clinical characteristics.
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Appendix 16 Comparison of clinical
characteristics models in data imputed with
BMI, ln(BMI) or BMI–2
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(95% CI) OR (95% CI) p-value
Beta coefficient
(95% CI) OR (95% CI) p-value
Beta coefficient





















































































































































TABLE 30 Performance statistics for first-trimester models for any-onset pre-eclampsia
Model





C-statistic) Estimate (95% CI) τ2 I2 Estimate (95% CI) τ2 I2
Model with BMI 0.677 (0.612 to 0.736) 0.139 83.9 0.915 (0.603 to 1.226) 0.155 86.4 0.012 (–0.630 to 0.654) 0.881 98.7
Model with ln(BMI) 0.670 (0.589 to 0.742) 0.228 88.7 0.874 (0.473 to 1.275) 0.297 92.1 0.015 (–0.627 to 0.656) 0.880 98.6
Model with BMI-2 0.678 (0.597 to 0.750) 0.229 87.3 0.872 (0.436 to 1.308) 0.336 93.1 0.014 (–0.637 to 0.664) 0.910 98.6




(95% CI) OR (95% CI) p-value
Beta coefficient
(95% CI) OR (95% CI) p-value
Beta coefficient
















































































































































































































































































































































































































































TABLE 32 Performance statistics for first-trimester models for early-onset pre-eclampsia
Model
C-statistic Calibration slope Calibration-in-the-large
Estimate (95% CI) τ2 (for logit C-statistic) I2 (for logit C-statistic) Estimate (95% CI) τ2 I2 Estimate (95% CI) τ2 I2
Model with BMI 0.663 (0.504 to 0.791) 0.469 71.2 1.032 (0.802 to 1.262) 0.006 4.0 0.085 (–0.407 to 0.576) 0.365 80.6
Model with ln(BMI) 0.711 (0.574 to 0.818) 0.351 62.2 1.054 (0.828 to 1.279) 0.000 0.0 0.089 (–0.374 to 0.552) 0.311 77.7
Model with BMI–2 0.719 (0.590 to 0.820) 0.260 49.1 1.001 (0.795 to 1.206) 0.000 0.0 0.090 (–0.377 to 0.557) 0.318 77.9




(95% CI) OR (95% CI) p-value
Beta coefficient
(95% CI) OR (95% CI) p-value
Beta coefficient




































































































































TABLE 34 Performance statistics for first-trimester models for late-onset pre-eclampsia
Model





C-statistic) Estimate (95% CI) τ2 I2 Estimate (95% CI) τ2 I2
Model with BMI 0.677 (0.615 to 0.733) 0.116 79.7 0.919 (0.621 to 1.217) 0.131 82.0 0.016 (–0.705 to 0.736) 1.105 98.8
Model with ln(BMI) 0.666 (0.590 to 0.733) 0.181 84.5 0.845 (0.476 to 1.215) 0.237 88.4 0.021 (–0.704 to 0.745) 1.108 98.7
Model with BMI–2 0.677 (0.599 to 0.746) 0.202 85.5 0.856 (0.453 to 1.259) 0.277 90.3 0.016 (–0.732 to 0.765) 1.192 98.9




(95% CI) OR (95% CI) p-value
Beta coefficient
(95% CI) OR (95% CI) p-value
Beta coefficient




























































































































































































































































































































































































































































TABLE 36 Performance statistics for second-trimester models for any-onset pre-eclampsia
Model





C-statistic) Estimate (95% CI) τ2 I2 Estimate (95% CI) τ2 I2
Model with BMI 0.703 (0.648 to 0.753) 0.076 79.3 0.969 (0.664 to 1.273) 0.129 88.3 0.011 (–0.772 to 0.795) 1.003 99.0
Model with ln(BMI) 0.690 (0.636 to 0.739) 0.062 76.2 0.993 (0.625 to 1.361) 0.181 89.9 0.010 (–0.789 to 0.809) 1.044 99.0
Model with BMI–2 0.684 (0.613 to 0.747) 0.131 86.9 0.992 (0.556 to 1.429) 0.291 93.3 0.011 (–0.888 to 0.910) 1.336 99.2




(95% CI) OR (95% CI) p-value
Beta coefficient
(95% CI) OR (95% CI) p-value
Beta coefficient







































































































TABLE 38 Performance statistics for second-trimester models for early-onset pre-eclampsia
Model





C-statistic) Estimate (95% CI) τ2 I2 Estimate (95% CI) τ2 I2
Model with BMI 0.723 (0.601 to 0.819) 0.223 56.4 1.105 (0.868 to 1.341) 0.000 0.0 0.037 (–0.465 to 0.539) 0.287 76.4
Model with ln(BMI) 0.702 (0.631 to 0.764) 0.000 0.0 1.169 (0.835 to 1.503) 0.031 16.9 0.049 (–0.451 to 0.549) 0.285 76.7
Model with BMI–2 0.719 (0.650 to 0.779) 0.006 3.7 1.126 (0.730 to 1.522) 0.093 45.0 0.035 (–0.445 to 0.514) 0.271 77.0




(95% CI) OR (95% CI) p-value
Beta coefficient
(95% CI) OR (95% CI) p-value
Beta coefficient
































































































































































































































































































































































































































































TABLE 40 Performance statistics for second-trimester models for late-onset pre-eclampsia
Model





C-statistic) Estimate (95% CI) τ2 I2 Estimate (95% CI) τ2 I2
Model with BMI 0.705 (0.649 to 0.756) 0.076 78.4 0.930 (0.656 to 1.204) 0.096 84.2 0.014 (–0.897 to 0.925) 1.358 99.1
Model with ln(BMI) 0.683 (0.613 to 0.746) 0.107 83.8 0.888 (0.493 to 1.283) 0.213 90.7 0.015 (–0.899 to 0.929) 1.360 99.2

































Appendix 17 Forest plots of predictive
performance estimates in the individual data











Overall (I2 = 79.3%)
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FIGURE 28 Forest plot of logit C-statistics for the second-trimester model predicting any-onset pre-eclampsia in data











Overall (I2 = 88.3%)
with estimated prediction interval
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Calibration
slope (95% CI)
FIGURE 29 Forest plot of calibration slope for the second-trimester model predicting any-onset pre-eclampsia in data
sets used for model development and internal validation. Note: weights are from random-effects model.
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FIGURE 30 Forest plot of calibration-in-the-large for the second-trimester model predicting any-onset pre-eclampsia in data sets used for model development and internal validation.

































Appendix 18 Comparison of clinical
characteristic and biochemical marker models
in data imputed with original biochemical
markers or natural log-transformed
biochemical markers
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TABLE 41 First-trimester models for any pre-eclampsia
Variable
Original biochemical markers Ln(biochemical markers)
Beta coefficient (95% CI) OR (95% CI) p-value Beta coefficient (95% CI) OR (95% CI) p-value
Age (years) –0.023 (–0.038 to –0.008) 0.977 (0.962 to 0.992) 0.003 –0.023 (–0.039 to –0.007) 0.977 (0.962 to 0.993) 0.006
SBP 0.016 (0.004 to 0.028) 1.016 (1.004 to 1.028) 0.011 0.024 (0.014 to 0.034) 1.024 (1.014 to 1.034) < 0.001
BMI 0.041 (0.009 to 0.074) 1.042 (1.009 to 1.077) 0.015 0.036 (0.016 to 0.056) 1.037 (1.016 to 1.057) < 0.001
Nulliparous 1.136 (0.597 to 1.675) 3.113 (1.816 to 5.337) < 0.001 1.267 (0.703 to 1.831) 3.551 (2.020 to 6.241) < 0.001
Previous PE 1.350 (0.812 to 1.888) 3.857 (2.252 to 6.607) < 0.001 1.488 (0.901 to 2.076) 4.430 (2.461 to 7.973) < 0.001
Renal disease 0.957 (0.319 to 1.594) 2.603 (1.376 to 4.925) 0.004 1.058 (0.449 to 1.667) 2.880 (1.566 to 5.296) 0.001
Hypertension 2.241 (1.962 to 2.520) 9.403 (7.113 to 12.430) < 0.001 2.215 (1.949 to 2.482) 9.165 (7.024 to 11.960) < 0.001
Diabetes 0.021 (–0.915 to 0.957) 1.021 (0.401 to 2.605) 0.965 0.178 (–0.737 to 1.094) 1.195 (0.479 to 2.985) 0.702
sFlt-1 –2.42 × 10–4 (–4.3 × 10–4 to –5.5 × 10–5) 0.9998 (0.9996 to 0.9999) 0.012 –0.052 (–0.109 to 0.005) 0.949 (0.897 to 1.005) 0.071
PlGF –0.005 (–0.008 to –0.002) 0.995 (0.992 to 0.998) 0.001 –0.030 (–0.062 to 0.002) 0.970 (0.940 to 1.002) 0.064
Intercept –5.893 (–7.478 to –4.309) –7.022 (–8.515 to –5.530)
TABLE 42 Performance statistics for first-trimester models for any pre-eclampsia
Model





C-statistic) Estimate (95% CI) τ2 I2 Estimate (95% CI) τ2 I2
Original biochemical markers 0.696 (0.516 to 0.832) 0.205 90.7 0.901 (0.355 to 1.447) 0.094 86.7 –0.004 (–0.939 to 0.931) 0.333 97.9

































TABLE 43 First-trimester models for early pre-eclampsia
Variable
Original biochemical markers Ln(biochemical markers)
Beta coefficient (95% CI) OR (95% CI) p-value Beta coefficient (95% CI) OR (95% CI) p-value
Age (years) –0.005 (–0.047 to 0.038) 0.995 (0.954 to 1.039) 0.831 –0.013 (–0.054 to 0.028) 0.987 (0.947 to 1.028) 0.523
SBP 0.053 (0.025 to 0.082) 1.055 (1.026 to 1.085) < 0.001 0.024 (–0.007 to 0.054) 1.024 (0.993 to 1.055) 0.125
DBP –0.004 (–0.04 to 0.033) 0.996 (0.960 to 1.033) 0.836 0.042 (0.004 to 0.080) 1.043 (1.004 to 1.083) 0.031
BMI –0.007 (–0.069 to 0.056) 0.993 (0.933 to 1.057) 0.831 0.006 (–0.049 to 0.061) 1.006 (0.952 to 1.062) 0.837
Previous PE 1.488 (0.694 to 2.281) 4.427 (2.002 to 9.789) < 0.001 1.689 (0.909 to 2.469) 5.412 (2.481 to 11.805) < 0.001
Renal disease 1.481 (0.401 to 2.560) 4.397 (1.494 to 12.942) 0.007 1.414 (0.325 to 2.503) 4.112 (1.384 to 12.216) 0.011
Hypertension 0.833 (0.033 to 1.633) 2.300 (1.034 to 5.117) 0.041 0.978 (0.201 to 1.755) 2.659 (1.222 to 5.786) 0.014
sFlt-1 –5.15 × 10–4 (–1.1 × 10–3 to 6.1 × 10–5) 0.9995 (0.9989 to 1.0001) 0.079
Intercept –10.206 (–13.561 to –6.851) –10.929 (–13.875 to –7.983)
TABLE 44 Performance statistics for first-trimester models for early pre-eclampsia
Model





C-statistic) Estimate (95% CI) τ2 I2 Estimate (95% CI) τ2 I2
Original biochemical markers 0.762 (0.576 to 0.883) 0.107 37.0 1.038 (0.666 to 1.410) 0 0 0.036 (–1.269 to 1.342) 0.610 91.7

















































































































































































































































































































































TABLE 45 First-trimester models for late pre-eclampsia
Variable
Original biochemical markers Ln(biochemical markers)
Beta coefficient (95% CI) OR (95% CI) p-value Beta coefficient (95% CI) OR (95% CI) p-value
Age (years) –0.025 (–0.040 to –0.009) 0.976 (0.961 to 0.991) 0.002 –0.024 (–0.042 to –0.006) 0.976 (0.959 to 0.994) 0.009
SBP 0.009 (–0.002 to 0.020) 1.009 (0.998 to 1.020) 0.113 0.020 (0.010 to 0.030) 1.020 (1.010 to 1.031) < 0.001
BMI 0.051 (0.024 to 0.077) 1.052 (1.024 to 1.080) < 0.001 0.040 (0.018 to 0.061) 1.040 (1.019 to 1.063) < 0.001
Nulliparous 1.409 (0.814 to 2.004) 4.093 (2.258 to 7.418) < 0.001 1.683 (1.035 to 2.330) 5.379 (2.816 to 10.276) < 0.001
Previous PE 1.197 (0.557 to 1.838) 3.311 (1.745 to 6.283) < 0.001 1.456 (0.774 to 2.138) 4.289 (2.168 to 8.486) < 0.001
Renal disease 0.758 (0.084 to 1.433) 2.135 (1.088 to 4.190) 0.028 0.886 (0.225 to 1.547) 2.426 (1.253 to 4.698) 0.009
Hypertension 2.374 (2.084 to 2.663) 10.739 (8.039 to 14.346) < 0.001 2.326 (2.049 to 2.604) 10.238 (7.756 to 13.515) < 0.001
sFlt-1 –2 × 10–4 (–3.8 × 10–4 to –2.4 × 10–5) 0.9998 (0.9996 to 1.0000) 0.026 –0.06 (–0.119 to –0.001) 0.942 (0.888 to 0.999) 0.048
PlGF –0.006 (–0.009 to –0.003) 0.994 (0.991 to 0.997) 0.001 –0.032 (–0.066 to 0.003) 0.969 (0.936 to 1.003) 0.072
Intercept –5.787 (–7.28 to –4.293) –7.168 (–8.776 to –5.559)
TABLE 46 Performance statistics for first-trimester models for late pre-eclampsia
Model





C-statistic) Estimate (95% CI) τ2 I2 Estimate (95% CI) τ2 I2
Original biochemical markers 0.688 (0.505 to 0.827) 0.212 91.9 0.857 (0.338 to 1.376) 0.085 84.4 –0.005 (–0.932 to 0.922) 0.322 97.5

































TABLE 47 Second-trimester models for any pre-eclampsia
Variable
Original biochemical markers Ln(biochemical markers)
Beta coefficient (95% CI) OR (95% CI) p-value Beta coefficient (95% CI) OR (95% CI) p-value
Age (years) –0.019 (–0.034 to –0.004) 0.981 (0.966 to 0.996) 0.012 –0.026 (–0.041 to –0.011) 0.974 (0.960 to 0.989) 0.001
SBP 0.019 (0.009 to 0.029) 1.019 (1.009 to 1.030) < 0.001 0.005 (–0.005 to 0.015) 1.005 (0.995 to 1.015) 0.357
DBP –0.009 (–0.021 to 0.004) 0.991 (0.979 to 1.004) 0.167 0.020 (0.006 to 0.033) 1.020 (1.006 to 1.034) 0.004
BMI 0.069 (0.055 to 0.084) 1.072 (1.057 to 1.088) < 0.001 0.069 (0.055 to 0.084) 1.072 (1.057 to 1.087) < 0.001
Nulliparous 2.099 (1.263 to 2.935) 8.156 (3.534 to 18.820) < 0.001 2.144 (1.344 to 2.944) 8.532 (3.833 to 18.993) < 0.001
Previous PE 1.831 (1.013 to 2.648) 6.237 (2.755 to 14.123) < 0.001 1.947 (1.172 to 2.722) 7.006 (3.227 to 15.209) < 0.001
Renal disease 1.423 (0.609 to 2.237) 4.150 (1.838 to 9.368) 0.001 1.467 (0.658 to 2.275) 4.335 (1.931 to 9.732) < 0.001
Hypertension 2.401 (2.120 to 2.682) 11.034 (8.334 to 14.608) < 0.001 2.389 (2.112 to 2.666) 10.905 (8.268 to 14.383) < 0.001
PlGF –0.003 (–0.004 to –0.002) 0.997 (0.996 to 0.998) < 0.001 –0.539 (–0.658 to –0.420) 0.583 (0.518 to 0.657) < 0.001
Intercept –7.895 (–9.314 to –6.476) –6.070 (–7.559 to –4.581)
TABLE 48 Performance statistics for second-trimester models for any pre-eclampsia
Model





C-statistic) Estimate (95% CI) τ2 I2 Estimate (95% CI) τ2 I2
Original biochemical markers 0.754 (0.526 to 0.894) 0.151 92.4 0.961 (0.358 to 1.564) 0.052 88.7 0.004 (–1.284 to 1.293) 0.262 98.0

















































































































































































































































































































































TABLE 49 Second-trimester models for early pre-eclampsia
Variable
Original biochemical markers Ln(biochemical markers)
Beta coefficient (95% CI) OR (95% CI) p-value Beta coefficient (95% CI) OR (95% CI) p-value
DBP 0.071 (0.044 to 0.099) 1.074 (1.045 to 1.104) < 0.001 0.065 (0.039 to 0.092) 1.068 (1.039 to 1.096) < 0.001
Previous PE 1.998 (1.046 to 2.949) 7.371 (2.847 to 19.084) < 0.001 2.360 (1.529 to 3.191) 10.594 (4.615 to 24.318) < 0.001
Renal disease 2.291 (0.151 to 4.431) 9.883 (1.163 to 83.975) 0.036 3.148 (0.961 to 5.335) 23.285 (2.613 to 207.474) 0.005
Autoimmune disease 1.012 (–1.075 to 3.100) 2.752 (0.341 to 22.193) 0.342 1.154 (–0.924 to 3.231) 3.169 (0.397 to 25.315) 0.277
sFlt-1 0.458 (0.096 to 0.820) 1.581 (1.100 to 2.271) 0.013
PlGF –0.003 (–0.005 to –0.001) 0.997 (0.995 to 0.999) 0.010 –0.988 (–1.283 to –0.693) 0.372 (0.277 to 0.500) < 0.001
Intercept –10.116 (–12.119 to –8.114) –9.343 (–12.661 to –6.025)
TABLE 50 Performance statistics for second-trimester models for early pre-eclampsia
Model





C-statistic) Estimate (95% CI) τ2 I2 Estimate (95% CI) τ2 I2
Original biochemical markers 0.786 (0.389 to 0.955) 0.304 61.2 1.054 (0.475 to 1.633) 0 0 0.024 (–1.308 to 1.357) 0.229 80.9

































TABLE 51 Second-trimester models for late pre-eclampsia
Variables
Original biochemical markers Ln(biochemical markers)
Beta coefficient (95% CI) OR (95% CI) p-value Beta coefficient (95% CI) OR (95% CI) p-value
Age (years) –0.020 (–0.036 to –0.004) 0.980 (0.965 to 0.996) 0.012 –0.027 (–0.043 to –0.012) 0.973 (0.958 to 0.989) 0.001
SBP 0.018 (0.008 to 0.029) 1.018 (1.008 to 1.029) 0.001 0.002 (–0.009 to 0.014) 1.002 (0.991 to 1.014) 0.697
DBP –0.014 (–0.028 to –0.001) 0.986 (0.973 to 0.999) 0.031 0.018 (0.002 to 0.033) 1.018 (1.002 to 1.034) 0.026
BMI 0.073 (0.058 to 0.088) 1.076 (1.060 to 1.093) < 0.001 0.074 (0.059 to 0.089) 1.077 (1.061 to 1.093) < 0.001
Nulliparous 2.539 (1.564 to 3.515) 12.673 (4.777 to 33.622) < 0.001 2.567 (1.647 to 3.487) 13.023 (5.190 to 32.681) < 0.001
Previous PE 1.734 (0.799 to 2.669) 5.664 (2.223 to 14.431) < 0.001 1.839 (0.962 to 2.716) 6.291 (2.617 to 15.120) < 0.001
Renal disease 1.303 (0.463 to 2.143) 3.680 (1.588 to 8.524) 0.002 1.318 (0.487 to 2.148) 3.735 (1.628 to 8.572) 0.002
Hypertension 2.432 (2.144 to 2.720) 11.380 (8.531 to 15.180) < 0.001 2.426 (2.144 to 2.709) 11.317 (8.531 to 15.012) < 0.001
PlGF –0.003 (–0.004 to –0.002) 0.997 (0.996 to 0.998) < 0.001 –0.424 (–0.545 to –0.302) 0.655 (0.580 to 0.739) < 0.001
Intercept –8.054 (–9.598 to –6.510) –6.760 (–8.323 to –5.198)
TABLE 52 Performance statistics for second-trimester models for late pre-eclampsia
Model





C-statistic) Estimate (95% CI) τ2 I2 Estimate (95% CI) τ2 I2
Original biochemical markers 0.746 (0.493 to 0.898) 0.181 93.2 0.936 (0.355 to 1.517) 0.047 86.5 0.004 (–1.295 to 1.303) 0.266 97.8


















































































































































































































































































































































Appendix 19 Predictive performance of final
shrunken prediction models for any-, early-
and late-onset pre-eclampsia in the individual
data sets used for model development
and validation
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Model Data set N Events (n)
Performance statistic (95% CI)
C-statistic Calibration slope Calibration-in-the-large
Any-onset pre-eclampsia
First-trimester clinical characteristics SCOPE42 5628 278 0.597 (0.547 to 0.645) 1.165 (0.722 to 1.608) 0.458 (0.335 to 0.581)
Allen et al.108 1045 14 0.757 (0.633 to 0.849) 1.253 (0.618 to 1.887) –0.888 (–1.421 to –0.356)
Poston et al. 2015149 1554 54 0.694 (0.565 to 0.799) 1.340 (0.491 to 2.189) –0.175 (–0.458 to 0.107)
Baschat et al.115 1704 106 0.738 (0.688 to 0.783) 0.747 (0.585 to 0.909) 0.291 (0.079 to 0.503)
Antsaklis et al.110 3328 32 0.585 (0.467 to 0.694) 0.291 (–0.264 to 0.846) –2.201 (–2.559 to –1.843)
WHO175 7273 141 0.637 (0.577 to 0.693) 0.808 (0.569 to 1.047) –0.638 (–0.806 to –0.469)
NICH LR159 3097 156 0.506 (0.425 to 0.587) 0.024 (–0.858 to 0.906) 0.411 (0.243 to 0.578)
van Kuijk et al. 2014166 230 43 0.684 (0.581 to 0.772) 0.705 (0.302 to 1.108) 0.780 (0.413 to 1.147)
STORK G135 812 46 0.723 (0.624 to 0.805) 1.466 (0.957 to 1.975) 1.064 (0.762 to 1.366)
Vinter et al.173 304 19 0.679 (0.549 to 0.786) 1.244 (0.260 to 2.227) 0.442 (–0.026 to 0.910)
POP161 4212 273 0.799 (0.765 to 0.829) 1.744 (1.578 to 1.909) 0.515 (0.389 to 0.642)
First-trimester clinical characteristics
and biochemical markers
SCOPE42 5628 278 0.583 (0.516 to 0.646) 0.891 (0.423 to 1.359) 0.354 (0.228 to 0.479)
WHO175 7273 141 0.687 (0.624 to 0.744) 0.778 (0.565 to 0.992) –0.835 (–1.007 to –0.664)
POUCH131 3019 44 0.674 (0.553 to 0.775) 0.737 (0.247 to 1.227) 0.204 (–0.138 to 0.545)
POP161 4212 273 0.807 (0.773 to 0.837) 1.464 (1.328 to 1.600) 0.282 (0.154 to 0.411)
Second-trimester clinical characteristics SCOPE42 5628 278 0.689 (0.658 to 0.719) 1.004 (0.819 to 1.190) 0.514 (0.391 to 0.636)
Poston et al. 2015149 1554 54 0.761 (0.691 to 0.819) 1.310 (0.914 to 1.706) –0.342 (–0.617 to –0.067)
Antsaklis et al.110 3328 32 0.621 (0.475 to 0.748) 0.468 (–0.191 to 1.128) –2.293 (–2.707 to –1.879)
WHO175 7273 141 0.653 (0.602 to 0.700) 0.677 (0.506 to 0.847) –0.585 (–0.756 to –0.414)
NICH LR159 3097 156 0.635 (0.586 to 0.682) 1.076 (0.755 to 1.396) 0.693 (0.531 to 0.856)
POUCH131 3019 44 0.688 (0.592 to 0.770) 0.714 (0.419 to 1.008) –0.15 (–0.487 to 0.186)
van Kuijk et al. 2014166 230 43 0.67 (0.543 to 0.776) 0.519 (0.151 to 0.887) 0.632 (0.222 to 1.041)
STORK G135 812 46 0.757 (0.659 to 0.835) 1.443 (1.019 to 1.867) 0.998 (0.693 to 1.303)

































Model Data set N Events (n)
Performance statistic (95% CI)
C-statistic Calibration slope Calibration-in-the-large
Second-trimester clinical characteristics and
biochemical markers
SCOPE42 5628 278 0.670 (0.637 to 0.701) 0.927 (0.743 to 1.110) 0.063 (–0.060 to 0.185)
WHO175 7273 141 0.768 (0.697 to 0.826) 0.782 (0.580 to 0.984) –0.549 (–0.726 to –0.371)
POP161 4212 273 0.814 (0.781 to 0.844) 1.264 (1.145 to 1.383) 0.482 (0.345 to 0.620)
Early-onset pre-eclampsia
First-trimester clinical characteristics SCOPE42 5628 44 0.783 (0.455 to 0.940) 1.680 (–0.026 to 3.387) 0.986 (0.673 to 1.300)
Allen et al.108 1045 1 NE 0.808 (–0.391 to 2.008) –1.566 (–3.551 to 0.420)
Poston et al. 2015149 1554 5 0.736 (0.419 to 0.915) 0.934 (–0.251 to 2.118) –0.462 (–1.374 to 0.451)
Baschat et al.115 1704 21 0.846 (0.716 to 0.923) 1.018 (0.752 to 1.284) 0.681 (0.226 to 1.135)
Antsaklis et al.110 3328 13 0.459 (0.272 to 0.659) –0.233 (–1.342 to 0.876) –0.019 (–0.539 to 0.500)
WHO175 7273 18 0.811 (0.659 to 0.905) 1.079 (0.728 to 1.430) –0.646 (–1.112 to –0.181)
NICH LR159 3097 12 0.536 (0.283 to 0.771) 0.189 (–1.446 to 1.824) 0.162 (–0.413 to 0.737)
van Kuijk et al. 2014166 230 15 0.672 (0.446 to 0.839) 0.620 (–0.301 to 1.541) 0.778 (0.221 to 1.335)
STORK G135 812 1 NE –1.513 (–7.175 to 4.150) –1.125 (–3.088 to 0.837)
Vinter et al.173 304 2 0.775 (0.261 to 0.971) 2.114 (–0.318 to 4.547) –0.033 (–1.425 to 1.359)
POP161 4212 10 0.779 (0.568 to 0.904) 1.168 (0.676 to 1.660) –0.235 (–0.858 to 0.388)
First-trimester clinical characteristics and
biochemical markers
SCOPE42 5628 44 0.664 (0.509 to 0.790) 0.934 (0.165 to 1.703) 0.899 (0.591 to 1.207)
WHO175 7273 18 0.879 (0.727 to 0.952) 1.010 (0.687 to 1.333) –0.714 (–1.188 to –0.241)
POUCH131 3019 12 0.773 (0.620 to 0.877) 0.889 (0.475 to 1.302) 0.479 (–0.049 to 1.008)
POP161 4212 10 0.743 (0.496 to 0.895) 1.195 (0.654 to 1.737) –0.703 (–1.326 to –0.081)
Second-trimester clinical characteristics SCOPE42 5628 44 0.674 (0.583 to 0.754) 1.268 (0.748 to 1.789) 0.978 (0.681 to 1.275)
Poston 2015149 1554 5 0.882 (0.703 to 0.959) 1.155 (0.497 to 1.814) –0.701 (–1.587 to 0.185)
Antsaklis110 3328 13 0.701 (0.331 to 0.917) 0.863 (–0.93 to 2.655) –0.258 (–1.581 to 1.064)
WHO175 7273 18 0.838 (0.671 to 0.930) 1.036 (0.744 to 1.327) –0.634 (–1.101 to –0.167)
NICH LR159 3097 12 0.556 (0.379 to 0.720) 0.422 (–0.594 to 1.437) 0.557 (–0.017 to 1.132)

















































































































































































































































































































































Model Data set N Events (n)
Performance statistic (95% CI)
C-statistic Calibration slope Calibration-in-the-large
van Kuijk et al. 2014166 230 15 0.672 (0.428 to 0.848) 0.659 (–0.270 to 1.588) 0.293 (–0.308 to 0.894)
STORK G135 812 1 NE 0.311 (–3.395 to 4.018) –0.970 (–2.932 to 0.991)
POP161 4212 10 0.558 (0.311 to 0.779) 0.404 (–0.806 to 1.613) –0.286 (–0.911 to 0.339)
Second-trimester clinical characteristics and
biochemical markers
SCOPE42 5628 44 0.805 (0.728 to 0.865) 1.175 (0.891 to 1.458) –0.159 (–0.458 to 0.141)
WHO175 7273 18 0.912 (0.778 to 0.968) 0.876 (0.598 to 1.153) –0.128 (–0.61 to 0.354)
POP161 4212 10 0.810 (0.575 to 0.931) 0.905 (0.453 to 1.356) 0.805 (0.156 to 1.455)
Late-onset pre-eclampsia
First-trimester clinical characteristics SCOPE42 5628 234 0.630 (0.578 to 0.679) 1.266 (0.844 to 1.688) 0.432 (0.298 to 0.565)
Allen et al.108 1045 13 0.738 (0.599 to 0.842) 1.258 (0.596 to 1.921) –0.757 (–1.308 to –0.205)
Poston et al. 2015149 1554 49 0.682 (0.548 to 0.791) 1.208 (0.388 to 2.027) –0.048 (–0.342 to 0.246)
Baschat et al.115 1704 85 0.701 (0.646 to 0.751) 0.601 (0.417 to 0.785) 0.281 (0.050 to 0.513)
Antsaklis et al.110 3328 19 0.676 (0.527 to 0.796) 0.781 (–0.075 to 1.637) –2.669 (–3.128 to –2.211)
WHO175 7273 123 0.606 (0.541 to 0.668) 0.672 (0.374 to 0.970) –0.588 (–0.768 to –0.409)
NICH LR159 3097 144 0.506 (0.42 to 0.591) 0.025 (–0.948 to 0.998) 0.495 (0.323 to 0.668)
van Kuijk et al. 2014166 230 28 0.686 (0.574 to 0.780) 0.674 (0.242 to 1.106) 0.536 (0.110 to 0.961)
STORK G135 812 45 0.733 (0.634 to 0.813) 1.442 (0.947 to 1.937) 1.226 (0.921 to 1.532)
Vinter et al.173 304 17 0.659 (0.521 to 0.774) 0.954 (0.026 to 1.883) 0.532 (0.039 to 1.026)
POP161 4212 263 0.798 (0.763 to 0.828) 1.667 (1.508 to 1.827) 0.621 (0.493 to 0.750)
First-trimester clinical characteristics and
biochemical markers
SCOPE42 5628 234 0.576 (0.521 to 0.630) 0.854 (0.435 to 1.274) 0.304 (0.169 to 0.438)
WHO175 7273 123 0.679 (0.612 to 0.739) 0.810 (0.540 to 1.08) –0.804 (–0.985 to –0.622)
POUCH131 3019 32 0.662 (0.555 to 0.755) 0.717 (0.224 to 1.211) 0.109 (–0.314 to 0.531)

































Model Data set N Events (n)
Performance statistic (95% CI)
C-statistic Calibration slope Calibration-in-the-large
Second-trimester clinical characteristics SCOPE42 5628 234 0.678 (0.644 to 0.711) 0.961 (0.760 to 1.161) 0.473 (0.340 to 0.606)
Poston et al. 2015149 1554 49 0.737 (0.667 to 0.797) 1.153 (0.746 to 1.560) –0.182 (–0.468 to 0.105)
Antsaklis et al.110 3328 19 0.721 (0.555 to 0.843) 1.023 (0.041 to 2.005) –2.720 (–3.195 to –2.245)
WHO175 7273 123 0.638 (0.586 to 0.688) 0.624 (0.408 to 0.839) –0.513 (–0.694 to –0.332)
NICH LR159 3097 144 0.636 (0.584 to 0.685) 1.107 (0.764 to 1.451) 0.752 (0.583 to 0.921)
POUCH131 3019 32 0.701 (0.604 to 0.784) 0.741 (0.422 to 1.060) –0.235 (–0.624 to 0.155)
van Kuijk et al. 2014166 230 28 0.655 (0.505 to 0.779) 0.457 (0.050 to 0.865) 0.611 (0.154 to 1.067)
STORK G135 812 45 0.761 (0.662 to 0.838) 1.346 (0.938 to 1.754) 1.195 (0.886 to 1.503)
POP161 4212 263 0.805 (0.765 to 0.840) 1.554 (1.397 to 1.710) 0.648 (0.517 to 0.780)
Second-trimester clinical characteristics and
biochemical markers
SCOPE42 5628 234 0.654 (0.617 to 0.688) 0.887 (0.686 to 1.087) 0.003 (–0.129 to 0.136)
WHO175 7273 123 0.754 (0.681 to 0.815) 0.812 (0.585 to 1.040) –0.531 (–0.717 to –0.345)



















































































































































































































































































































































Appendix 20 Calibration plots for final










































































































FIGURE 31 Calibration plots for model 3, which includes first-trimester clinical characteristics for predicting late-onset









































































































FIGURE 32 Calibration plots for model 4, which includes second-trimester clinical characteristics for predicting any-onset
pre-eclampsia. (a) SCOPE;42 (b) WHO;175 (c) NICH LR;159 and (d) POP.161
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FIGURE 33 Calibration plots for model 6, which includes second-trimester clinical characteristics for predicting















































































FIGURE 34 Calibration plots for model 7 which includes first-trimester clinical characteristics and biochemical markers
for predicting any-onset pre-eclampsia. (a) SCOPE;42 (b) WHO;175 and (c) POP.161
APPENDIX 20
















































































FIGURE 35 Calibration plots for model 9, which includes first-trimester clinical characteristics and biochemical markers
for predicting late-onset pre-eclampsia. (a) SCOPE;42 (b) WHO;175 and (c) POP.161














































































FIGURE 36 Calibration plots for model 10, which includes second-trimester clinical characteristics and biochemical
markers for predicting any-onset pre-eclampsia. (a) SCOPE;42 (b) WHO;175 and (c) POP.161
DOI: 10.3310/hta24720 Health Technology Assessment 2020 Vol. 24 No. 72
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Allotey et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
















































































FIGURE 37 Calibration plots for model 12, which includes second-trimester clinical characteristics and biochemical
markers for predicting late-onset pre-eclampsia. (a) SCOPE;42 (b) WHO;175 and (c) POP.161
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Appendix 21 Decision curve analysis for
developed models in each data set
Early-onset pre-eclampsia models
Threshold probability
























































































































FIGURE 38 Decision curves for the final (shrunken) model predicting early-onset pre-eclampsia using first-trimester
clinical characteristics, in data sets used in the development and validation of the model. (a) SCOPE;42 (b) Allen et al.;108
(c) Poston et al. 2015;149 (d) Baschat et al.;115 (e) Antsaklis;110 (f) WHO;175 (g) NICH LR;159 (h) Van Kuijk et al. 2014;166
(i) STORK G;135 (j) Vinter et al.;173 and (k) POP.161 (continued )
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FIGURE 38 Decision curves for the final (shrunken) model predicting early-onset pre-eclampsia using first-trimester
clinical characteristics, in data sets used in the development and validation of the model. (a) SCOPE;42 (b) Allen et al.;108
(c) Poston et al. 2015;149 (d) Baschat et al.;115 (e) Antsaklis;110 (f) WHO;175 (g) NICH LR;159 (h) Van Kuijk et al. 2014;166
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FIGURE 39 Decision curves for the final (shrunken) model predicting early-onset pre-eclampsia using second-trimester
clinical characteristics, in data sets used in the development and validation of the model. (a) SCOPE;42 (b) Poston et al.
2015;149 (c) Antsaklis et al.;110 (d) WHO;175 (e) NICH LR;159 (f) POUCH;131 (g) Van Kuijk et al. 2014;166 (h) STORK G;135 and
(i) POP.161 (continued )
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FIGURE 39 Decision curves for the final (shrunken) model predicting early-onset pre-eclampsia using second-trimester
clinical characteristics, in data sets used in the development and validation of the model. (a) SCOPE;42 (b) Poston et al.











































































FIGURE 40 Decision curves for the final (shrunken) model predicting early-onset pre-eclampsia using first-trimester
clinical characteristics and biochemical markers, in data sets used in the development and validation of the model.
(a) SCOPE;42 (b) WHO;175 (c) POUCH;131 and (d) POP.161
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(c)
FIGURE 41 Decision curves for the final (shrunken) model predicting early-onset pre-eclampsia using second-trimester
clinical characteristics and biochemical markers, in data sets used in the development and validation of the model.
(a) SCOPE;42 (b) WHO;175 and (c) POP.161
Threshold probability



































































FIGURE 42 Decision curves for the final (shrunken) model predicting late-onset pre-eclampsia using first-trimester
clinical characteristics, in data sets used in the development and validation of the model. (a) SCOPE;42 (b) Allen et al.;108
(c) Poston et al. 2015;149 (d) Baschat et al.;115 (e) Antsaklis;110 (f) WHO;175 (g) NICH LR;159 (h) Van Kuijk et al. 2014;166
(i) STORK G;135 (j) Vinter et al.;173 and (k) POP.161 (continued )
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FIGURE 42 Decision curves for the final (shrunken) model predicting late-onset pre-eclampsia using first-trimester
clinical characteristics, in data sets used in the development and validation of the model. (a) SCOPE;42 (b) Allen et al.;108
(c) Poston et al. 2015;149 (d) Baschat et al.;115 (e) Antsaklis;110 (f) WHO;175 (g) NICH LR;159 (h) Van Kuijk et al. 2014;166
(i) STORK G;135 (j) Vinter et al.;173 and (k) POP.161
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Threshold probability

























































































































































FIGURE 43 Decision curves for the final (shrunken) model predicting late-onset pre-eclampsia using second-trimester
clinical characteristics, in data sets used in the development and validation of the model. (a) SCOPE;42 (b) Poston et al.
2015;149 (c) Antsaklis;110 (d) WHO;175 (e) NICH LR;159 (f) POUCH;131 (g) Van Kuijk et al. 2014;166 (h) STORK G;135 and
(i) POP.161
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FIGURE 44 Decision curves for the final (shrunken) model predicting late-onset pre-eclampsia using first-trimester
clinical characteristics and biochemical markers, in data sets used in the development and validation of the model.














































FIGURE 45 Decision curves for the final (shrunken) model predicting late-onset pre-eclampsia using second-trimester
clinical characteristics and biochemical markers, in data sets used in the development and validation of the model.
(a) SCOPE;42 (b) WHO;175 and (c) POP.161
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